Design and Synthesis of 3-Dimensional Fragments to Explore Pharmaceutical Space by Wheldon, Mary Christine
  
Design and Synthesis of 3-Dimensional Fragments to 
Explore Pharmaceutical Space 
 
Mary Christine Wheldon 
 
 
Doctor of Philosophy 
University of York 
 
 
Chemistry 
 
September 2016 
 
 
ii 
 
Abstract 
This thesis describes an approach to the design, analysis and synthesis of saturated 
nitrogen heterocyclic fragments to explore pharmaceutical space. Firstly, the 
development of a computational protocol for the shape analysis of fragments is 
described (Chapter 2). Principal moments of inertia (PMI) plots were used to generate 
a set of selection criteria to select compounds found in the 3-dimensional area of the 
PMI plot. The computational method was applied to different scaffolds, piperidine, 
pyrrolidine and azepane, to generate a 3-dimensional fragment library.  
    
 
 
 
 
The computational analysis of a disubstituted piperidine fragment library provided a 
20 compound sub-set library for synthesis. The progress of this synthesis is described 
(Chapter 3). Six final fragments (shown below) have been prepared and synthesis 
towards ten of the other fragments is reported. The synthesis was planned with careful 
consideration of synthetic routes to minimise the number of different steps and routes 
employed.  
 
Finally, the application of our computational protocol to a virtually enumerated lead-
like library is presented (Chapter 4). The shape diversity and physicochemical 
properties of 190 different lead-like compounds from six different saturated nitrogen 
heterocyclic scaffolds is described. The analysis of these data to select compounds 
with suitable lead-like properties and interesting 3-dimensional shapes is summarised. 
 
Structures of fragments analysed Example PMI plot 
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Chapter 1:  Introduction 
Drug discovery has changed and developed over many years to fit with the key needs 
and facilities of the time. There have been a number of methods developed to find 
suitable leads for drug development programmes. These have included discovery of 
drugs from natural products with known biological activity, development of drugs 
from existing leads or drugs, also known as patent busting and high-throughput 
screening (HTS), the screening of a very large number of lead-like compounds against 
a given target.1 Each of these methods has had a significant impact on drug 
development over history, with many success stories.2 However, each of these 
methods has pitfalls and there is a constant need to rethink and readjust drug discovery 
methods to drive forward programmes and discoveries of new leads for ever more 
challenging targets.  
 
Recently, a shift in drug development has occurred with the drawbacks of screening 
lead-like molecules emerging. Rees and co-workers reported that hit rates are 
generally low in high throughput screens, with progression of only a small number of 
compounds.2,3 There have also been a number of discussions relating to the increase 
in lipophilicity and molecular weight during lead optimisation as a result of the use of 
optimising against hydrophobic interactions to increase potency.2,4 In addition, a 
number of reports link the high molecular weight and lipophilicity to drug attrition in 
later stages of drug development.1,4,5 It was noted that compounds successful in 
clinical trials had, on average, a lower molecular weight than those at early stage 
development.1,6 Less polar, more lipophilic compounds are also being linked to toxic 
effects and it was shown that a high molecular weight and lipophilicity have a 
significant effect on absorption, distribution and metabolism properties.1,7 A reduction 
in the molecular weight and lipophilicity of screening collections might lessen or 
eliminate these issues.1,2   
 
This is exemplified by the schematic diagram published by Rees (Figure 1.1). During 
optimisation, molecular weight and lipophilicity increases, as discussed above. It can 
be seen from Figure 1.1, that an increase in these properties for a smaller compound, 
or fragment, would give a final compound still within the desirable area of properties. 
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However, with a larger lead-like compound, a similar increase in molecular weight 
and lipophilicity would give a compound outside the desirable area.3  
 
Figure 1.1: Figure showing the relationship between number of heavy atoms and potency. 
The number of heavy atoms increases as potency increases. Fragments have a better chance 
of remaining in the Rule of 5 compliant area as they start with a lower number of heavy 
atoms.3 
This reduction in the size of compounds in screening libraries and the development of 
new libraries to investigate this paved the way for the introduction of fragment-based 
drug discovery (FBDD).  
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1.1 Fragment-based drug discovery 
Fragment screening was first reported by Fesik and co-workers in 1996.8 Here, small, 
low molecular weight ligands were screened against a protein target using NMR 
spectroscopy. After the initial ligand was found to bind, screening of close analogues 
provided an optimised ligand. Another ligand was then sought to bind in an adjacent 
site, repeating the optimisation process. After this, the two ligands, binding with 2 µM 
and 100 µM affinity respectively were linked to produce a compound with 19 nM 
affinity (Figure 1.2 and Figure 1.3).  
 
 
 
 
Figure 1.2: The premise of fragment-based drug discovery schematic; (1) Screen for first 
ligand, (2) Optimise first ligand, (3) Screen for second ligand, (4) Optimise second ligand, 
(5) Link Ligands 
 
 
Figure 1.3: The premise of fragment-based drug discovery in chemical terms; finding, 
optimising and linking small molecules, “fragments”, to develop lead compounds for drug 
development.8 
1 2 
3 4 5 
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Here, Fesik highlighted the benefit of this method: although the unlinked molecules 
have low affinity (micromolar to millimolar), after linking the binding affinity is the 
combined binding constants less the change for linking. Therefore, a compound in the 
micromolar binding range can be obtained from two millimolar binding range 
compounds.8 
 
Since this publication, there has been significant growing interest in fragment 
screening and development of this method of drug discovery. Jhoti and colleagues 
noted that after analysis of fragments in the Astex screening library, the fragments 
generally had the same properties. Typically, they are small molecules of molecular 
weight less than 300 Da, have a cLogP less than 3 and have less than 3 hydrogen bond 
donors and acceptors. They also noted that the number of rotatable bonds is less than 
3 and polar surface area is less than 60 Å2.9,10 As a result, these fragment properties 
were termed the “Rule of 3”, in a similar vein to the “Rule of 5” outlined by Lipinski 
for orally available drugs.11  
 
An advantage of screening small molecular weight fragments is that chemical space 
can be sampled more effectively. For larger, drug-like, compounds with around 30 
heavy atoms or molecular weight around 500 Da, chemical space is covered by around 
1060 compounds.1,12,13 By reducing the size of the screened molecules to around 12 
heavy atoms, the size of chemical space decreases to around 107.12 This means that a 
lead-like screening library of 1 million compounds covers an infinitesimally small area 
of chemical space.14 However, screening a library of compounds with less than 12 
heavy atoms covers approximately 0.001% of the available chemical space.5,13  A 
library of around 1000 fragments can have the same chemical diversity as a 10,000,000 
compound lead-like library.15,16 
 
Another advantage of small fragments over large lead-like compounds is the number 
of hits obtained from screening. Generally, the number of hits obtained from HTS is 
often considerably lower than would be expected and lower than with fragment 
screening. A number of reports have noted that as the size or complexity of a molecule 
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increases there is a greater probability of mis-matches with the binding site. This may 
be due to poor complementarity with the target protein and sub-optimal interactions 
and clashes.1,3,5,12,13,17 Therefore, since smaller molecules or fragments have a lower 
chance of forming these clashes or mis-matches, hit rates are in fact higher.2 
 
This view of complexity was, however, noted by Hann and Leach to be taken 
cautiously. As the complexity of the ligand decreases, the ability to detect binding 
decreases.18 It has been well reported that although fragments have a higher hit rate, 
the binding affinity is much weaker.4,12,13,19 Therefore, decreasing the complexity of 
compounds will only be beneficial if the binding can be detected.18 This has been 
summarised well by Zartler and Shapiro.4 Figure 1.4 shows how the chance of 
measuring binding increases with ligand complexity, although the probability of 
finding a match decreases, as there is an increased possibility of negative interactions 
with more complex ligands.4 The chance of the binding mode being unique, however, 
increases with complexity. Ultimately, there is a better chance of finding a detectable 
and unique binding mode in a final compound if molecules start off simpler and 
smaller.15 
 
Figure 1.4: Graph showing the probability of a match with the target decreasing as the 
probability of measuring binding increases.4 
Although binding affinity is low for smaller fragment-like molecules, when binding is 
detected, the interactions are generally as efficient and, if not, better quality than those 
formed by larger lead-like molecules.5,12 Generally, all the available points of 
interaction are used in the binding of fragments and therefore fragments are more 
efficient binders. It was also noted in a report by Murray and Rees that for a fragment 
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with 100 µM affinity, the fragment binds with a free energy of –22.8 kJ mol-1. This 
can be compared to a large drug-sized molecule with an affinity of 3 nM, which binds 
with a free energy of –63.6 kJ mol-1. Clearly, the ratio of size to binding energy is 
much higher for that of the fragment. They conclude that it is this high energy binding 
compared to the molecular weight of the fragment that provides the key to such high 
quality binding.1 This also forms the basis for ligand efficiency. Ligand efficiency is 
the binding free energy for a ligand divided by the number of heavy atoms in the 
ligand. This metric is useful to determine the impact of increasing molecular bulk on 
the activity of the compound. Generally fragments have very good ligand efficiency 
due to their small size and efficient interactions.20 Therefore measuring ligand 
efficiency of fragment hits and through fragment development can ensure a high 
quality ligand with good potency for the given molecular weight. 
 
Due to the weak binding, fragments generally need to be screened at a high 
concentration.4,21 Therefore, screening methods need to be capable of detecting such 
interactions. Fragments generally bind with an affinity of between 10 mM and 100 
µM, which is much weaker than the affinities usually observed in HTS and therefore 
normal biochemical in vitro receptor assays are not suitable.1 A number of biophysical 
methods such as NMR spectroscopy, X-ray crystallography, surface plasmon 
resonance (SPR) and thermal shift that are used to screen fragments are detailed 
below.2,19 These are often used orthogonally to generate a detailed picture of fragment 
binding.19,22  
 
In the seminal paper on fragment screening by Fesik and co-workers,8 NMR 
spectroscopy was used to detect binding and to aid development of selected fragments. 
NMR spectroscopy is a common method used in fragment screening as it is a relatively 
high throughput method. There are two general types of NMR spectroscopy screening 
methods, ligand-detected NMR spectroscopy and protein-detected NMR 
spectroscopy. For both of these methods, a large number compounds can be screened.3 
In ligand-detected NMR spectroscopy, information can be obtained to distinguish 
active site versus non-active site binders, whereas in protein-detected NMR 
spectroscopy, interactions between the ligand and the protein can be investigated.3 
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However, there are limitations to these methods. Ligand-detected NMR spectroscopy 
generally uses a large excess of ligand compared to protein, and therefore it is 
generally the effect on the bulk ligand population of interactions with the protein that 
is detected. This high concentration of ligand can also affect the pH of the screening 
media, which can lead to chemical shift changes.22 Protein-detected NMR 
spectroscopy also requires labelled protein for detailed NMR spectroscopy 
experiments.3 Nevertheless, NMR spectroscopy is a widely used method. 
 
X-ray crystallography has become a potentially more popular method for fragment 
screening as methods and technologies have been developed recently. Typically, this 
method is less high throughput than NMR spectroscopy screening experiments. This 
method, however, gives very detailed, high resolution information about the binding 
site and mode.3,4 The use of X-ray crystallographic information is key in the 
development and evolution of fragments.4,22 There have been, however, a number of 
issues with X-ray crystallography noted. Davis and Erlanson highlighted the fact that 
the crystal structure obtained was a model based on an experimentally collected 
electron density map and therefore was subject to interpretation. It was also noted that 
these data provide no information on affinity and that some more potent fragments 
may not crystallise well in the given system.22 
 
Surface plasmon resonance (SPR) has become one of the most popular methods of 
screening fragments in recent times. SPR involves an immobilised protein, generally 
on a chip, which is then subjected to varying concentrations of fragment solutions. If 
a fragment binds to the protein a change in reflective properties of the chip is observed 
which is dependent on the ratio of the fragment mass to the protein mass.22 A very 
large number of compounds can also be screened by this method and quantitative 
dynamics data, such as binding constants, can be obtained.23 This method, however, 
does not give detailed information on the ligand or binding mode and can suffer from 
a large number of false positives.3 
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Another very popular method for fragment screening is thermal shift. In this method, 
a protein and ligand are mixed and heated. The melting temperature of the protein is 
then measured. The melting temperature is thought to increase if the ligand stabilises 
the protein against thermal denaturation and this is classed as a hit as the ligand is 
clearly bound to the protein. This method is quick and cheap and therefore a very 
useful method of screening. However, Davis and Erlanson report that false negative 
results are possible with this method and the hit rate can be quite sporadic.22 Abell and 
co-workers also noted that results of thermal shift screening are not always 
reproducible and that generally thermal shift should be used as a enrichment exercise 
before screening by other methods.24 
 
Each of these methods have both positive and negative attributes. Therefore, it has 
been noted by a number of groups that fragment hits should be confirmed by at least 
two different methods before progression.2,19,22  
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1.2 Fragment library design 
As FBDD has become a recognised method of drug discovery, the compounds in 
screening libraries have become particularly important and the design of fragment 
libraries has become a key focus for many groups. Mills highlighted the importance 
of designing a chemically diverse fragment library, as critical decisions on project 
initiation and continuation can be based on results from fragment screening.15 Chen 
and Hubbard highlighted that a fragment library should be a resource that can be 
screened against a variety of targets and increase the number of distinct chemotypes 
in the screening output.25 As discussed above (Section 1.1), fragment library 
compounds generally have similar properties, as described by the “Rule of Three”. 
However, as FBDD developed, it became apparent that these were not the only 
desirable characteristics of fragments.  
 
Since fragments bind relatively weakly, they require screening at high concentration 
4,21 and therefore fragments need to have a high aqueous solubility. Ideally fragments 
should have a solubility of greater than 5 mM in 5% DMSO solution.26,27 This can be 
imparted from low molecular weight, low lipophilicity and ionisable groups. Such 
properties can be an issue in the synthesis of fragments, where aqueous soluble polar 
compounds are difficult to make and isolate. Furthermore, very polar fragments are 
less likely to bind with the screening target.21,27 With an increased aqueous solubility 
comes a need to ensure that the compounds are stable in various media. Davis and 
Erlanson discussed the need to ensure that compounds have good stability over long 
periods of time, not only as solid material, but also as solutions in DMSO and water.22 
The stability of the compounds in water is also important for storage in DMSO which 
is very hygroscopic. If compounds are stored below 0 °C the solutions may be subject 
to freeze-thaw cycles. This could cause dramatic changes to concentration and stability 
and dissolution of the compound, which could ultimately lead to false positives in 
screening data.22 
 
Another problem associated with screening at high concentrations is the need to ensure 
the removal of low-level impurities. David and Erlanson noted that when screening at 
a high concentration, such as 1mM, a 1% impurity that is not normally detected would 
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be present at 10 µM and this could cause misleading and erroneous results.22 Metals 
are also a common impurity found to cause false results in screens; for example, zinc 
has been detected in surface plasmon resonance screens.22 
 
As well as addressing solubility issues and avoiding false results from impurities, there 
have been a number of investigations into compounds regularly found in screening 
libraries that cause false results or are repeat hitters. It has been suggested by a number 
of groups that these types of compounds should be avoided.26,28 The first group of 
compounds to avoid are classed as reactive compounds. These compounds, for 
example, could react with biological targets to form covalent bonds and are related to 
toxicity.22,28 Some examples of these types of groups are shown in Figure 1.5. 
 
Figure 1.5: Moieties that could be potentially reactive and cause toxicity.22 
Another group of compounds to avoid in screening libraries are termed pan-assay 
interference compounds (PAINS). Work by Baell and Holloway showed that a 
selection of the same compounds hit many different targets in HTS.29 Generally, the 
compounds contain reactive features such as Michael acceptors. These can react 
reversibly or irreversibly with nucleophilic residues in the protein. PAINS have also 
been reported to bind covalently to targets which, although it can give them selectivity 
for a target, it can significantly affect interpretation of biology and development. Some 
PAINS may not necessarily be reactive but are strongly fluorescent or coloured, 
causing false data read-outs during fluorescence-based assays.30 Examples of these 
moieties are shown in Figure 1.6. 
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Figure 1.6: Example of pan-assay interference compounds.22 
 
Another group of compounds noted for their tendency to affect assay and screening 
results are 2-amino thiazoles. Work by Scanlon and colleagues investigated whether 
this group of compounds should be eliminated from screening libraries due to their 
promiscuous behaviour. This behaviour was exemplified by phenylthiazol-2-amine 
(Figure 1.7) which when screened against 14 different protein targets was found to hit 
each of them. Although these data suggested that this type of compound should be 
eliminated from screening libraries, there are a number of example of this type of core 
in successful drug compounds, such as antibiotics, treatments for Parkinson’s disease 
and leukemia. The work by Scanlon and colleagues, however, concluded that even 
though these promiscuous 2-aminothiazole (PrATs) fragments had desirable 
physicochemical properties the propensity to cause false hits suggested that these 
types of compounds should be avoided in fragment screening libraries.31 
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Figure 1.7: Promiscuous 2-AminoThiazoles (PrATs) 
 
Davis and Erlanson also highlighted that even if compounds pass through 
physicochemical property, stability, purity and reactivity screening, they may still 
cause problems through aggregation. Due to the high concentration of screening 
solutions, some small compounds can form microscopic aggregates in aqueous 
buffer.19,22 These aggregates can then inhibit a range of assays, producing false results. 
A range of different compounds are known to produce this affect and work by Shoichet 
and co-workers went some way to predicting if a compound would be susceptible to 
aggregation, with the production of a free web-based tool to help understand assay 
results.32 An alternative to avoid this is to add non-ionic detergents to the screening 
mixture to help reduce and eliminate aggregation. Some examples of aggregators are 
shown in Figure 1.8.22 
 
Figure 1.8: Compounds reported as aggregators that can inhibit enzymes and protein targets. 
 
Although there has been discussion about the types of compounds that should be 
avoided in fragment libraries there has been substantial discussion in the literature 
relating to the desirable characteristics of fragments, libraries and how to populate 
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them.15,21,22,28,33 A fragment library should also have certain characteristics as a whole 
such as synthetic tractability and molecular diversity.2,9  
 
A number of groups have discussed the effect of the screening method on the size of 
a fragment library.19,26 As described above, a fragment library does not need to be as 
large as a library for HTS, as chemical space is more efficiently sampled with smaller 
compounds. There does, however, need to be some indication on what would be a 
suitable size. Pickett discussed how the available screening method should determine 
how large the screening library should be. If a lower throughput technology is to be 
routinely used then a smaller library may be desirable to minimise the time and cost 
of screening.19 
 
As the size of a library might be limited, it is essential to populate the library with 
desirable fragments. A diverse range of key pharmacophores that drive fragment 
binding should be present. The compounds should have suitable complexity as to 
encourage binding and not hinder it, but also not have too little complexity so detection 
becomes difficult. Fragment structure should be sufficiently varied so that the 
molecules represent different chemotypes and have novelty over other hits.15,19 
Kolmodin suggested that after acceptable compounds are identified, a screening 
library sub-set of these compounds should be selected. These selected compounds will 
provide good coverage of the acceptable compounds and would ensure that close 
structural analogues are available.34 The need for close analogues has been highlighted 
by a number of groups and even the availability of solid material. Murray and Rees 
suggested that 50–100 mg of solid should be readily available.27 The availability of 
close analogues could be used to facilitate fragment optimisation or to probe binding 
interactions between the fragment and protien.15,27,34 
 
Closely related analogues are particularly important in the evolution of fragments 
towards lead compounds. A number of groups have suggested that fragments should 
have growth points or synthetic handles for quick and easy elaboration of 
fragments.15,19,27,34 Murray and Rees highlighted the need to have the ability to 
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elaborate fragments from different points and in different directions and that the 
methodology to do this should be in place before the screening of fragments. This 
approach would help increase the chance of success in optimisation.27 They suggested 
that groups such as amine and hydroxyl could offer potential as growth points as well 
as offering points of interaction.27 Schultz and co-workers noted a similar point about 
growth vectors but aired caution about the fact that points for growth and synthetic 
handles should not be left too reactive that they may interfere with screening in a 
similar way to PAINS.26 Kolmodin and co-workers suggested that synthetic handles 
such as hydroxyl groups and carboxylic acids could be masked as methyl ester or other 
less reactive functional groups.34  Brennan was able to take this a step further and 
design a poised fragment library. This involves the identification of a “poised” bond 
in a fragment compound which can be deconstructed into two synthons, for which 
robust chemistry exists to re-join. For example, an amide group can be split into an 
acid chloride and an amine. In the event of an amide fragment hit, a range of synthons 
(acid chlorides and amines) can be reacted to rapidly product analogues for testing. 
This can allow for investigation of binding modes or elucidation of more potent hits.35 
 
The availability of closely related analogues relies on commercial availability and 
synthetic tractability of the fragments. Murray noted that there is limited coverage of 
fragment space by commercial suppliers, even for very simple fragments, never mind 
for more complex heteroaromatic scaffolds.13 Rees and Murray also noted that 
compounds in screening collections and closely related analogues should have robust 
methodology to support their synthesis and be available in less than 4 steps from 
commercially available compounds.27 Inevitably, this has led to an increase in 
aromatic compounds in fragment libraries, which is supported by the robust chemistry 
available to build and functionalise aromatic compounds, as noted by Chan and co-
workers.36 
 
Work by other groups has shown that many fragment libraries are dominated by 
aromatic rings and planar compounds.5,14,19,37 Baker commented that there are 
considerably more stereocentres and saturated carbon atoms in approved drugs and 
natural products compared to screening libraries.14 Waldmann and co-workers 
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highlighted that this may be because most fragment libraries have been delineated 
from already known drug molecules and hence already cover identified areas of 
chemical space.38 This is a problem that has not only been recognised in fragment 
libraries but also in lead-like compound libraries.39,40 A selection of typical fragments 
taken from a report by  Murray and Rees, is shown in Figure 1.9 and highlights that 
small aromatic compounds dominate fragment libraries.1 
 
Figure 1.9: Example fragment compounds: generally low molecular weight, aromatic 
compounds. 
The number of aromatic and planar fragments has led groups to suggest that increasing 
the number of diversely shaped fragments could be a method to introduce complexity 
and diversity into fragment libraries and explore new areas of chemical space.14,37-39,41   
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1.3 Success of fragment-based drug discovery 
Since the seminal paper by Fesik,8 a number of groups have reported clinical 
candidates derived from fragment screens. These were summarised in a report by Jhoti 
and co-workers.42 Here, it was highlighted that there have been compounds that have 
entered the clinic, with two being approved by the FDA, as summarised below. 
 
Vemurafenib was the first compound derived from a fragment hit to be approved.5,43,44  
This drug is used to treat late-stage melanoma and was passed for use in the clinic in 
August 2011. Plexxicon screened 20,000 fragment compounds with a molecular 
weight between 150 and 350 Da. From these 20,000 compounds, 238 were found to 
bind to a number of kinase targets and inhibited their activity by at least 30%. After 
cocrystalisation, around 100 compounds showed bound structures. From these 
compounds, 7-azaindole derivative 1 was selected. This fragment offered a number of 
hydrogen bonding interactions as well as a number of positions for substitution and 
derivatisation.44 Structure-guided optimisation was used to develop the fragment and 
major developments are shown in Scheme 1.1. The final compound PLX4032 
(Vemurafenib) has superior pharmacokinetic properties and excellent efficacy in 
patients.5,44  
 
Scheme 1.1 
The other compound approved for treatment derived from a fragment screen is 
Venetoclax, an anti-cancer agent. The therapeutic target was the Bcl-2 family of 
proteins, which are over-expressed in cancer cells. The specific target was a protein-
protein interaction which had proved difficult to target with small molecules in the 
conventional way. Therefore, Rosenberg and colleagues employed an NMR 
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spectroscopy based screen of fragment molecules. This furnished two hits, 2 and 3, 
with reasonable potency (0.30 mM and 4.3 mM respectively) (Figure 1.10).45 
  
Figure 1.10: Two fragment hits that target Bcl-2. 
Manipulation of these fragments and structure-based design of new targets led to the 
highly potent compound 4 (ABT-737).45 This compound however, lacked good oral 
bioavailability and therefore further optimisation was undertaken.46 Development 
gave compound 5 (ABT-263)46, which was further developed to give the final 
compound 6 (ABT-199, Venetoclax) (Figure 1.3). This compound has proved very 
efficacious in the clinic causing tumour lysis within 24 hours of treatment.47  
 
Scheme 1.2 
A number of other FBDD-derived compounds are in stage III clinical trials, of 
particular note is the BACE inhibitor MK-8931, used in the treatment of Alzheimer’s 
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disease. Scientists at Merck/Schering-Plough carried out fragment screening, using 2D 
NMR spectroscopy and structure determination by X-ray crystallography to find 
BACE inhibitors. This approach led to the discovery of thioamidine fragment 7.5,48,49 
Subsequent fragment combination and structure-based drug design led to a series of 
iminothiadiazine dioxide derivatives.48,50 Further work and optimisation led to the 
discovery of Verubecestat (MK-8931) (Scheme 1.3). This compound is one of the 
most advanced BACE1 inhibitors with high selectivity, which limit off-target 
effects.48 The discovery of this inhibitor also highlights the benefits of the alternative 
screening approach offered by fragment-based drug discovery, as this target had 
proved very difficult to work with in conventional high throughput screens.5  
 
Scheme 1.3 
These success stories, as well as numerous others,42 highlight the impact of fragment-
based drug discovery in such a short period of time. 
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1.4 3-Dimensional fragment libraries 
The need to increase molecular complexity and diversity in fragment libraries has 
become more important with the increasing need to explore new areas of chemical 
space and with the desire to investigate more challenging targets. In a report by Chan 
and co-workers, it was highlighted that FBDD was generally focussed on aromatic, 
sp2 rich, planer compounds. These types of molecules can impair the shape diversity 
of the library and hinder the exploration of chemical and pharmaceutical space.36 This 
has led to an interest in more 3-dimensional fragments that can access new areas of 
chemical space. A further benefit to more 3-dimensional fragments was emphasised 
by Young. Nature generally recognises molecules in a 3-dimensional fashion and 
therefore it is intuitive that more 3-dimensional ligands will gain the best interaction 
and broad biological activity.41  
 
With the increasing interest in 3-dimensional fragments, the 3D fragment consortium 
was assembled from several UK not-for-profit drug discovery groups.37 The 
consortium’s aim was to build a shared library of between 300 and 500 fragments, 
which would particularly focus on architecturally diverse fragments. It was noted that 
the “flatness” of current fragments could be responsible for the low success rates with 
certain targets. To highlight this, current fragment libraries and fragments from 
compounds successful in the clinic were compared. Two principal moment of inertia 
(PMI) plots51 for the fragments in current screening libraries and fragments found in 
drug molecules are shown in Figure 1.11. PMI plots are a 2-dimensional way to 
represent 3-dimensional chemical space, where each corner of the graph represents a 
different extreme area of chemical shape; rod (e.g. an alkyne), spherical (e.g. 
adamantane) and disc-like (e.g. benzene).37,41 Further information on PMI plots is 
provided in Section 1.5.5. 
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Figure 1.11: PMI plot (a) shows fragments in current screening libraries, which lie close to 
the rod-disc line. PMI plot (b) shows fragments found in drug molecules which have a much 
larger spread across the plot.51 
 
The PMI plot in Figure 1.11(a) shows the fragments from current screening libraries. 
The points lie close to the rod-disc line, with only a limited spread across the whole 
plot. This is contrasted by the fragments found in drug molecules in the PMI plot in 
Figure 1.11(b). This has a much larger spread across the plot, with a number of 
compounds towards the top right of the plot. This illustrates the need to broaden the 
structural diversity of current fragment libraries.  
 
As discussed, Nature recognises compounds in a 3-dimensional manner, and therefore 
natural products would be an excellent starting point for designing fragment 
compounds. Natural products have played a pivotal role in drug discovery and 
development and these types of compounds often occupy new and different areas of 
chemical space.38,41 For this reason, Waldmann reported a natural-product-derived 
fragment library. This involved the fragmentation of known natural products into 
smaller fragment-like molecules, taking into consideration some of the rules outlined 
earlier such as the “Rule of 3” and elimination of toxic moieties. An example of 
fragment generation form the natural product Renieramycin P is shown in Scheme 
1.4.38  
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Scheme 1.4 
The fragment library generated from this process was found to have high structural 
diversity compared to commercial fragment libraries and was found to occupy a 
considerably different area of chemical space. The library generated also represented 
the starting natural product library well, suggesting that the architectural diversity and 
3-dimensionality desired from the natural products had not been lost.38 
 
A paper entitled “Escape from Flatland” by Lovering draws together the problem of 
2-dimensionality in screening collections and drug compounds and suggests methods 
to analyse and rectify the issue.40  Lovering highlighted that saturation and number of 
stereocentres is an effective method to determine architectural diversity. This was 
exemplified with the isomers of dimethylpyridine and dimethylpiperidine (Figure 
1.12). Dimethylpyridine is a flat, unsaturated aromatic compound and only has a total 
of 6 different isomers. However, the fully saturated dimethylpiperidine allows for 
methyl groups to be placed on the same carbon or on different carbons with cis/trans 
relative stereochemistry and gives an increased number of isomers, 32 in total. 
Examples are shown in Figure 1.12.* 
                                                 
* Lovering incorrectly calculated the number of isomers of both dimethylpyridine (5) and 
dimethylpiperidine (34). 
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Figure 1.12: Comparison of only 6 isomers of dimethylpyridine, a saturated aromatic 
heterocycle and 8 of the possible 32 isomers of dimethylpiperidine, a saturated heterocycle. 
Lovering’s rationale for this increase in saturation was that molecular complexity and 
diverse chemical space can be accessed by compounds without increasing the 
molecular weight significantly, and that saturated compounds already have a greater 
level of 3-dimensionality. Another benefit of increasing saturation and decreasing 
aromatic character is the possible increase in solubility linked to increased saturation, 
a factor that had already been identified as leading to drug attrition. In addition, with 
increased opportunity to install out-of-plane substituents, the possibility of 
receptor/ligand complementarity and some elimination of off-target activity is 
increased.40 
 
Investigating the change in saturation and number of stereocentres across drug 
development processes emphasised the benefit of architectural complexity and 
saturation. It was shown that, from discovery to drug, saturation increased by 31% as 
did the number of stereocentres (by 21%). The complexity of a possible drug 
compound is key to its success and therefore should be an important part of drug 
screening and development.40 
 
Diversity-oriented synthesis has also been identified as a method to increase the 
architectural diversity of compound collections, and was first investigated for HTS 
libraries.40,41 This method was used by Young and co-workers to generate compounds 
with different properties for better biological target interrogation. Ideally, diversity 
oriented synthesis uses short and efficient pathways to obtain structurally and 
physically diverse compounds. Young and co-workers developed the build-couple-
pair algorithm to generate structurally and stereochemically diverse compounds. A 
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stereochemically diverse starting material was obtained, such as 10, which was then 
“coupled” to the same (or different) starting material to give 11. It is at this stage that 
the stereogenicity of the final fragment was installed. In the last stage, the compound 
was “paired”. In this example, intramolecular reaction using ruthenium-catalysed ring-
closing metathesis gave the final, rigid, architecturally-interesting fragment 12. An 
example of this approach is shown in Scheme 1.5. A selection of fragments 
synthesised using the build/couple/pair approach are shown in Figure 1.13.41 
 
Scheme 1.5 
 
 
Figure 1.13: Examples of fragments synthesised using the diversity-oriented synthesis 
build/couple/pair method. 
 
The introduction of more 3-dimensional compounds into screening libraries and the 
methods to do this has received some attention. Not only do these types of compounds 
help to explore new areas of chemical space, but they correlate with more desirable 
properties such as increased solubility, lower lipophilicity and decreased albumin-
binding and cytochrome P450 inhibition.36  Murray and Rees highlighted the need to 
develop the synthesis of 3-dimensional fragments and the significant lack of 
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methodology to functionalise and synthesise small fragments without having to devise 
new routes.27 
 
Despite the significant interest in 3-dimensional fragments and numerous benefits to 
having these compounds in a fragment library, there have been some comments on the 
effectiveness of 3-dimensional fragments and their ability to bind.  Chan and co-
workers reported that binding frequency and selectivity increased on introduction of 
more 3-dimensional sp3-hybridised compounds into the screening collection.36 
However, this is not a result mirrored in other reports. Pickett and colleagues noted 
that an increase in 3-dimensionality could increase the complexity of the fragments 
and, as discussed earlier, this could lead to a lower hit rate as there is more chance of 
mis-match or clashes.37 With an increased structural complexity there is also a reduced 
probability of the shape matching that of the receptor. They noted that in order to take 
advantage of more 3-dimensional fragments, there needs to be a careful balance 
between complexity, size, shape and diversity of fragments.19 Murray and co-workers 
highlighted this point, with a comparison of the similar sized planar and 3-dimensional 
fragments. Functionalised molecules with more shape diversity are obviously more 
complex than a relatively planar undecorated fragment of the same weight. This led 
them to conclude that if more complex and diverse fragments are to be included in 
fragment libraries then they should be smaller in mass than other more 2-dimensional 
fragments in the library, generally with less than 16 heavy atoms.13 
 
Despite the concerns with the added complexity of 3-dimensional fragments, evidence 
suggests that more 3-dimensional fragments are having positive results in drug 
development programmes, such as the success targeting protease β-secretase (BACE). 
There is definitely a need to explore more 3-dimensional areas of pharmaceutical 
space.14,37 
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1.5 3-Dimensional shape analysis of compounds 
As the assessment of the shape of compounds has become increasingly more important 
in medicinal chemistry, a number of methods have been developed to generate and 
analyse the shapes and conformations of compounds. Bender and colleagues 
highlighted the importance of computational analysis in drug design and that 
development of novel computational methods would allow for better and more 
efficient exploration of therapeutically-relevant space.52 It has also been noted that the 
analysis of shape is one way to assess the diversity of a set of compounds.51-53 A 
number of methods have been developed and are discussed below.  
 
1.5.1 Fraction of sp3 centres 
In 2009, Lovering disclosed a new method to assess the molecular complexity of 
compounds by investigating the number of saturated sp3 carbon centres.40 Lovering 
developed this method as a simpler alternative to the method developed by 
Badertscher, which involved a much more mathematically demanding calculation of 
the saturation in a compound. Lovering’s formula is shown in Equation (1). 
𝐹sp3 =
number of sp3hybridised carbons
total carbon count
  (1) 
As part of Lovering’s paper, compounds from development and marketed drugs were 
analysed using a Pipeline Pilot protocol with the ability to calculate the Fsp3. This 
method provided a good indication that compounds closer to market had a higher value 
of Fsp3 and therefore had more molecular complexity.  
 
There have, however, been criticisms of this method. Firth, Brown and Blagg noted 
that Fsp3 poorly characterises whether the sp3 carbon atoms are connected to extended 
vectors out of the main plane (which would offer more varied shape and structure). 
They exemplified this with the comparison of two compounds, 13 and 14, with the 
same Fsp3 but quite different computationally-determined conformations (Figure 
1.14).53 
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Figure 1.14: Comparison of two compounds with the same Fsp3 value (0). 
Both compounds, 13 and 14, have an Fsp3 of zero which suggests that the compound 
should be planer. However, this is clearly not the case for compound 14 which has a 
V-like shape, with the pseudo-sp3 nitrogen substituent coming out below the main 
scaffold. Compound 13 is flat as predicted from the Fsp3 value. This shape difference, 
however, is likely to be predicted by other computational shape analysis methods.53  
 
1.5.2 Rapid Overlay of Chemical Structures (ROCS)  
This method in general assesses the atom-centred overlapping Gaussians and 
calculates the maximal intersection of the volume between molecules and then 
compares molecules based on these molecular shapes. Grant reported this method as 
a further improvement on the simple method of treating a molecule as a set of 
intersecting spheres, with the exposed surface of these spheres giving the boundary of 
molecular volume. Since this method does not take into account the quantum nature 
and the electron charge distribution of molecules, Grant and co-workers developed a 
revised method.54  
 
The revised method involves a Gaussian description of molecular shape, using a 
generalised coalescence theorem to generate molecular volumes, areas and nuclear 
coordinates. This method specifically deals with the electron charge distributions in a 
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simple manner and without the need for complex, computationally demanding 
quantum mechanical calculations.54 These calculations consider the chemical 
similarity and atom types, not just the molecular shape.52 
 
1.5.3 Molecular Globularity 
The term “globularity” or “globular compounds” was first introduced by Timmerman 
in 1954.55 Meyer further developed this term and applied it to a computational analysis 
of compounds in 1986.56 This method of determining shape and size starts with the 
optimisation of geometry and conformation using molecular mechanics. Next, the 
molecule is treated as a solid in space, where spheres are traced around the atomic 
nuclei.56 In this case of globularity measurement, van der Waals radii are used which 
subsequently give the van der Waals volume (Vw) and surface area (Sw). These values 
can then be used to provide a quantitative measure of globularity or deviation from 
sphericity. It can be imagined that branching is likely to change these values away 
from a perfect spherical value. A compound will have the volume Vw, from which the 
radius and surface area can be calculated (Equation (2) and (3)).  
𝑟𝑒,𝑤 = (
3𝑉𝑤
4𝜋
)
1/3
   (2) 
 
𝑆𝑒,𝑤 = 4𝜋𝑟𝑒,𝑤
2~4.836𝑉𝑤
2/3  (3) 
 
For a perfect sphere, the calculated Se,w will be equivalent to the van der Waals surface 
area Sw (Se.w / Sw = 1). Therefore, measuring the ratio of these values (Equation (4)) 
gives a measure of globularity (Gw). 
𝐺𝑤 =  
𝑆𝑒,𝑤
𝑆𝑤
    (4) 
If one axis was to become longer compared to the others, the Sw value will be out of 
proportion to Se,w and the Gw will decrease. 
57 
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1.5.4 Plane of Best Fit (PBF) 
An alternative method for analysing shape has recently been developed by Firth, 
Brown and Blagg.53 This method was expected to deliver quick, unambiguous and 
quantitative characterisation of shape diversity. The method determines the how far 
removed molecules are from a 2-dimensional plane and was termed “plane of best fit” 
(PBF). This involved fitting a plane across the heavy atoms of a molecule and 
subsequently calculating the average of the distance away from this plane of the other 
heavy atoms. In order to carry this out, the conformation of a given compound is 
computationally calculated and the plane fitted to the shape. This is exemplified by 
cyclohexane shown in Figure 1.15.  
 
Figure 1.15: Plane fitted to the lowest energy conformation of cyclohexane. 
It was highlighted in the paper that this analysis was carried out on a single conformer 
of a compound. This is similar to other methods (e.g. PMI analysis), although the 
method is amenable to the analysis of a number of conformations.53 
 
The conformation is generated computationally with salts removed and hydrogens 
omitted. Then, the plane of best fit is calculated using the least squares method from 
the generated coordinates. The plane of best fit is given by Equation (5). 
 
𝐴𝑥 + 𝐵𝑦 + 𝐶𝑧 + 𝐷 = 0  (5) 
 
This equation can then be manipulated to calculate the distance, ∆, of each heavy atom 
away from the plane, which is given by Equation (6). 
∆ =  
|𝐴𝑥𝑖+𝐵𝑦𝑖+𝐶𝑧𝑖+𝐷|
√𝐴2+ 𝐵2+ 𝐶2
   (6) 
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It was noted that the PBF score has a theoretical range of 0 to ∞. However, in general, 
drug-like molecules have a score of less than 2.53 
 
In order to assess the applicability of the method, a number of compound set analyses 
were carried out and compared to other current methods of shape analysis. In general, 
for all of the compound collections, the PBF method was comparable to molecular 
globularity and PMI, but differed significantly from Fsp3. As discussed earlier 
(Section 1.5.1), Fsp3 is not a good descriptor of shape, as the Fsp3 value does not 
determine whether the sp3 centre leads to out of plane shapes. This method is 
comparable to currently employed methods and offers a high-throughput rapid method 
of shape analysis, the only rate-limiting factor being the generation of conformations 
This method also allows comparison of compounds as values are irrespective of 
molecular size as the PBF score is normalised according to the number of heavy 
atoms.53 
 
1.5.5 Principal Moments of Inertia (PMI) 
An alternative method of shape and diversity analysis was developed by Saur and 
Schwarz.51 Initially, they set out to investigate how small multiple-scaffold libraries 
compared to large single-scaffold libraries. A molecular descriptor to help with this 
analysis needed to fulfil three criteria: correlate with and be predictive for biological 
activity, be translatable into chemical structure, and be rapid to calculate. It was 
decided that the molecular shape fitted well with these criteria.51 Generally, compound 
shape can be rationalised and modified if desired and other examples of shape 
calculation exemplify the ability to calculate this property quickly. 
 
Saur and Schwarz proposed that the evaluation of normalised ratios of principal 
moments of inertia would be a suitable method to describe molecular shape.51 In order 
to obtain the normalised principal moments of inertia, a 3-dimensional structure must 
be derived and from this the three principal moments of inertia can be calculated 
computationally using molecular mechanics. These values are sorted into ascending 
size to give I1, I2 and I3. From these values the normalised ratios are obtained (Equation 
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(7)). The two lower values (I1 and I2) are divided by the largest value (I3). By choosing 
to normalise the ratios, the dependence on the size of the compound under analysis is 
eliminated. 
NPR1 =  
I1
I3
  and NPR2 =  
I2
I3
    (7) 
These values can then be plotted easily on a 2-dimensional graph. This graph is 
triangular in shape, where the corners are defined as rod [0,1], disc [0.5,0.5], and 
sphere [1,1]. This is shown in Figure 1.16. 
 
 Figure 1.16: The triangular shaped PMI plot with the three extreme shapes. 
 
As alternative methods for shape and diversity analysis have been developed, the 
methods have been scrutinised and investigated further. Bender and colleagues 
compared PMI to a number of other methods and noted that PMI behaved quite 
differently.52 This could be attributed to this method comparing molecular shapes to 
archetypal shapes, rod, disc and sphere and disregarding size. It was also noted that 
although the shape properties of a chemical library can be analysed using PMI, there 
is generally no correlation of these values with diversity of coverage in bioactivity 
space. It was noted by Bender that compounds binding to different proteins fall in the 
similar areas of chemical space according to their normalised principal moments of 
inertia.52  
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In summary, each of the 3-dimensional shape analysis methods has a number of 
positives and are often quick, rapid and quantitative methods to analyse compound 
shape and assess shape diversity of a compound set. For best results, methods could 
be combined and compared to give the full representation and analysis of compound 
libraries, bearing in mind the use of molecular mechanics to generate conformations 
and structural shapes. More computationally demanding methods may give a more 
realistic representation, but would inevitably be more low-throughput.  
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1.6 Project outline 
This project aims to design, analyse and synthesise 3-dimensional fragments for 
ultimate use in fragment-based drug discovery. Our approach will focus on the use of 
different sized saturated nitrogen heterocycles as a way to introduce structural and 
shape diversity into a fragment library. We hope to demonstrate that architecturally 
interesting, 3-dimensional fragments can be obtained from such simple building 
blocks. Saturated scaffolds are generally more 3-dimensional and offer access to 
different binding vectors and globular shapes. These also offer more complexity than 
the aromatic counterpart for only a small increase in molecular weight.36 The 
prevalence of saturated nitrogen heterocycles in current drug molecules was 
highlighted by Chan, with 5- and 6-membered rings being the most common. 
Piperidine is the second most frequently found saturated heterocycle with pyrrolidine 
coming fifth.36 A report by Lawson also highlighted that piperidine was the third most 
common ring, after benzene and pyridine in FDA-approved small molecule drugs.58 
Therefore, pyrrolidine, piperidine and azepane scaffolds will be investigated. 
 
We decided that our three different heterocycles would be substituted with two 
different substituents: methyl/hydroxymethyl and methyl/methyl ester. The 
hydroxymethyl and ester groups offer a handle for further functionalisation as well as 
hydrogen bonding capabilities. The methyl group is commonly used in medicinal 
chemistry; it can alter the lipophilicity and solubility as well as bioavailability and 
metabolism of a drug molecule59 and appears in 67% of the top selling drugs of 2011.60 
This will give us six different libraries as shown in Figure 1.17. To offer more variation 
in our fragments, the nitrogen will be functionalised in four different ways: NH, NMe, 
NC(O)Me (amide) and NSO2Me (sulfonamide). 
 
Figure 1.17: The different scaffolds with hydroxymethyl and ester substituents, where R is 
NH, NMe, NC(O)Me (amide) and NSO2Me (sulfonamide). 
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Our plan was to use shape analysis to assess the shape diversity of all of the 
enumerated isomers (not including enantiomers) of these six different scaffolds. In 
order to carry out unbiased and efficient shape analysis a computational method will 
be developed. Principal moments of inertia (PMI) plots will be used to assess shape 
diversity and develop criteria to select compounds that focus on the under-represented, 
3-dimensional area of chemical space. The results of our efforts in this area are 
described in Chapter 2.  
 
The compounds identified by the selection criteria will form six sub-set libraries. We 
will focus on the synthesis of the hydroxymethyl piperidine sub-set fragments (Figure 
1.18). The synthesis will be carefully designed so as to minimise the number of 
different routes used to obtain all the fragments. It will also be important to ensure that 
within these routes the number of steps to access the final fragments are minimised 
and it is hoped that methodology allowing the flexible installation of different groups 
will be used. Our synthetic efforts on 3-dimensional fragment synthesis are discussed 
in Chapter 3. 
 
Figure 1.18: Some of the hydroxymethyl piperidine fragments 
In addition, we also briefly explored the use of shape analysis to characterise the 3-
dimensional shape diversity of a virtual lead-like library generated from compounds 
accessible using O’Brien group lithiation methodology. This is described in Chapter 
4. 
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Chapter 2:  Design, Analysis and Selection of 3-Dimensional 
Fragments 
Design and assessment of fragments are both fundamental to building a diverse and 
useful fragment library.  In our planned project, it is key to ascertain how 3-
dimensional and structurally diverse a set of compounds are in order to select suitable 
compounds for synthesis. As discussed in Section 1.5.5, the area of 3-dimensional 
chemical space covered by a compound library can be assessed using a PMI plot.41,61 
In order to do this, the different conformations of a compound are generated and 
energies for each are calculated computationally. These can then be normalised and 
the lowest energy conformations plotted on a PMI plot. All the isomers (not including 
enantiomers) of six different scaffolds Figure 2.1 were enumerated and functionalised 
with four different nitrogen substituents (Figure 2.1).  
 
Figure 2.1: The six different scaffolds and nitrogen substituents. 
These compounds were then computationally analysed and the conformations 
generated. We describe the development of the computational protocol using the 
hydroxymethyl piperidine library in Section 2.1 – 2.4. The use of the PMI plots to 
generate selection criteria is also described and these criteria are used to analyse the 
other scaffolds (Section 2.5). The analysis, selection of sub-set libraries and 
combination to give a fragment library focussed on the under-represented, 3-
dimensional area of the PMI plot is also described in Section 2.5.  
 
Once the computational protocol had been developed the physicochemical properties 
of our selected fragments were analysed and this is presented in Section 2.6. The 
comparison of our selected fragments to a commercial library is described in Section 
2.7.  
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2.1 Enumeration of hydroxymethyl piperidine scaffold 
To start, we decided to investigate the design, analysis and selection of fragments 
approach with a disubstituted piperidine scaffold. Disubstituted piperidines bearing 
two different substituents, methyl and hydroxymethyl, provide a total of 23 isomers 
(excluding enantiomers). In order to create interesting fragments and architectural 
diversity, the nitrogen was functionalised in four different ways: NH, NMe, NC(O)Me 
and NSO2Me. These groups offer a variety of properties, such as hydrogen bonding 
capabilities, give different shapes and offer a different hybridisation of the nitrogen 
(sp2 versus sp3) and it is expected that they have suitable fragment-like 
physicochemical properties. This gives a total of 92 different compounds. All of the 
23 different isomers are shown in Figure 2.2.  
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Figure 2.2: All 23 different isomers of disubstituted piperidine. The four different nitrogen 
substituents are also shown. 
We propose that it is not necessary to synthesise all of the 92 possible fragments. 
Therefore, a sub-set library will be selected. This will have a fraction of the original 
92 fragments and will focus on more spherical shapes and the under-represented 3-
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dimensional area of the PMI plot. PMI data on the 92-member library was generated 
and subsequently analysed to select suitable compounds. The importance of an 
unbiased, efficient and unlimited analysis led to the development of a computational 
approach to this analysis.  
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2.2 Introduction to the computational protocol 
Conformation generation and PMI data were obtained through a collaboration with 
Rod Hubbard and Paul Bond at York Structural Biology Laboratory.62 Paul Bond 
provided the initial Pipeline Pilot protocol from which I obtained the data, this data 
was analysed, if issues or development was needed this was fed back to Paul Bond 
and a new iteration of the protocol was produced with my input. Data was obtained 
and tested again and the process repeated until the protocol gave satisfactory data. 
Conformer generation used Pipeline Pilot 8.5 (see Section 6.1 for further details). The 
BEST algorithm was used to generate conformers as this algorithm ensures the best 
coverage of conformational space. During conformation generation, constraints can 
be applied to reduce the number of conformers generated. Two of these constraints are 
the conformational energy difference and the RMSD. The conformational energy 
difference gives the difference in energy between each conformer and the lowest 
energy conformer of that particular compound. Therefore, the larger this number the 
more conformers that will be generated. The RMSD indicates the difference in Å 
between atoms, or points of a conformer and the standard. If the RMSD is 0 Å, a 
conformer that only varies slightly from the standard will be kept, whereas if the 
RMSD is 1 Å, only very different conformers will be kept. Hence, the larger the 
RMSD, the fewer conformers that will be selected.  
 
The influence of these constraints was investigated in more detail. It was decided to 
select the two different energy cut offs of 7.0 and 20.0 kcal mol-1 and three different 
values of RMSD to give a range in the amount of conformers that would be generated. 
Table 2.1 shows how the number of conformations generated were affected by the 
constraints. All of the 92 compounds Fr1 – Fr92 were analysed, with all possible 
conformations generated within the constraints. The conformations were generated 
without an implicit solvent model, under vacuum conditions (See Section 6.1 for 
further details). 
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Entry 
Conformational energy  
difference / kcal mol-1 
RMSD / Å 
Total number of  
conformations 
1 20.0 1.0 589 
2 20.0 0.5 1740 
3 20.0 0.0 2609 
4 7.0 1.0 279 
5 7.0 0.5 533 
6 7.0 0.0 702 
Table 2.1: Data for each conformer generation run and the total number of conformers 
generated from the analysis of the 92 piperidine fragments Fr1 – Fr92. 
As can be seen in Table 2.1, changing the conformational energy difference and 
RMSD constraints significantly affects the number of conformers generated from the 
92 fragments. The largest number of conformers was generated when the 
conformational energy difference cut off was 20.0 kcal mol-1 and the RMSD 0.0 Å 
(Entry 3). This was to be expected, as no restrictions had been applied. It can be seen, 
also as expected, that the largest RMSD gave the fewest number of conformers 
(Entries 1 and 4), and that having a conformational energy difference cut off of 7.0 
kcal mol-1 (Entries 4 to 6) reduced the number in comparison to the 20.0 kcal mol-1 
cut off (Entries 1 to 3). The number of conformers generated by not applying 
constraints still gives a manageable data set size, especially for use with computational 
analysis. Therefore, further analysis of different scaffolds used a protocol with no 
constraints. 
 
After initial exploration of the protocol and constraints, the protocol was further 
optimised to give the best conformational data. This was to ensure that conformations 
were generated in the most relevant model system. For example, the system calculated 
the conformations with an approximation for solvation. All conformations of each of 
the 92 piperidine fragments Fr1 – Fr92 were generated using the BEST algorithm 
with no RMSD or energy constraints. This gave a total number of 2848 conformations. 
It was this version of the protocol and data that was used for further analysis.  
 
PMI plots in the current literature generally show just the lowest energy conformer of 
a given compound.37,63 However, the protocol generates numerous different energy 
conformations of a given compound. The generation of all conformations can offer a 
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good insight into how the 3-dimensionality of a given compound can vary due to 
different conformations. This information can then be used to give the library 3-
dimensional conformational diversity as well as architectural diversity. This is 
exemplified in Figure 2.3, where the lowest energy conformations of each of the 
piperidine fragments Fr1 – Fr92 in the 92-member library (Figure 2.3 (a)) is compared 
to the PMI plot of all the different conformers for the 92-member library (Figure 2.3 
(b)). It is clear that there is a much larger spread across the plot by investigating the 
different conformations.  
 
Colour        
Conformational 
energy difference / 
kcal mol-1 
< 1 < 2 < 3 < 4 < 5 < 6 < 7 
Figure 2.3: (a) PMI plot of the lowest energy conformer for all piperidine fragments Fr1 – 
Fr92. There is a good spread across the plot, but conformations are weighted towards the 
rod-disc axis. b) PMI plot of all the conformations (with a conformational energy difference 
of less than 7.0 kcal mol-1) for all piperidine fragments Fr1 – Fr92. This shows a good 
coverage of all of the plot, with a number of conformers in the top right, more spherical area 
of the plot, there will be however a number of high energy conformations that might not be 
truly accessible.  
The PMI plot with all the conformations seemed a suitable starting point for analysis 
and selection of compounds for a smaller sub-set library. Our plan was to use Figure 
2.3 (b) and devise selection rules, so that conformations in the under-represented area 
of 3-dimensional space in the PMI plot were prioritised. It was hoped that the selected 
compounds will have 3-dimensional and conformational diversity and would be 
focussed away from the rod-disc axis.  
 
The large number of data points on the PMI plot in Figure 2.3 (b) meant that a method 
to segment the plot was required. We chose to divide the plot into 10 areas, using 
(a) (b) 
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diagonal lines as shown in Figure 2.4. The position of each conformer on the plot is 
determined by the npr1 and npr2 values, which are effectively the (x,y) coordinates, 
obtained from the normalisation of the 3-dimensional axis coordinates of a 
compound’s conformation. The number of conformers in each area or “category” can 
easily be determined computationally. The more spherical, or 3-dimensional 
compounds will be in the lowest value category (e.g. 1 or 2).  
 
 
 
 
 
 
 
 
Figure 2.4: PMI plot showing the 10 different categories. 
The 2848 conformations of the piperidine fragments Fr1 – Fr92 shown in Figure 2.3 
(b) was analysed further to determine the spread of conformers across the plot. These 
results are shown in Table 2.2 and Figure 2.5.  
 
 
 
 
 
 
 
 
10   9   8    7    6     5     4     3    2     1 
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Conformational 
energy difference / 
kcal mol-1 
RMSD / 
Å 
PMI Category 
1 2 3 4 5 6 7 8 9 10 
20.0 0.0 0 0 0 8 41 172 336 904 1150 237 
Table 2.2: The total number of conformers in each PMI category for the 2848 conforations 
generated for all of the 92 piperidine fragmetns Fr1 – Fr92. 
 
Figure 2.5: Graph showing the number of conformers in each of the PMI categories 1 to 10.  
 
Figure 2.5 clearly shows that the spread of conformers varies across the plot. The most 
spherical area of the plot, categories 1–3, contains no conformers, but there are some 
in category 4 and increasing numbers in categories 5 and 6. The most interesting result 
is that there are relatively few conformers in category 10. This is the area closest to 
the rod-disc line of a PMI plot and is associated with very flat molecules. This result 
indicates that the conformations of the compounds in this data set have a high degree 
of 3-dimensionality. This clearly shows that it is possible to obtain shape diversity 
from very simple scaffolds.  
 
It was our intention that the selection of compounds for the sub-set library would be 
based on the position of the conformations on the PMI plot and the energy of each of 
these conformations. Analysis of all of the 2848 conformations was carried out to 
investigate the spread of conformational energy differences across the different 
categories of the PMI plot. The conformational energy difference gives the difference 
in energy between each conformer and the lowest energy conformer, for a given 
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fragment. Two analyses were carried out. Firstly, the energy levels were divided into 
1.0 kcal mol-1 groups (Table 2.3) and secondly, the lowest energy levels were split 
into 0.5 kcal mol-1 groups (Table 2.4). 
PMI Category 
Conformational Energy Difference / kcal mol-1 
0 - 1 1 - 2 2 - 3 3 - 4 4 - 5 5 - 6 6 - 7 7-20 
4 1 0 1 1 1 1 0 3 
5 3 3 0 4 4 8 5 14 
6 15 9 20 23 21 19 11 54 
7 20 13 29 34 23 33 30 154 
8 48 46 70 66 64 78 103 429 
9 135 103 103 62 67 114 134 432 
10 52 23 18 20 22 21 22 59 
Total 274 197 241 210 202 274 305 1145 
Table 2.3: Data showing the distribution of conformers by PMI category and conformational 
energy. 
PMI Category 
Conformational Energy Difference / kcal mol-1 
<0.5 0.5 – 1.0 1.0 – 1.5 1.5 – 2.0 2.0 – 2.5 
4 1 0 0 0 0 
5 3 0 1 2 0 
6 10 5 5 4 9 
7 13 7 7 6 10 
8 31 17 17 29 46 
Total 58 29 30 41 65 
Table 2.4: Data showing the distribution of conformers by PMI category and conformational 
energy. 
The lower conformational energy difference values 0-2.5 kcal mol-1 were split into 0.5 
kcal mol-1 groups as these energy differences will give the most energetically 
accessible conformations. This is exemplified with the two conformations of 
disubstituted piperidine Fr16. The lowest energy conformation of Fr16 (Figure 2.6 
(a)) has a chair conformation with an axial methyl group and an equatorial 
hydroxymethyl group. In contrast, the conformation with an energy difference of 11.1 
kcal mol-1 (Figure 2.6 (b)) has a twisted 6-membered ring, producing unfavourable 
interactions. 
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Figure 2.6: Comparison of two different conformations of the same piperidine Fr16. 
 
From the data in Table 2.3 and Table 2.4, it is possible to see that there are a large 
number of conformers with a low conformational energy difference. It is also clear 
that in the more 3-dimensional areas of the PMI plot (PMI categories 4, 5 and 6), the 
conformations generally have a lower conformational energy difference. This is a 
promising result, suggesting that these more 3-dimensional conformations are 
accessible.  
 
In order to select a suitable subset focussed on the under-represented area of the PMI 
plot, with suitable conformational energy difference, the data set was analysed further. 
The number of compounds at a given conformational energy difference and PMI 
category are shown in Figure 2.7. The number of compounds is given by the size of 
the graph point (numbers adjacent). As we were aiming to select between 20 and 30 
compounds for the sub-set, this graph provides a useful insight into the factors that 
govern the selection of a suitable number. The trade-off between conformational 
energy difference and PMI category can clearly be seen in Figure 2.7.  
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Figure 2.7: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories.  
As expected, the higher the conformational energy cut off and the more PMI categories 
included then the higher the number of compounds that would be selected. Likewise, 
the lower the conformational energy cut off, and the fewer PMI categories chosen, 
then the lower the number of compounds that would be selected. In order to obtain a 
suitable number of compounds, there has to be a balance between the energy cut off 
and PMI category cut off. For a large spread across the plot (e.g. all PMI categories), 
the energy cut off must be low, otherwise the number of compounds becomes too 
large. However, the energy cut off should not be so low as to eliminate compounds 
that might have conformers with accessible energies. This is best exemplified with an 
example: if the PMI category goes up to 8 and the conformational energy difference 
is 1.0 kcal mol-1, 48 compounds would be identified; this is over half the number of 
starting compounds. Similarly, when the PMI category is reduced to 3, 4, 5 and 6 and 
the conformational energy difference cut off is at 4.0 kcal mol-1, 35 compounds would 
be identified. Both are beyond our target numbers for the sub-set library. The most 
promising results comes from the area around a conformational energy cut off of 
between 1.0 and 2.0 kcal mol-1 and selecting compounds from categories 1-6 and 1-7. 
We planned that the number of different isomers selected would be no more than 15 
out of the possible 23. Therefore, closer analysis of conformers with an energy of less 
than 1.5 kcal mol-1 in PMI category 7 was undertaken. As with the plot as a whole, 
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PMI category 7 can be further segmented into 10 smaller categories. The number of 
conformations, compounds and isomers given in each of these sub-categories is shown 
in Table 2.5.  
Entry 
Energy / 
kcal mol-1 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 25 17 11 
2 < 1.5 1 to 6.1 26 18 11 
3 < 1.5 1 to 6.2 26 18 11 
4 < 1.5 1 to 6.3 32 22 14 
5 < 1.5 1 to 6.4 38 26 14 
6 < 1.5 1 to 6.5 41 27 14 
7 < 1.5 1 to 6.6 46 30 15 
Table 2.5: Analysis of the library between PMI cateogories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
From Table 2.5, we can see that the most suitable number of compounds and isomers 
would be obtained by selecting from categories 1 to 6.3 (Entry 4). It was our plan that 
the 22 compounds selected would form the sub-set library of compounds. The 
compound numbers of these 22 compounds can now be associated with the structure, 
which to this point has remained anonymous. The structures of the 22 selected 
compounds for the sub-set library (out of the starting 92) are shown in Figure 2.8.  
 
47 
 
 
Figure 2.8: The 22 selected compounds, shown as 14 isomers. The R groups are shown 
where one isomer has different nitrogen functionalisation. 
The selected 22 compounds have at least one low energy conformer (conformational 
energy difference < 1.5 kcal mol-1) in the top right of the PMI plot (PMI categories 3, 
4, 5 and 6), and are therefore appropriate to explore as 3-dimensional fragments. 
Although the compounds were selected based on conformations at the top right of the 
PMI plot, it is likely that the compounds will also have conformations that fall in 
categories outside 3 to 6 and this can be considered a bonus. Therefore, all of the 
conformers that have a conformational energy difference of <1.5 kcal mol-1 for the 
selected 22 compounds are shown in Figure 2.9(a). For comparison, the conformers 
of all the 92-member library compounds with energy <1.5 kcal mol-1 are shown in 
Figure 2.9(b). Figure 2.9 (b) has 386 conformers for the 92 compounds and is 
effectively the PMI plot that was used to select the fragments. The conformations in 
Figure 2.9 (b) are weighted towards the rod-disc axis, whereas the selected compounds 
(Figure 2.9 (a)) have a higher percentage of conformers in the more interesting, under-
represented, 3-dimensional area of the PMI plot.  
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Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.9: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 22 
final compounds. This is contrasted by PMI (b), which shows conformers with an energy of 
less 1.5 kcal mol-1 for all 92 starting compounds. There are a total of 386 conformers on PMI 
(b), compared to 76 conformers on PMI (a).  
It may be concluded that the compounds selected for the sub-set library are focussed 
on the more interesting 3-dimensional area of the plot and access under-represented 
areas of fragment chemical space. These conformers are low in conformational energy 
difference and are therefore expected to be readily accessible.  
 
 
 
 
 
 
 
 
 
 
(a) (b) 
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2.3 “Enantiomer problem” 
In carrying out further analysis of the piperidine hydroxymethyl fragments, an 
unexpected anomaly between different enantiomers of some of the compounds was 
noted from the output of data from Pipeline Pilot. It was found that, for some 
compounds, if the enantiomers of a given disubstituted piperidine fragment were input 
and analysed, the conformations generated computationally were not the same. As a 
result the different enantiomers had different positions on the PMI plot. This was not 
expected as different enantiomers should have mirror image conformations and would 
therefore give the same PMI result. These difference are presented in more detail 
below.  
 
At this point, it was decided that a systematic approach to drawing the compounds 
should be formulated as this would help comparisons between different systems. 
These guidelines are detailed below. 
 The group with lowest priority (R1) is drawn “up”. 
 The “up” wedge gets larger away from the molecule, the “down” wedge gets 
smaller away from the molecule. 
 Nitrogen substituent order is always NH, NMe, NSO2Me and NC(O)Me. 
 Any geminal disubstituted fragments come first. 
 Start with lowest priority group (R1) in the 2-position, and R2 opposite. 
 The diastereomer order is always trans then cis.  
 R2 then moves around the ring to the position of R1. 
 Then move R1 to the 3-position and then repeat.  
 Continue until all isomers are drawn. 
 Different scaffolds will have a new letter assigned to the name and 
enantiomers, where required, will be defined as (a) for R1 = “up” and (b) for 
R1 = “down”. 
These guidelines also help to ensure investigation of all isomers and aims to avoid 
error. The newly drawn isomers are shown in Figure 2.10. It must be noted that the 
fragments described in Section 2.2 have a different numbering system. From here 
onwards, the new numbering system will be adopted.  
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Figure 2.10: All 23 isomers of piperidine hydroxymethyl fragments drawn using the new 
guidelines, where the methyl group is “up”. 
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The guidelines were then repeated to give the enantiomers of the 92-compounds, in 
which R1 was drawn in the “down” position. Separate conformer generation and PMI 
analysis were carried out on the two sets of enantiomers (Me “up” and Me “down”). 
Initial analysis considered the difference in conformations generated for the whole set 
(Table 2.6) and how this varied across the PMI plot.  
 Data Set 
PMI Category 
Total 
1 2 3 4 5 6 7 8 9 10 
1 Me “up” 0 0 0 6 44 180 326 889 1155 240 2840 
2 
Me 
“down” 
0 0 0 8 33 168 351 900 1110 218 2788 
Table 2.6: Number of conformers in each of the PMI categories for the two different 
hydroxymethyl piperidine enantiomer data sets.  
From Table 2.6, it can be seen that there is a noticeable difference in the two different 
data sets and the total number of conformations generated for each 92-member library. 
It is also clear that there is a variation in the spread of the conformations across the 
plot. For a more simple comparison, the lowest energy conformations are shown 
plotted on a PMI plot (Figure 2.11). Figure 2.11 (a) shows the R1 = “up” data set, 
Figure 2.11  (b) shows the R1 = “down” data set and Figure 2.11 (c) shows the two 
different data sets overlaid.  
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Figure 2.11: Three different PMI plots showing the two different enantiomer data sets (R1 = 
“up” (a) and R1 = “down” (b)). The two enantiomer data sets are overlaid in (c), R1 = 
“down” blue. All plots show the lowest energy conformer.  
The results in Figure 2.11 show how some data points have very similar PMI positions 
and others are significantly different. Some of the most significantly different pairs of 
enantiomers are shown in Figure 2.12. Unfortunately, the observation of difference 
between enantiomers is quite random, and no real correlation could be worked out.  
 
 
 
 
(a) (b) 
(c) 
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Figure 2.12: Some of the compounds where the calculated conformations of enantiomers are 
significantly different. 
At this point, we had to decide how to treat the “enantiomer problem”. In the end, we 
decided that each enantiomeric data set should be fully evaluated in the way described 
previously and then the results of the two sub-sets could be combined to identify the 
final sub-set of compounds. This was considered the best approach as the drawn 
structures in the previously described approach effectively had “mixtures” of the two 
enantiomeric series.  
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The number of compounds that would be selected at each of the conformational energy 
difference cut offs was analysed for the R1 = “up” data set. This is summarised in 
Figure 2.13.  There is a trade-off between conformational energy difference and PMI 
category. The most suitable number of compounds would be selected from a 
conformational energy difference of <1.5 kcal mol-1 and between PMI categories 6 
and 7. Further analysis of PMI category 6 and the number of conformers, compounds 
and isomers obtained is given in Table 2.7.  
 
Figure 2.13: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories. 
Entry 
Energy / kcal 
mol-1 
PMI 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 23 17 11 
2 < 1.5 1 to 6.1 24 18 11 
3 < 1.5 1 to 6.2 24 18 11 
4 < 1.5 1 to 6.3 30 22 14 
5 < 1.5 1 to 6.4 37 26 14 
Table 2.7: Analysis of the library between PMI categories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
The same analysis was then carried out on the R1 = “down” data set. The number of 
compounds selected at each of the conformational energy difference cut offs was 
analysed and are shown in Figure 2.14. As with the R1 = “up” data set, there is a trade-
off between conformational energy difference and PMI category. The most suitable 
number of compounds would be selected from a conformational energy difference of 
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<1.5 kcal mol-1 and between PMI categories 6 and 7. Further analysis of PMI category 
6 is given in Table 2.8.  
 
Figure 2.14: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories. 
Entry 
Energy / kcal 
mol-1 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 27 18 11 
2 < 1.5 1 to 6.1 29 19 11 
3 < 1.5 1 to 6.2 32 20 12 
4 < 1.5 1 to 6.3 37 24 15 
5 < 1.5 1 to 6.4 39 25 15 
Table 2.8: Analysis of the library between PMI cateogories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
Comparing data sets for the enantiomeric pairs of the 92 compounds and information 
in Table 2.7 and Table 2.8, it can be seen that the number of conformers, compounds 
and isomers differ for the two different enantiomer data sets. However, these 
differences are not that significant when we analysed the compounds and isomers that 
were selected. The compound numbers for the compounds that would be selected from 
an energy <1.5 kcal mol-1 and up to 6.2 PMI category are detailed in Table 2.9.  
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 Data set Selected Compound Numbers 
1 
Me 
“up” 
1 2 5 6 9  19  25 26 38 40 41 42 53 65 66 71 72 89 
2 
Me 
“down” 
1 2 5 6 9 16 19 20 25 26 38 40 41 42 53 65 66 71 72 89 
3 Isomer 1 2 3 4 5 7 10 11 14 17 18 23 
Table 2.9: Fragments selected from the individual analysis of both enantiomer data sets, with 
the relevant isomer number. 
There is little difference in the compounds selected from each data set, with only two 
variations in compounds and only one variation in isomer. As this difference is small, 
it was decided that the two compound selections could be combined to give the final 
compound sub-set. The structures of these compounds are shown in Figure 2.15.  
 
Figure 2.15: The 20 fragment selected sub-set, combined from both enantiomer data set 
analyses. 
The PMI plot with the selected 20 compounds was generated. This plot includes the 
two different enantiomer data set points and shows 121 conformations covering the 
whole of the PMI plot (Figure 2.16 (a)). This can be compared to the PMI plot showing 
the 777 conformers of both enantiomers of all 92 compounds, with a conformational 
energy difference of < 1.5 kcal mol-1 (Figure 2.16 (b)).  
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Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.16: PMI (a), shows conformers with an energy of < 1.5 kcal mol-1 for all 20 
selected fragments. This is contrasted by PMI (b), which shows conformers with an energy 
of less 1.5 kcal mol-1 for both enantiomer conformers for all 92 starting compounds.  
This comparison shows that the new sub-set compounds compares well to the original 
92-member library. There is a good spread of conformations across the plot with focus 
on the more 3-dimensional area of the plot. There are a large number of conformers 
with a low energy conformational energy difference which suggests a large number of 
accessible conformations. There are a range of different compounds and isomers 
which give the sub-set library architectural and conformational diversity.  
 
 
 
 
 
 
 
 
(a) (b) 
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2.4 New protocol analysis: overview of selection process and results 
Due to the “enantiomer problem” observed in the previous analysis, the protocol was 
further developed with the aim to reduce or eradicate any further issues. In particular 
this would remove the need to analyse two sets of data separately and combine them. 
The protocol was developed to calculate the mirror image of the input compound and 
run both data sets through the program and then combine both data sets at the end, see 
Section 6.1.4. The 92 compounds, as drawn in Section 2.3, were passed through this 
new protocol. The data generated from these compounds was then analysed in the 
same way as previously described. A PMI plot of the 92 lowest energy conformations 
is shown in Figure 2.17.  
 
Figure 2.17: PMI plot showing the lowest energy conformations of the hydroxymethyl 
piperidine fragments generated using the new protocol. 
All the conformations generated were then analysed to determine the spread of 
conformers across the plot and the energy of these conformers was analysed (Table 
2.10). 
PMI Category 
Conformational Energy Difference / kcal mol-1 
0 - 1 1 - 2 2 - 3 3 - 4 4 - 5 5 - 6 6 - 7 7-20 
4 1 0 0 1 1 1 0 3 
5 3 3 1 5 4 10 3 15 
6 16 8 12 26 23 21 14 58 
7 16 15 30 28 29 44 37 173 
8 41 42 60 64 76 88 119 481 
9 130 114 96 79 75 128 158 471 
10 49 20 14 22 21 22 25 63 
Total 256 202 213 225 229 314 356 1264 
Table 2.10: Table showing the number of conformers in each PMI category and their 
conformational energy differences. 
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The total number of conformers in each of the PMI categories are shown in Table 2.11 
below. The enantiomer data set for Me “down” is also presented. This data set was 
analysed to confirm that there was no difference in enantiomers with the new protocol.  
 Data Set 
PMI Category 
Total 
1 2 3 4 5 6 7 8 9 10 
1 Me “up” 0 0 0 7 44 178 372 971 1251 236 3059 
2 
Me 
“down” 
0 0 0 7 44 178 372 971 1251 236 3059 
Table 2.11: Comparison of the number of conformers in each PMI category for both 
enantiomer data sets, there is clearly no difference between enantiomers. 
The data showed the same general trend as the previous analysis in the spread of 
conformers across the plot with an increasing number in 4, 5 and 6. There are a large 
number of conformers in category 9, but a significant drop off in category 10, 
suggesting that there are a few conformers that have a more rod/disc like shape. This 
shows that the 92-member library has shape diversity. Information in Table 2.10 
shows that the conformers in more 3-dimensional areas of the plot (PMI categories 
4,5,6) have low conformational energy differences which suggest that these more 3-
dimensional conformations are accessible.  
 
As with previous iterations, the number of compounds selected based on 
conformational energy difference and position on the PMI plot was analysed. This is 
shown in Figure 2.18. The most suitable number of compounds for the sub-set library 
are obtained from a conformational energy difference of < 1.5 kcal mol-1 and between 
category 6 and 7. Further analysis of this is shown in Table 2.12.  
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Figure 2.18: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories. 
Entry 
Energy / kcal 
mol-1 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 26 18 11 
2 < 1.5 1 to 6.1 27 19 11 
3 < 1.5 1 to 6.2 27 19 11 
4 < 1.5 1 to 6.3 33 23 14 
5 < 1.5 1 to 6.4 37 24 14 
Table 2.12: Analysis of the library between PMI cateogories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
The data in Table 2.12 shows that as with the previous analysis (Section 2.3), the most 
suitable number of compounds and isomers for the sub-set library is given by 
categories 1 to 6.2. With the new protocol, 19 compounds would be selected and the 
compound numbers for these are given in Table 2.13 (“New”). These can be compared 
to the compounds selected from the previous iteration, labelled “Old”. 
 Data set Selected Compound Numbers 
1 New 1 2 5 6 9  19 20 25 26 38 40 41 42 53 65 66 71 72 89 
2 Old 1 2 5 6 9 16 19 20 25 26 38 40 41 42 53 65 66 71 72 89 
3 Isomer 1 2 3 4 5 7 10 11 14 17 18 23 
Table 2.13: The fragment number for the selected sub-set of fragments compared to the 
fragments selected in the previous analysis; there is only one compound different. 
It can be seen that the new sub-set only varies by one compound, A16. This is ideal as 
synthesis of some of the original sub-set had already been started (See Chapter 3 for 
fragment synthesis). It is these 19 compounds that represent the final selection of 
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compounds for the hydroxymethyl piperidine library sub-set. The structures of these 
19 compounds are shown in Figure 2.19.  
 
Figure 2.19: The selected hydroxymethyl piperidine19 fragment sub-set. 
The PMI plot showing all the conformers of these 19 compounds with a 
conformational energy difference of < 1.5 kcal mol-1 is shown in Figure 2.20 (a). This 
can be compared to the PMI plot of the original 92-member library (Figure 2.20 (b)). 
This again shows that the selected sub-set of compounds focusses on the under-
represented, 3-dimensional area of the plot, with less conformations falling close to 
the rod-disc axis which is more heavily weighted in the original 92-member library. 
These plots show that the hydroxymethyl piperidine scaffold produce a fragment 
library with interesting shape and conformational diversity. 
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Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.20: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 19 
selected fragments. This is contrasted by PMI (b), which shows conformers with an energy 
of less 1.5 kcal mol-1 for all 92 starting compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
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2.5 Computational selection from different scaffolds and substituents 
As the Pipeline Pilot protocol had now been optimised and the analysis investigated 
with the hydroxymethyl piperidine library, it is possible to summarise the process and 
apply this method to different scaffolds and substituents. The steps for the analysis are 
as follows: 
 All fragments are drawn according to the rules defined in Section 2.3. 
 The structures are converted into SMILES strings.  
 The SMILES strings are input into the new Pipeline Pilot protocol to generate 
conformations with an energy up to 20 kcal mol-1 and an RMSD cut off of 0.1. 
 All the conformations are analysed for the number of conformers in each PMI 
category at different conformational energy cut offs.  
 All the conformations are then analysed to determine the number of 
compounds selected at different PMI category cut offs and conformational 
energy cut offs.  
 The conformational energy difference cut off will always be < 1.5 kcal mol-1, 
but the PMI category may vary, therefore the number of conformers, 
compounds and isomers are selected at different PMI categories are analysed 
further. 
 The most suitable number of compounds and isomers for the sub-set library is 
selected and the compound numbers are associated with the structures.  
 A PMI plot of these selected compounds is then generated.  
This method of compound analysis and sub-set selection was then applied to a number 
of different nitrogen heterocycles with varying substituents.  
2.5.1 Methyl ester, methyl-disubstituted piperidine library 
Firstly, the closely related methyl and methyl ester disubstituted piperidine was 
analysed. The similarity in the substituents of the ester and hydroxymethyl could make 
synthesis of selected compounds simpler, as simple reduction of the ester would 
provide the hydroxymethyl group. The 92 different compounds provided from the 23 
different isomers of the disubstituted piperidine were drawn based on the guidelines 
set out previously (Section 2.3) and are shown in Figure 2.21.  
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Figure 2.21: The 23 different isomers of ester, methyl disubstituted piperidine. The four 
different nitrogen substituents are also shown. 
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These 92 compounds were then subjected to the standard analysis. The PMI plot of 
the lowest energy conformers of the 92 compounds is shown in Figure 2.22. There is 
a relatively small spread of conformers across the PMI plot and most lie towards the 
rod-disc axis compared to the hydroxymethyl piperidine library (See Figure 2.16). 
This is perhaps surprising given that they look like they should be 3-dimensional in 
shape.  
 
Figure 2.22: PMI plot of the lowest energy conformations of the 92 ester piperidine 
fragments. 
As with the previous analyses, all the conformations generated for the 92 compounds 
were analysed to determine the spread of conformers across the different PMI 
categories and their relative conformational energies was analysed (Table 2.14).  
Category 
Conformational Energy Difference / kcal mol-1 
Total 
1 2 3 4 5 6 7 8 
3 0 0 0 0 0 0 0 1 1 
4 0 0 0 0 1 0 0 2 3 
5 1 0 2 1 5 8 4 25 46 
6 15 6 13 10 16 18 30 105 213 
7 38 16 24 29 49 49 73 430 708 
8 115 79 68 73 92 146 179 905 1657 
9 276 107 104 67 100 163 195 692 1704 
10 88 17 25 18 15 13 17 48 241 
Total 533 225 236 198 278 397 498 2208 4573 
Table 2.14: Table showing the number of conformers in each PMI category and their 
conformational energy differences. 
These data show that there is a similar trend to that seen for the hydroxymethyl 
piperidine library. There are no conformers in the most spherical area of the PMI plot 
(PMI categories 1 to 3), but some in the 3-dimensional categories 3, 4, 5 and 6. There 
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is a drop-off from the most populated category 9 to category 10, showing that this 
simple scaffold has few conformers that have the flattest shapes.  
 
A sub-set of compounds could now be selected from the original 92-member library. 
The analysis in Figure 2.23 shows how the number of compounds selected varies with 
conformational energy difference and PMI category, with closer analysis of the 6 to 7 
category shown in Table 2.15.  
 
Figure 2.23: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories. 
Entry 
Energy / 
kcal mol-1 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 19 13 7 
2 < 1.5 1 to 6.1 26 17 11 
3 < 1.5 1 to 6.2 29 18 12 
4 < 1.5 1 to 6.3 31 19 13 
5 < 1.5 1 to 6.4 35 20 13 
Table 2.15: Analysis of the library between PMI cateogories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
 
A suitable number of compounds is given when the PMI categories selected go up to 
6.2. This is also the same PMI categories as selected in the hydroxymethyl piperidine 
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analysis. This gives 18 compounds and 12 isomers, the compound numbers associated 
with these are given in Table 2.16. The structures of the 18 compounds are shown in 
Figure 2.24. 
 
Figure 2.24: The selected methyl ester piperidine18 fragment sub-set. 
 
Data 
set 
Selected compound numbers 
1 Ester  2  6 9  20  26 29 30  
2 OH 1 2 5 6 9 19 20 25 26    
3 Isomer 1 2 3 5 7 8  
4 Ester 38 40 41 42 53 65 66 71 72 75 76  
5 OH 38 40 41 42 53 65 66 71 72   89 
6 Isomer 10 11 14 17 18 19 23 
Table 2.16: The fragment number for the selected sub-set of fragments compared to the 
fragments selected in the hydroxymethyl piperidine analysis. 
The PMI plot of the all the conformers with a conformational energy difference of < 
1.5 kcal mol-1 is in Figure 2.25 (a). This can be compared the full 92 member library 
PMI plot, showing conformers with conformational energy difference of < 1.5 kcal 
mol-1 (Figure 2.25 (b)).  
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Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.25: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 18 
selected fragments. This is contrasted by PMI (b), which shows conformers with an energy 
of less 1.5 kcal mol-1 for all 92 starting compounds. 
 
These plots show that the sub-set library has a good coverage of the under-represented 
3-dimensional fragment space. Table 2.16 also details the compound numbers 
associated with the methyl, hydroxymethyl piperidine sub-set. Interestingly, there is a 
significant overlap in compound numbers. These are associated with the same isomer 
and only differ in the hydroxymethyl/ester substituent. In fact, fourteen compounds 
are duplicated in the library. This could significantly simplify the amount of synthesis 
that would be required if the same synthetic route could be used to access both 
compounds. The two PMI plots of the hydroxymethyl and ester piperidine selected 
sub-sets are shown in Figure 2.26 (a) and (b). Figure 2.26 (c) shows the PMI plot of 
an overlay of the two different selected libraries with colours representing the 
substituent (See key). 
 
(a) (b) 
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Plot (a) 
and (b) 
Colour       
Conformational 
energy difference / 
kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Plot (c) 
Colour   
R2 CH2OH CO2Me 
Figure 2.26: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 19 
selected hydroxymethyl piperidine fragments. This is contrasted by PMI (b), which shows 
conformers with an energy of less 1.5 kcal mol-1 for all 18 selected methyl ester piperidine 
fragments. PMI (c) shows both libraries overlaid. 
The comparison of methyl/hydroxymethyl with methyl/methyl ester really highlight 
that even small changes to a molecule can produce quite different shaped 
conformations. It is evident that the ester piperidine sub-set focuses more on the area 
towards the rod-disc axis, contrasting with the hydroxymethyl which covers more of 
the spherical area of the plot. The combined sub-sets cover a large area of the plot and 
show that the piperidine scaffold has both shape and conformational diversity.  
 
 
 
(a) (b) 
(c) 
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2.5.2 Hydroxymethyl, methyl-disubstituted pyrrolidine library 
It is desirable to also populate our fragment library with different scaffolds. Therefore, 
we decided to analyse other simple saturated nitrogen heterocycles for their shape 
diversity and with a desire to select compounds that are more 3-dimensional. Thus 
disubstituted pyrrolidine with hydroxymethyl and methyl substituents was selected for 
analysis. Disubstituted pyrrolidine gives 14 different isomers and functionalising the 
nitrogen with H, Me, SO2Me and Ac gives a 56-member library. These compounds 
are shown in Figure 2.27. 
 
Figure 2.27: The 14 different isomers of hydroxymethyl, methyl disubstituted pyrrolidine. 
The four different nitrogen substituents are also shown. 
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The 56 compounds were then subjected to the same analysis as the piperidine 
compounds. The PMI plot of the lowest energy conformers of the 56 compounds is 
shown in Figure 2.28. This shows a small spread of conformers across the plot, with a 
few compounds reaching out into the more spherical area of the plot. 
 
Figure 2.28: PMI plot of the lowest energy conformations of the 56 hydroxymethyl 
pyrrolidine fragments. 
All the conformations and PMI data were then generated computationally for these 56 
compounds. Analysis was carried out in the same way as for the piperidines. The 
number of conformers, their position on the plot and their conformational energy was 
analysed and is detailed in Table 2.17.  
Category 
Conformational Energy Difference / kcal mol-1 
Total 
1 2 3 4 5 6 7 8 
2 0 0 0 0 0 1 0 1 2 
3 0 0 0 0 1 0 0 0 1 
4 2 0 1 0 0 0 0 0 3 
5 0 2 0 3 0 0 0 1 6 
6 10 7 7 8 2 3 3 1 41 
7 16 26 17 15 12 11 4 3 104 
8 50 51 47 48 24 28 18 32 298 
9 84 65 76 47 55 41 26 28 422 
10 49 17 15 12 2 1 0 0 96 
Total 211 168 163 133 96 85 51 66 973 
Table 2.17: Data showing the distribution of conformers by PMI category and 
conformational energy. 
The data in Table 2.17 show that there is a large spread of conformers across the plot, 
although the most spherical conformers (PMI categories 2 to 5) have a high 
conformational energy difference. There are increasingly more in PMI categories 6 
72 
 
and 7, some with lower energy suggesting accessible 3-dimensional conformers. There 
is a lower number of conformers in category 10, which suggest a low amount of flat 
conformations. This information shows that the simple pyrrolidine scaffold has both 
shape and conformational diversity.  
 
For our fragment library, we did not plan to synthesise all compounds and so a sub-
set library was be selected. Disubstituted pyrrolidine provides 14 isomers and 56 
compounds and therefore a suitable size for the sub-set library would be no more than 
7 isomers and 15 compounds. The data set was then analysed to determine the number 
of compounds obtained from different areas of the plot and with different energies. 
The full library analysis is show in Figure 2.29. It can be seen that there is a trade-off 
in PMI category and conformational energy. In order to select compounds from the 
most spherical area of the plot, a conformational energy difference cut off of 1.5 kcal 
mol-1 was selected. The most suitable number of compounds is provided between 
categories 6 and 7. Therefore, this category was further analysed (Table 2.18).  
 
Figure 2.29: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories. 
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Entry 
Energy / 
kcal mol-1 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 18 7 4 
2 < 1.5 1 to 6.1 18 7 4 
3 < 1.5 1 to 6.2 23 10 5 
4 < 1.5 1 to 6.3 25 10 5 
5 < 1.5 1 to 6.4 27 10 5 
6 < 1.5 1 to 6.5 33 11 5 
7 < 1.5 1 to 6.6 34 11 5 
8 < 1.5 1 to 6.7 37 13 6 
9 < 1.5 1 to 6.8 39 14 7 
10 < 1.5 1 to 6.9 42 15 8 
11 < 1.5 1 to 7 48 18 9 
Table 2.18: Analysis of the library between PMI categories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
 
Table 2.18 shows that a suitable number of compounds is selected from category 6.2 
and a conformational energy difference < 1.5 kcal mol-1. These 10 compounds are 
shown in Figure 2.30.  
 
Figure 2.30: The selected hydroxymethyl pyrrolidine 10 fragment sub-set. 
 
The PMI plot of these 10 compounds (Figure 2.31 (a)) can be compared to the original 
56-member library (Figure 2.31 (b)). Both of these plots show conformers with a 
conformational energy difference of < 1.5 kcal mol-1. The selected sub-set has a clear 
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focus on the under-represented part of the plot. There are a number of low energy 3-
dimensional fragments. These plots clearly show that both the sub-set and original 
library have conformational and shape diversity.  
 
Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.31: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 10 
selected fragments. This is contrasted by PMI (b), which shows conformers with an energy 
of less 1.5 kcal mol-1 for all 56 starting compounds. 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
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2.5.3 Methyl ester, methyl-disubstituted pyrrolidine library 
Next, a set of disubstituted pyrrolidine compounds with methyl ester and methyl 
substituents was analysed. The 56 compounds are shown in Figure 2.32 and the PMI 
plot of the lowest energy conformations is shown in Figure 2.33. 
 
 
Figure 2.32: The 14 different isomers of ester, methyl disubstituted pyrrolidine. The four 
different nitrogen substituents are also shown. 
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Figure 2.33 PMI plot of the lowest energy conformations of the 56 ester pyrrolidine 
fragments. 
The spread of conformers across the plot and the relative conformational energies were 
then analysed and the results are shown in Table 2.19. 
Category 
Conformational Energy Difference / kcal mol-1 
Total 
1 2 3 4 5 6 7 8 
3 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 
5 5 1 1 1 0 0 2 7 17 
6 12 1 2 0 4 3 4 26 52 
7 42 27 10 8 5 17 22 74 205 
8 103 81 39 28 44 60 37 174 566 
9 197 80 62 52 78 44 48 75 636 
10 95 27 8 1 15 2 5 0 153 
Total 454 217 122 90 146 126 118 356 1629 
Table 2.19: Data showing the distribution of conformers by PMI category and 
conformational energy. 
The data in Table 2.19 show that there are no conformers in the most spherical part of 
the plot but increasing numbers towards the centre of the plot, with most conformers 
in categories 8 and 9. This is different to the hydroxymethyl pyrrolidines, which had 
conformers more towards the top right of the plot. There are low numbers in category 
10 suggesting few flat, 2-dimensional conformers. There is a large spread of low 
energy conformations, and those conformers in the middle to top right of the plot 
(categories 5, 6 and 7) have lower conformational energy differences and are therefore 
likely to be accessible.  
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In order to select a suitable number of compounds for the sub-set library, the whole 
data set was analysed and the number of compounds selected from different PMI 
categories and conformational energies was determined. The results are shown in 
Figure 2.34. Similarly to the hydroxymethyl pyrrolidines, a suitable number of 
compounds is selected between categories 6 and 7, with an energy difference of less 
than 1.5 kcal mol-1. Further analysis is shown in Table 2.20.  
 
Figure 2.34: Graph showing the number of compounds selected at different conformational 
energy difference and PMI categories. 
Entry 
Energy / 
kcal mol-1 
Category 
Number of 
Conformers 
Number of 
Compounds 
Number of 
Isomers 
1 < 1.5 1 to 6 18 8 5 
2 < 1.5 1 to 6.1 19 9 6 
3 < 1.5 1 to 6.2 20 9 6 
4 < 1.5 1 to 6.3 23 10 7 
5 < 1.5 1 to 6.4 28 14 9 
6 < 1.5 1 to 6.5 30 15 9 
7 < 1.5 1 to 6.6 34 17 10 
8 < 1.5 1 to 6.7 40 19 11 
9 < 1.5 1 to 6.8 52 22 12 
10 < 1.5 1 to 6.9 58 23 12 
11 < 1.5 1 to 7 75 27 13 
Table 2.20: Analysis of the library between PMI cateogories 6 and 7 to determine suitable 
compounds for the library by varying energy cut off and PMI categories. 
Table 2.20 shows that a suitable number of compounds and isomers is selected from 
category 6.2 with a conformational energy difference of <1.5 kcal mol-1. This is also 
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the same selection point as the hydroxymethyl pyrrolidine library. The 9 selected 
compounds are shown in Figure 2.35 .  
 
Figure 2.35: The selected ester pyrrolidine 9 fragment sub-set. 
The PMI plots showing all conformers with a conformational energy difference of < 
1.5 kcal mol-1 for the 9 compound sub-set (Figure 2.36 (a)) and the original 56-member 
library (Figure 2.36 (b)) can be compared. It can be seen that there the selected sub-
set library has a good spread across the plot, selecting more 3-dimensional conformers, 
and shows that both the sub-set and original library have shape and conformational 
diversity.  
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Figure 2.36: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 9 
selected fragments. This is contrasted by PMI (b), which shows conformers with an energy 
of less 1.5 kcal mol-1 for all 56 starting compounds. 
Comparing the ester pyrrolidine selected sub-set to the hydroxymethyl pyrrolidine 
sub-set highlights some similarities in the isomers that would be selected for synthesis. 
The fragment numbers from both sub-sets are shown in Table 2.21. It can be seen that 
five compounds are the same, only varying in the hydroxymethyl/ester substituent. 
This means that with careful synthetic planning both the ester and hydroxymethyl may 
be accessible from the same route, hence minimising the number of different synthetic 
routes.  
  
Data 
set 
Selected Compound Numbers 
1 OH 1 2 3 4 5 9 14 15     30  52 
2 Ester  2 3 4 5    16 22 29 30 45   
3 Isomer 1 2 3 4 6 8 12 13 
Table 2.21: The fragment number for the ester pyrrolidine selected sub-set of fragments 
compared to the fragments selected in the hydroxymethyl pyrrolidine analysis. 
The PMI plots of the selected sub-set libraries for hydroxymethyl and ester pyrrolidine 
are shown in Figure 2.37, as well as the overlaid plot of the two selected pyrrolidine 
libraries. Colouring is based on the substituent type (see Key). The comparison of 
these two sub-sets demonstrates that even small changes to a molecule can produce 
quite different shaped conformations. Both sub-set libraries focus on the more 
spherical area of the plot, although the ester pyrrolidine library has more 
conformations closer to the unfavourable rod-disc axis. This plot shows that this 
(a) (b) 
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library has good conformational diversity and accesses new areas of 3-dimensional 
chemical space.  
 
 
Plot (a) 
and (b) 
Colour       
Conformational 
energy difference / 
kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Plot (c) 
Colour   
R2 CH2OH CO2Me 
Figure 2.37: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 10 
selected hydroxymethyl pyrrolidine fragments. This is contrasted by PMI (b), which shows 
conformers with an energy of less 1.5 kcal mol-1 for all 9 selected methyl ester pyrrolidine 
fragments. PMI (c) shows both libraries overlaid. 
It is also possible to compare the combined selected hydroxymethyl and ester 
pyrrolidine sub-set library with the original hydroxymethyl and ester pyrrolidine 
library. Figure 2.38 shows that the sub-set library covers a large area of chemical 
space, some of the bulk has been removed from the areas closer to the rod-disc axis, 
highlighting that the more 3-dimensional fragments have been selected for the library.  
(a) (b) 
(c) 
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Figure 2.38: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for the 
combined 19 selected hydroxymethyl and ester fragments. This is compared to PMI (b), 
which shows all the conformers with an energy of less 1.5 kcal mol-1 for both 56 original 
pyrrolidine fragments. 
 
2.5.4 Hydroxymethyl, methyl- and methyl ester, methyl-disubstituted azepane 
libraries 
The azepane heterocycle is another simple saturated scaffold that could be considered 
for the fragment library. It is anticipated that the 7-membered ring would be more 
conformationally flexible due to the larger ring size compared to the pyrrolidine and 
piperidine scaffolds. As with the previous heterocycles, there will be two different 
azepane systems, hydroxymethyl and methyl-disubstituted azepane and methyl ester, 
methyl-disubstituted azepane. Disubstituted azepane has 33 different isomers (not 
including enantiomers), which when functionalised 4 different ways, with H, Me, 
SO2Me and Ac, gives 132 different compounds, shown generally in Figure 2.39. Full 
analysis will not be presented. 
 
 
 
 
(a) (b) 
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Figure 2.39: The hydroxymethyl, methyl disubstituted azepane and methyl ester, methyl 
disubstituted azepane scaffolds. The four different nitrogen substituents are also shown. 
 
The 132 compounds from both systems were computationally analysed. All 
conformations were generated and relevant data obtained using our Pipeline Pilot 
protocol. These data were then analysed to determine the structural diversity of the 
scaffold. The PMI plot showing the lowest energy conformation of both 
hydroxymethyl and methyl ester libraries are shown in Figure 2.40. This shows that 
there is a significant spread of compounds across the plot and that the scaffold clearly 
demonstrates structural diversity. The scaffold accesses new areas of 3-dimensional 
space well. 
 
Figure 2.40: PMI (a) the lowest energy conformations of the 132 hydroxymethyl azepane 
fragments. PMI (b) the lowest energy conformations of the 132 methyl ester azepane 
fragments. 
The data for both systems was then further analysed to ascertain the number of 
compounds selected at each energy level and PMI category. As with previous analysis, 
not all compounds need to be synthesised and therefore a smaller sub-set is selected 
focussing on the more 3-dimensional fragments.  
 
(a) (b) 
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For the hydroxymethyl azepane library, it was found that a suitable number of 
compounds is selected from PMI categories 1 to 5.3 with a conformational energy 
difference of < 1.5 kcal mol-1 to give a total of 27 compounds and 16 isomers. The 27 
member sub-set library fragments are shown in Figure 2.41.  
 
Figure 2.41: The selected hydroxymethyl azepane 27 fragment sub-set. 
A PMI plot of the 27 selected fragments can be generated and is shown in Figure 2.42 
(a). This shows that the sub-set has very good coverage of chemical space, with a 
number of low energy fragments reaching into the more 3-dimensional area of 
chemical space. This plot can be compared to a plot of the full 132 member 
hydroxymethyl library (Figure 2.42 (b)). Here it can be noted that the selected sub-set 
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has very good coverage of the top right of the plot with only a small percentage of 
conformations towards to the rod-disc axis.  
 
Colour       
Conformational 
energy difference 
/ kcal mol-1 
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Figure 2.42: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 27 
selected fragments. This is contrasted by PMI (b), which shows conformers with an energy 
of less 1.5 kcal mol-1 for all 132 starting compounds. 
 
The same analysis on the methyl ester azepane library showed that selection from PMI 
categories 1 to 6, with a conformational energy difference < 1.5 kcal mol-1, gave 29 
compounds and 17 isomers. These compounds are shown in Figure 2.43 below.  
(a) (b) 
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Figure 2.43: The selected ester azepane 29 fragment sub-set. 
The PMI generated for all the conformations with less than 1.5 kcal mol-1 
conformational energy difference of the 29 selected compound sub-set is shown in 
Figure 2.44 (a). Comparing this to the original 132-member library with 
conformations less than 1.5 kcal mol-1 conformational energy difference (Figure 2.44 
(b)) shows that there is good conformational diversity and shape diversity. The ester 
substituent, however, does not produce a large number of conformations in the top 
right of the plot; the conformations are more evenly spread across the plot. The sub-
set has selected the most 3-dimensional compounds which can be seen by the lower 
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percentage of compounds near the rod-disc axis compared to the original library. 
 
Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.44: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 29 
selected ester azepane fragments. This is contrasted by PMI (b), which shows conformers 
with an energy of less 1.5 kcal mol-1 the original 132 member methyl ester azepane 
fragments. 
It is now possible to collect together the selected hydroxymethyl azepane sub-set and 
the ester azepane sub-set to investigate any similarities and differences between the 
two sets. The fragment numbers of both sets are shown in Table 2.22. This also 
highlights the similar and different isomers in both data sets. 
 
Data 
set 
Compound Numbers 
1 OH 1 2  5 6 9 10  15 16 20  33  
2 Ester 1 2 4 5 6 9  12 15  20 26 33  
3 Isomer 1 2 3 4 5 7 9  
4 OH  38 40 41 42 45 46  50    77 78 
5 Ester 37 38 40    46 49 50 54 69 70 77 78 
6 Isomer 10 11 12 13 14 18 20 
7 OH 81 82  86 90 92 109 110 113     
8 Ester 81 82 83 86 90 92   113     
9 Isomer 21 22 23 28 29     
Table 2.22: The fragment number for the ester azepane selected sub-set of fragments 
compared to the fragments selected in the hydroxymethyl azepane analysis. 
 
Table 2.22 shows that there are a number of the same isomer and some with similar 
nitrogen functionalisation, these only vary in the R2 substituent. In total there are 20 
isomers which are the same, and this should significantly reduce the quantity of 
(a) (b) 
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synthetic methods to develop. A comparison of the two different sub-sets PMI plot is 
shown in Figure 2.45 with an overlaid PMI plot with both data sets on Figure 2.45 (c), 
where spots are coloured based on substituent.  
  
 
Plot (a) 
and (b) 
Colour       
Conformational 
energy difference / 
kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Plot (c) 
Colour   
R2 CH2OH CO2Me 
Figure 2.45: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for all 27 
selected hydroxymethyl azepane fragments. This is contrasted by PMI (b), which shows 
conformers with an energy of less 1.5 kcal mol-1 for all 29 selected methyl ester azepane 
fragments. PMI (c) shows both libraries overlaid. 
These plots also show how the two different sub-sets cover slightly different areas of 
the plot. Both scaffolds have a number of conformers in the top right of the plot, but 
the left of the plot seems to vary slightly between scaffold. The hydroxymethyl 
azepane fragments have more coverage in the lower area of the plot towards the disc 
area, whereas the ester fragments have greater population of fragments in the top left 
of the plot. The gap in the middle of the hydroxymethyl plot is well covered by the 
ester fragments.  A combined PMI plot of the two azepane fragment sub-sets is shown 
(a) (b) 
(c) 
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in Figure 2.46 (a). This can be compared to the plot of the combined azepane original 
libraries with all conformations of less than 1.5 kcal mol-1 (Figure 2.46 (b). This shows 
that the azepane scaffold produces fragments which have shape and conformational 
diversity and a large area of chemical space is covered by this simple scaffold. 
 
Colour       
Conformational 
energy difference 
/ kcal mol-1 
0 < 0.3 < 0.6 < 0.9 < 1.2 < 1.5 
Figure 2.46: PMI (a), shows conformers with an energy of less than 1.5 kcal mol-1 for the 
combined 56 selected hydroxymethyl and ester fragments. This is compared to PMI (b), 
which shows all the conformers with an energy of less 1.5 kcal mol-1 for both 132 original 
azepane fragments. 
 
 
2.5.5 Combined piperidine, pyrrolidine and azepane library 
Each of the six analyses presented so far has provided a smaller sub-set of compounds 
suitable for a 3-dimensional fragment library. These analyses can now be combined to 
give an overall picture of the selected fragment library. The PMI plots showing each 
of the two combined libraries, (PMI (a) showing the 19 pyrrolidine fragments, PMI 
(b) showing the 37 piperidine fragments and PMI (c) showing 56 azepane fragments) 
is shown as well as the combined PMI plot of the 112 fragments (Figure 2.47 (d)) of 
all the pyrrolidine, piperidine and azepane conformers with less than 1.5 kcal mol-1 
conformational energy difference.  
 
(a) (b) 
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Plot (a), 
(b) and 
(c) 
Colour   
R1 CH2OH CO2Me 
Plot (d) 
Colour    
Scaffold Pyrrolidine Piperidine Azepane 
Figure 2.47: All plots show conformers with an energy of less than 1.5 kcal mol-1 for both 
hydroxymethyl and ester substituted fragments. PMI (a) shows 19 pyrrolidine fragments, 
PMI (b) shows 37 piperidine fragments, PMI (c) shows 56 azepane fragments and PMI (d) 
combined plot of all three scaffolds (112 fragments). 
These plots show how each of the different scaffolds contribute to the library. It can 
be seen that the azepane library has the greatest spread of conformers across the plot 
and is the scaffold with the most spherical conformers. However, there is quite a bit 
of difference between the piperidine and pyrrolidine scaffolds. Each of the two 
libraries seems to occupy a space left by the other, for example the bottom of the plot, 
is sparsely populated by the pyrrolidine fragments (red), but is covered by a number 
of piperidine fragments (orange). The coverage is shared by the two scaffolds at the 
top right of the plot, where a larger area is covered by the two different scaffolds. The 
more sparsely populated area at the top right contains more azepane conformers. It can 
(a) (b) 
(c) (d) 
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also be noted that category 10 has only a few conformers. This is ideal as this area of 
the plot is already well covered by existing fragment libraries, and shows that our 
fragments have shape diversity despite the simple nature of the scaffold.  
 
In summary, this combined sub-set library of 112 compounds demonstrates that it is 
possible to generate shape diversity from simple scaffolds. Furthermore, by 
introducing conformational diversity, a large area of the plot can be covered, giving 
access to new areas of 3-dimensional chemical space.  
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2.6 Physicochemical properties of selected library 
To date, we have analysed the shape diversity of the simple heterocyclic fragments 
and selected the more 3-dimensional fragments to form the basis for our 3-dimensional 
fragment library. However, it is important to analyse the physicochemical properties 
of both the original library and the selected sub-set. By doing this we are able to check 
that the properties are “fragment like”. As discussed in Section 1.1, fragments 
generally have similar properties and are said to follow a certain set of criteria or “Rule 
of 3”. These data as well as other properties not encompassed in the “Rule of 3” can 
be calculated for each of the compounds in the library. The values can be 
computationally generated using Pipeline Pilot 8.5 built-in components and the data 
for each full library of each scaffold and set of substituents was generated (See Section 
6.1.1 for details).  
 
2.6.1 Physicochemical properties of piperidine fragments 
It is important to determine if all the members of the full library fit with desirable 
criteria. Taking piperidine as our initial example, each compound in the 92-member 
library was analysed for their physicochemical properties. As the analysis occurs after 
the run to generate all conformations, the data is generated for all of conformations of 
a given compound. However, the physicochemical properties do not vary based on 
conformation.  Therefore, only the lowest energy conformation data was used. The 
data in Table 2.23 summarises the piperidine data set as a whole including the 
breakdown for the two different piperidine substituents. 
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 R2  ALogP 
MW 
(HAC) 
H Bond 
Acceptor 
H Bond 
Donor 
Molecular 
PSA / Å2 
1 
CH2OH 
Average -0.44 163.24 (11) 1.75 1.5 42.01 
2 Smallest -1.18 130.21 (9) 1 1 24.67 
3 Largest 0.363 207.29 (13) 3 2 65.99 
        
4 
Ester 
Average 0.0176 191.20 (13) 2.80 0.5 47.83 
5 Smallest -0.733 157.21 (11) 2 0 30.74 
6 Largest 0.716 235.30 (15) 4 1 72.06 
        
7 
Full 
Average -0.212 177.22 (12) 2.28 1 44.92 
8 Smallest -1.18 130.21 (9) 1 0 24.67 
9 Largest 0.716 235.30 (15) 4 2 72.06 
Table 2.23: Table showing analysis of the physicochemical properties of the piperidine 
fragments. 
These data (Table 2.23) show that in each of the 92-member substituent libraries and 
the full 184-member combined library the average molecular weight falls well below 
the guidelines provided by the “Rule of 3” (< 300 Da). The highest values also fall 
below the limit. This is also the case for the number of hydrogen bond donors, although 
not for acceptors, where the ester library provides some compounds with more than 3 
hydrogen bond acceptors. The average value, however, falls below the three maximum 
suggestion. The range in the number of donor and acceptor sites varies slightly 
showing that the fragments have a good range of sites to provide hydrogen bond 
handles. The ALogP value falls well below the guideline of 3. Even the highest values 
of ALogP in the libraries is still two log units lower than the maximum. This suggests 
that our fragments are very polar and offer a huge potential for adding more lipophilic 
groups during fragment development. The polar surface area is more mixed. Generally 
a polar surface area of less than 60 Å2 is desirable for fragments, this is to allow for an 
increase during development, generally an orally bioavailable drug has a polar surface 
of around 120 Å2, however this is considerably smaller (< 60 Å2) for drugs requiring 
brain penetration. For our fragments on average the polar surface area is less than the 
60 Å2 value, although the largest value of each substituent library is greater. These 
data show that we are not only designing compounds with shape diversity, but also 
suitable physicochemical properties for a fragment library.  
 
It is expected that the selected sub-set library will also follow the “Rule of 3” 
guidelines as the parent library does, but it is important to check that the properties of 
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the selected fragments are varied and that selection has not given a narrow range of 
physicochemical properties. Table 2.24 shows the data for the selected sub-set 
libraries.  
 R2  ALogP MW (HAC) 
H Bond 
Acceptor 
H Bond 
Donor 
Molecular 
PSA / Å2 
1 
CH2OH 
Average -0.660 149.23 (10.2) 1.37 1.74 36.65 
2 Smallest -1.18 130.21 (9) 1 1 24.67 
3 Largest 0.363 207.29 (13) 3 2 65.99 
        
4 
Ester 
Average -0.0367 181.00 (12.5) 2.61 0.667 41.50 
5 Smallest -0.665 157.21 (11) 2 0 30.74 
6 Largest 0.716 235.30 (15) 4 1 72.06 
        
7 
Full 
Average -0.321 164.78 (11.3) 1.97 1.22 39.00 
8 Smallest -1.18 130.21 (9) 1 0 24.67 
9 Largest 0.716 235.30 (15) 4 2 72.06 
Table 2.24: Table showing analysis of the physicochemical properties of the selected sub-set 
library of piperidine fragments. 
These data show that the selected library follows a similar trend to that of the original 
library with only subtle differences in values. The selected library has lower values 
than the original library for molecular weight and the polar surface area, but the 
selected sub-set represents original library well. The selected sub-set library has a good 
range of values and fits the desirable physicochemical properties for a fragment 
library.  
 
2.6.2 Physicochemical properties of pyrrolidine and azepane fragments 
A similar analysis of the physicochemical properties can also be carried out for the 
other fragment library scaffolds, pyrrolidine and azepane. Although the data for all 
compounds and conformers was generated, only the lowest energy conformation was 
considered. 
 
Analysis of both full 56-member pyrrolidine hydroxymethyl and methyl ester libraries 
have been undertaken, and show that these pyrrolidine fragments fit within the “Rule 
of 3” guidelines. This was also the case for the selected sub-sets for both of these 
fragment scaffolds, with analysis summarised in Table 2.25. 
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 R2  ALogP MW (HAC) 
H Bond 
Acceptor 
H Bond 
Donor 
Molecular 
PSA / Å2 
1 
CH2OH 
Average -0.839 144.01 (9.7) 1.6 1.6 39.76 
2 Smallest -1.48 116.18 (8) 1 1 24.67 
3 Largest -0.151 193.26 (12) 3 2 65.99 
        
4 
Ester 
Average -0.568 167.00 (11.4) 2.44 0.667 42.90 
5 Smallest -1.12 144.19 (10) 2 0 30.74 
6 Largest 0.26 221.27 (14) 4 1 72.06 
        
7 
Full 
Average -0.710 154.69 (10.5) 2 1.16 41.25 
8 Smallest -1.48 116.18 (8) 1 0 24.67 
9 Largest 0.260 221.27 (14) 4 2 72.06 
Table 2.25: Table showing analysis of the physicochemical properties of the selected sub-set 
library of pyrrolidine fragments. 
The pyrrolidine sub-set library provides compounds with suitable characteristics for a 
successful fragment library, with all following the “Rule of 3” guidelines. The 
fragments have a low average ALogP value, suggesting a larger proportion of polar 
fragments. This low ALogP value and the moderate average molecular weight 
provides a good starting point to build on to the fragment without the risk of generating 
an unfavourably high ALogP value.  
 
The physicochemical properties of the azepane library were also computationally 
generated and analysed. Analysis of the hydroxymethyl azepane library and the methyl 
ester azepane library showed that the fragments generally obey the criteria outlined in 
the “Rule of 3”. Therefore, the selected sub-sets also showed good fragment 
properties, as outlined in Table 2.26 
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 R2  ALogP MW (HAC) 
H Bond 
Acceptor 
H Bond 
Donor 
Molecular 
PSA / Å2 
1 
CH2OH 
Average -0.258 159.40 (11.0) 1.22 1.81 33.06 
2 Smallest -0.728 144.23 (10) 1 1 24.67 
3 Largest 0.819 221.32 (14) 3 2 65.99 
        
4 
Ester 
Average 0.167 190.0 (13.2) 2.31 0.759 40.5 
5 Smallest -0.411 172.24 (12) 2 0 30.74 
6 Largest 1.17 249.33 (16) 4 1 72.06 
        
7 
Full 
Average -0.0380 175.47 (12.2) 1.79 1.27 36.92 
8 Smallest -0.728 144.23 (10) 1 0 24.67 
9 Largest 1.17 249.33 (16) 4 2 72.06 
Table 2.26: Table showing analysis of the physicochemical properties of the selected sub-set 
library of azepane fragments. 
Both hydroxymethyl and ester selected libraries fit within the “Rule of 3” guidelines. 
Comparing the azepane selected sub-set to the piperidine and pyrrolidine selected 
libraries it should be noted that the azepane fragments have a lower polar surface area 
and a higher ALogP. This suggests that the library contains fragments with a range of 
physicochemical properties. An analysis of the combined full and selected libraries 
was then undertaken. Table 2.27 compares the properties for the selected 112 
compound combined sub-set library and the full library. 
 Data set  ALogP MW (HAC) 
H Bond 
Acceptor 
H Bond 
Donor 
Molecular 
PSA / Å2 
1 
Selected 
Average -0.246 168.4 (11.6) 1.88 1.23 38.34 
2 Smallest -1.48 116.18 (8) 1 0 24.67 
3 Largest 1.17 249.33 (16) 4 2 72.06 
        
4 
Full 
Average -0.116 181.05 (12.3) 2.26 1 45.00 
5 Smallest -1.57 116.18 (8) 1 0 24.67 
6 Largest 1.17 249.33 (16) 4 2 72.06 
Table 2.27: Table showing analysis of the physicochemical properties of combined selected 
library and the combined full library. 
These data show that there is a small difference in the selected library and the full 
library. The average size of fragments in the selected library is smaller, although the 
average heavy atom count is closer. The lower ALogP of the selected library suggests 
that more polar compounds have been selected. This allows for addition of lipophilic 
groups in fragment development without approaching an unfavourable ALogP level. 
In conclusion, the compounds in the selected library meet all the criteria outlined in 
the “Rule of 3” and have favourable properties to allow for fragment development. 
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2.7 Comparison of library with a commercial fragment library 
Our selected fragment library was specifically designed to explore more 3-
dimensional areas of chemical space and introduce more simple saturated scaffolds 
into fragment libraries. To show this, we compare our library to a commercial 
fragment library. The Maybridge Rule of 3, core 1000 fragment64 library is a 
commercially library available to purchase and screen. This library of compounds was 
subjected to our PMI analysis protocol to generate conformations of these compounds 
and determine their position on the PMI plot.  
 
Figure 2.48 (a) shows the lowest energy conformation of each of the 1000 compounds 
in the Maybridge library. This is compared to our full 560-member (Figure 2.48 (b)) 
and the 112-member sub-set library (Figure 2.48 (c)).  
 
 
Figure 2.48: PMI (a), shows compounds from the Maybridge Rule of 3 fragment library,  
PMI (b) shows the combined pyrrolidine, piperidine and azepane libraries and PMI (c) 
shows the combined selected sub-set library for all three scaffolds. Each plot only shows the 
lowest energy conformer for each compound.  
(a) (b) 
(c) 
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The Maybridge library clearly contains more flat molecules as shown by the number 
of compounds close to the rod-disc axis of the PMI plot. This can be more closely 
analysed and it is found that 69% of compounds are in PMI category 10, with only 
3.6% of compounds in the more spherical part of the plot (PMI categories 1 to 7). It is 
clear that there are considerably less compounds in this category of our library (1.8%) 
and more compounds covering the more 3-dimensional areas of chemical space. The 
full library has 20% of compounds in PMI categories 1 to 7 and the selected library 
61.6%. These data are also presented in Figure 2.49 which shows the percentage of 
each compound in each of the PMI categories for each library.  
 
Figure 2.49: Graph showing the percentage of compounds in each category of the PMI plot 
for each library. 
The graph shows that we have succeeded in selecting compounds with particular focus 
on the more interesting, under-represented, 3-dimensional area of the PMI plot and 
have less compounds in the area closest to the rod-disc axis.  
 
For full comparison, the physicochemical properties of the Maybridge library were 
analysed. The key properties are summarised in Table 2.28. 
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 Data set  ALogP 
MW 
(HAC) 
H Bond 
Acceptor 
H Bond 
Donor 
Molecular 
PSA / Å2 
1 
Selected 
Average -0.246 
168.4 
(11.6) 
1.88 1.23 38.34 
2 Smallest -1.48 116.18 (8) 1 0 24.67 
3 Largest 1.17 
249.33 
(16) 
4 2 72.06 
4 
Full 
Average -0.116 
181.05 
(12.3) 
2.26 1 45.00 
5 Smallest -1.57 116.18 (8) 1 0 24.67 
6 Largest 1.17 
249.33 
(16) 
4 2 72.06 
7 
Maybridge 
Rule of 3 
Average 1.30 
180.1 
(12.5) 
1.94 0.787 45.92 
8 Smallest -2.68 82.1 (6) 0 0 3.24 
9 Largest 3.95 295.8 (21) 4 3 117.5 
Table 2.28: The physicochemical properties of the selected sub-set fragment library, the full 
fragment library and the Maybridge Rule of 3, core 1000 library.  
As expected, the Maybridge Rule of 3 average is within the desired criteria for all of 
the properties. The most extreme values, however, vary considerably and some lie 
quite far away from the general desirable criteria. The Maybridge library values 
compare well to the full and selected libraries. Molecular weight is very similar 
between all of the libraries, as is polar surface area. There is, however, a considerable 
difference in the average ALogP for the Maybridge library. The much higher ALogP 
for the Maybridge library may suggest that there is a lower proportion of very polar 
compounds in the Maybridge library. Further analysis shows that 58% of the 
Maybridge library compounds contain one aromatic ring, compared to none in ours. 
This may be where our selected library falls down, as very polar compounds can have 
issues further into development and issues with too polar compounds struggling to 
cross cell membranes.65 However, this may not be a major issue if the fragments are 
diversified and further functionalised later in development. This data shows that our 
selected library covers a different range of physical properties, which may not be 
efficiently sampled by the commercial library.  
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2.8 Conclusions and Overview 
We have been able to develop a computational approach for the analysis and selection 
of a range of saturated nitrogen heterocycles. This computational protocol has been 
optimised and provides reliable conformational data. We have demonstrated that 
shape diversity can be obtained from simple scaffolds and that by analysing the 
different conformations of a compound, we have been able to access new and 
interesting areas of pharmaceutical space. It has been possible to develop criteria to 
select fragments focused on the under-represented, 3-dimensional area of the PMI plot 
and new areas of pharmaceutical space and move away from the undesirable rod-disc 
axis. Introducing different synthetically accessible substituents gave additional 
fragments that cover different areas of chemical space and this highlights that simple 
modifications can open up new interesting areas of chemical space. Comparison of 
our full and selected sub-set libraries highlight that our scaffolds and compound 
collections cover more 3-dimensional space than current libraries and access new 
areas of chemical space. Our fragments also fit with the “Rule of 3” desirable criteria 
for fragment compounds and have suitable properties that could be further developed 
in the drug development process. The selection of a smaller sub-set of these 
compounds has made synthesis more amenable. 
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Chapter 3:  Synthesis Towards Selected Disubstituted 
Piperidines 
The analysis of different heterocycles in Chapter 2 yielded a number of smaller sub-
set libraries that we wished to synthesise. As the main focus and development centred 
on disubstituted piperidines, it was the synthesis of these that was tackled. It was 
important to minimise the number of different routes and steps used to synthesise the 
final fragments and therefore the synthetic strategy is presented in Section 3.1. The 
use of these compounds as valuable building blocks also highlights the importance of 
simple and efficient synthesis. The use of a model piperidine system to optimise the 
installation of the different nitrogen substituents (Figure 3.1) is described in Section 
3.2.  
 
Figure 3.1: Four different nitrogen substituents 
A range of synthetic methods were employed in the preparation of the piperidine 
fragments. These included enolate alkylation methodology (Section 3.3), lithiation-
trapping of N-Boc piperidines (Section 3.4), amino zinc enolate carbocyclisation 
methodology (Section 3.5 and 3.6), a condensation and aza-annulation approach 
(Section 3.7) and reduction of disubstituted pyridines (Section 3.8). 
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3.1 Synthetic strategy 
The computational analysis in Section 2.4 selected 20 fragments for synthesis (Figure 
3.2). Fragment and building block synthesis should be tractable in order to make 
suitable amounts (~ 100-200 mg) of a given compound available for testing, analysis 
and further development. It would therefore be beneficial to try and group similar 
fragments to minimise the number of synthetic routes.  
 
Figure 3.2: The 20 fragments selected for synthesis using our analysis protocol. 
It was envisaged that the fragments could be grouped based on the position of the 
substituents. Therefore, the following groupings were devised.  
 A1 – A9 – geminal disubstituted piperidines 
 A16, A19 and A20 – 2,6-disubstituted piperidines 
 A38, A40, A41 and A42 – 2,3-disubsituted piperidines 
In addition, some of the fragments have similar substitution patterns, such as A65, 
A66, A71, A72 and A89, with adjacent methyl and ester arrangement. It could be 
imagined that these fragments may be synthesised using related methodology. The 
synthesis towards the selected fragments is described below. 
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3.2 Optimisation of N-functionalisation methods using a model piperidine 
In order to vary the structures within the sub-set library, four different nitrogen 
substituents will be used to functionalise the compounds (Figure 3.3). These are NH, 
N-methyl, N-methanesulfonyl and N-acetyl groups. It would be desirable to develop a 
synthetic sequence that can be used to install these groups in the minimum number of 
steps and in good yield. It is also essential to ensure that the synthetic sequence is 
carried out in a suitable order to prevent the formation of any undesirable by-products.  
 
Figure 3.3: The four different nitrogen substituents installed to give the final fragments. 
It was decided that a model piperidine would be used to investigate suitable methods 
and conditions for N-functionalisation. Thus, N-protected, methyl ester piperidine 16 
was selected. Using a literature method,66 treatment of pipecolic acid 15 with thionyl 
chloride and methanol and subsequent Boc protection gave methyl ester 16 in 94% 
yield (Scheme 3.1). 
 
Scheme 3.1 
The first nitrogen substituent would simply be the free amine. Before deprotection, it 
is desirable to reduce the ester. If the deprotection was carried out first, the isolation 
and purification of the amino alcohol may be difficult. This synthetic order avoids this 
complication. Alcohol 17 was obtained through the treatment of methyl ester 16 with 
lithium aluminium hydride in 88% yield. We planned to remove the Boc group using 
HCl in Et2O, a procedure that allows for evaporation of solvent under reduced pressure 
after reaction completion to give clean deprotected amine as the hydrochloride salt. 
Treatment of piperidine alcohol 17 with commercially available 2 M HCl in Et2O gave 
deprotected amino alcohol 18.HCl in 100% yield (Scheme 3.2). 
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Scheme 3.2 
Next, a reliable route to the N-methyl substituent was needed. It was proposed that 
direct reduction of the Boc group of methyl ester 16 using lithium aluminium hydride 
would yield the N-methyl group, as shown by Bowen and co-workers in the synthesis 
of various piperidines.67 Treatment of piperidine ester 16 with lithium aluminium 
hydride at reflux gave piperidine 19 in 82% yield (Scheme 3.3). As hoped, the 
simultaneous reduction of the ester group to give the hydroxymethyl occurred, 
negating the need for separate steps. The clean reaction also meant that purification 
was not required. 
 
Scheme 3.3 
We expected that the other two model fragments containing N-sulfonyl and N-acetyl 
groups could be made by functionalisation of the deprotected amino ester 20 followed 
by reduction to give the alcohol. The ester would be reduced after N-functionalisation 
to prevent unwanted reaction of the alcohol with acetyl chloride or methanesulfonyl 
chloride. In effect, the ester is acting as a protecting group for the hydroxymethyl 
substituent. The Boc group was removed from methyl ester 16 using HCl formed in 
situ from the reaction of acetyl chloride and ethanol. This gave deprotected methyl 
ester 20.HCl as the hydrochloride salt in 82% yield (Scheme 3.4). 
 
104 
 
 
Scheme 3.4 
From here, the nitrogen substituent was installed. Treatment of hydrochloride salt 
20.HCl with acetyl chloride gave acetamide 21 in 99% yield. Subsequent reduction of 
acetamide ester 21 using lithium aluminium hydride gave a poor 19% yield of 
acetamide amino alcohol 22. This could be due to over-reduction of the acetamide, but 
by-products were obtained in too low yield to be identified. Due to the poor results 
from the reduction using lithium aluminium hydride, lithium borohydride was 
investigated as a milder reducing agent. The reduction of piperidine ester 21 with 
lithium borohydride was carried out in THF at room temperature to give a 29% yield 
of acetamide alcohol 22 (Scheme 3.5). 
 
Scheme 3.5 
Sulfonamide 24 can also be prepared from the deprotected methyl ester hydrochloride 
salt 20.HCl. Reaction of 20.HCl with methanesulfonyl chloride gave sulfonamide 
ester 23 in 87% yield. Subsequent reduction of the ester 23 with lithium aluminium 
hydride was much more straightforward than the amide and gave sulfonamide alcohol 
24 in 85% yield (Scheme 3.5).  
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These reactions demonstrate that if we had access to the N-Boc methyl ester precursors 
of fragments then we have reactions in place to introduce all the N-groups in a few 
simple and mild steps and in good yield.   
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3.3 Synthesis of geminal disubstituted piperidines 
The fragments A1, A2, A5, A6 and A9 (Figure 3.4) have geminal substituents and 
therefore it was envisaged that the same methodology could be used to synthesise each 
group of isomers.  
 
Figure 3.4: The five geminal disubstituted piperidines selected for synthesis. 
The previous syntheses of these types of compound in the literature have focused on 
enolate alkylation chemistry, starting from the different piperidine esters to give 
disubstituted piperidine esters. For example, work by Ikeda and co-workers in the 
synthesis of 2-(but-3-ynyl)-1-(o-iodobenzoyl) piperidines used lithium 
bis(trimethylsilyl)amide to deprotonate N-Boc piperidine ester 16 in THF at –78 °C 
for 15 min. Subsequent trapping with methyl iodide gave methylated ester 25 in 
quantitative yield (Scheme 3.6).68  
 
Scheme 3.6 
Onomura and colleages reported the racemic synthesis of 2,2-disubstituted piperidine 
27 by the methylation of enantiomerically pure piperidine ester 26 using sodium 
hexamethyldisilazide and three equivalents of methyl iodide in 89% yield (Scheme 
3.7). The deprotonation in this case was started at –78 °C and warmed to –20 °C for 
30 min.69 
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Scheme 3.7 
The synthesis of a 3,3-disubstituted piperidine also using 1.2 equivalents of sodium 
hexamethyldisilazide was reported by McNamara and co-workers. Here the enolate of 
free piperidine 28 was alkylated with MeI (Scheme 3.8). It was reported that enolate 
alkylation occurred preferentially over N-alkylation, but the yield was not given.70 
 
Scheme 3.8 
Paterniti and co-workers also reported the synthesis of 3,3-disubsituted piperidines. 
However, in this case, N-Boc protection was used and the enolate formation was 
carried out with LDA at –78 °C. Alkylation was then carried out with methyl iodide 
to give piperidine 32 in 90% yield (Scheme 3.9).71 LDA was also employed as the 
base in the enolate alkylation of 4-ester piperidine 31 as reported by Gordeev and 
colleagues.72 Alkylation with methyl iodide gave 4,4-disubstituted piperidine 33 in 
70% yield. 
 
Scheme 3.9 
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As there have been a number of different bases used in the literature with varying 
conditions, the enolate alkylation of N-Boc piperidine 16 was undertaken using lithium 
bis(trimethylsilyl)amide in THF at –78 °C for 1 h and methyl iodide in our hands, due 
mainly to availability of reagents. Starting with 2-ester substituted piperidine 16, these 
conditions gave a 91:9 mixture of product 25 and starting material 16, which could not 
be separated by column chromatography (Table 3.1, Entry 1). The ratio of 25:16 was 
determined by integrating the δ 3.71 and δ 3.70 signals in the 1H NMR spectrum of 
the crude product. In order to increase conversion to product, other conditions were 
explored. DMPU was added to the lithium bis(trimethylsilyl)amide reaction. DMPU 
is known to increase the nucleophilicity and basicity of reagents which is believed to 
be due to it breaking apart aggregates.73 This was also compared with potassium 
bis(trimethylsilyl)amide.  The results are summarised in Table 3.1.  
 
Entry Base Product:Starting materiala Yieldb 
1 LHMDS 91:9 68% 
2 LHMDS + DMPU 42:58 72% 
3 KHMDS 98:2 96% 
Table 3.1: Comparison of different bases and conditions used in the enolate alkylation of 
piperidine methyl ester 16. a Obtained from the 1H NMR spectrum of the crude product. b % 
yield of crude product.  
It appeared that addition of DMPU to the LHMDS reaction had a detrimental effect 
on conversion to product 25, with only a small increase in yield (Entry 2). The best 
result was obtained with KHMDS, giving a 98:2 mixture of product 25 and starting 
material 16 and a crude yield of 96% (Entry 3). These conditions were carried forward 
for use in a large-scale synthesis of methylated ester 25. Treatment of methyl ester 
piperidine 16 (5.0 mmol) with KHMDS and subsequent trapping with methyl iodide 
gave a 95:5 mixture (by 1H NMR spectroscopy) of methylated ester 25 and starting 
methyl ester piperidine 16 (94% and 5% yield of methylated ester 25 and piperidine 
16 respectively) after column chromatography (Scheme 3.10). These inseparable 
compounds were carried forward as a mixture.  
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Scheme 3.10 
Our hope was that after reduction of the mixture of 25 and 16, the resulting alcohols 
would be separable. For the synthesis of fragment A1, the methylated ester 25 needed 
to be reduced and the Boc group deprotected. Thus, the 95:5 mixture of methylated 
piperidine 25 and starting ester 16 was treated with lithium aluminium hydride. This 
gave a separable mixture of methylated amino alcohol 34 and amino alcohol 17, which 
were obtained in a 65% yield and quantitative yield from 25 and 16 respectively 
(Scheme 3.11). 
 
Scheme 3.11 
The pure amino alcohol 34 was then taken on and treated with HCl in Et2O to obtain 
the deprotected methylated piperidine A1.HCl as a hydrochloride salt in 58% yield 
(Scheme 3.12). The methylated fragment A2 could be synthesised from the already 
reduced piperidine alcohol 34. Reduction straight from the mixture of 25 and 16 would 
lead to two very polar, difficult to separate products. Therefore, reduction from 
piperidine alcohol 34 negates the need for purification. The reduction of the Boc group 
using lithium aluminium hydride gave the methylated disubstituted piperidine A2 in 
76% yield (Scheme 3.12).  
 
Scheme 3.12 
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The enolate alkylation methodology used above was then applied to the synthesis of 
fragments A5, A6 and A9. Fragments A5 and A6, were prepared from nipecotic acid 
35. Reaction of nipecotic acid 35 with thionyl chloride in methanol followed by Boc 
protection gave piperidine ester 36 in 81% yield (Scheme 3.13). The new enolate 
alkylation conditions were then employed on piperidine ester 36. Deprotonation with 
KHMDS followed by trapping with methyl iodide gave methylated piperidine ester 37 
in 97% yield after column chromatography (Scheme 3.13). In this case, methylated 
piperidine ester 37 was obtained as a single product and there was no remaining 
starting material. 
 
Scheme 3.13 
The methylated piperidine ester 37 was then reduced using lithium aluminium hydride 
to give amino alcohol 38 in 91% yield. Subsequent deprotection of this substrate with 
HCl in Et2O gave the final fragment A5.HCl in 94% yield (Scheme 3.14). Fragment 
A6 was prepared by direct reduction of piperidine ester 37 using lithium aluminium 
hydride. This gave methyl amino piperidine A6 in 96% yield (Scheme 3.14). 
 
Scheme 3.14 
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The final fragment in this group is 4,4-disubstituted piperidine A9. The starting methyl 
ester 31 for this synthesis was prepared from isonipecotic acid 38. Reaction with 
thionyl chloride in methanol and subsequent Boc protection gave the methyl ester 31 
in 85% yield (Scheme 3.15). Enolate alkylation of piperidine ester 31 using our 
standard conditions gave disubstituted piperidine 33 in quantitative yield (Scheme 
3.15).  
 
Scheme 3.15 
Methylated piperidine ester 33 was then reduced using lithium aluminium hydride to 
give amino alcohol 39 in quantitative yield (Scheme 3.16). Deprotection of amino 
alcohol 39 using HCl in Et2O gave a quantitative yield of 4,4-disubstituted piperidine 
A9.HCl (Scheme 3.16). 
 
Scheme 3.16 
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3.4 Synthesis of 2-hydroxymethyl, 6-methyl disubstituted piperidines 
Our next set of targets were fragments A16, A19 and A20, which bear a 2,6-
disubstitution pattern in both cis and trans configurations (Figure 3.5). It must be noted 
that fragment A16 was selected in a previous version of the protocol (Section 1.2). 
The synthesis of this fragment had already started and was therefore completed despite 
not being selected by our current version of the protocol. A number of routes to 
different 2,6-disubstituted piperidines have been previously reported in the literature 
and a selection of the main approaches will be briefly summarised. The methods 
described focus on methyl, ester and some hydroxymethyl substituted piperidines as 
these are the most relevant to the synthesis of A16, A19 and A20.  
 
Figure 3.5: The three 2,6-disubstituted fragments selected for synthesis. 
Blechert and colleagues reported a route to cis-43 via ruthenium-catalysed cross 
metathesis of alkyl-substituted olefins and subsequent reductive amination.74 First, 
cross-coupling of N-protected homoallylic amine 40 with enone 41 in the presence of 
the ruthenium catalyst 44 gave amino enone 42 in 85% yield. Then, reaction with H2 
and Pd/C provided disubstituted piperidine ester cis-43 in 85% yield, selectively as 
the cis diastereomer (Scheme 3.17). Hydrogenation of the intermediate iminium ion 
on the face opposite the ester group explains the diastereoselectivity.74 
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Scheme 3.17 
A four-step synthesis of 2,6-disubstituted piperidines was reported by Lubell and co-
workers.75 This route from aspartic acid features an aldol condensation, dehydration 
and reductive amination. Initially, methyl alkyl ketone was treated with LDA to give 
the lithium enolate, which was then reacted with an aldehyde in an aldol condensation 
to give amino-ester 45 in 68% yield (Scheme 3.18). Amino-ester 45 was then treated 
with methansulfonyl chloride and triethylamine in CH2Cl2 to give the enone 46 in 86% 
yield by an elimination reaction of the methansulfonate (Scheme 3.18). 
Diastereoselective hydrogenation of enone 46 subsequently gave pipecolate tert-butyl 
ester cis-47 in 90% yield (Scheme 3.18).75  
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Scheme 3.18 
The lithiation-trapping of N-Boc nitrogen heterocycles, first reported by Beak76, has 
been reported by a number of groups as a method to synthesise 2,6-disubsituted 
piperidines. Hart and Wu reported the lithiation of protected hydroxymethyl N-Boc 
piperidine 48 using s-BuLi/TMEDA and trapping with methyl iodide to give 
disubstituted piperidine trans-50 in 71% yield (Scheme 3.19). The product was then 
used in their preparation of the natural product (+)-Himbacine.77 In a similar process, 
Pissarnitski reported the lithiation of N-Boc methylpiperidine 49 and trapping with 
DMF as a method to obtain 2,6-disubstituted piperidine trans-51 (Scheme 3.19). 
Aldehyde 51 was used in the synthesis of γ-sectretase inhibitors.78 An explanation of 
the trans-diastereoselectivity of both of these reactions is presented later. 
 
Scheme 3.19 
Both of these synthetic routes follow the conditions originally outlined by Beak in 
1989.76 It involves the treatment of an N-Boc heterocycle with s-BuLi and a ligand 
such as TMEDA followed by trapping with a suitable electrophile to give α-substituted 
N-heterocycles. Investigation into the lithiation-trapping of mono-substituted N-Boc 
heterocycles is well precedented.79-81 The lithiation-trapping of 2-substituted N-Boc 
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piperidines preferentially gives trans stereochemistry, as shown in the lithiation-
trapping of 2-methyl N-Boc piperidine 49 with dimethylsulfate (Scheme 3.20).82  
 
Scheme 3.20 
Our plan was to use Beak’s methodology to access fragment A16. Using lithiation-
trapping gives us the opportunity to use a range of electrophiles to introduce the 
different substituents and could also open up synthetic variation in the future. 
 
There are two alternative routes to furnish disubstituted piperidine 54. Piperidine 
methanol 53 can undergo lithiation-trapping with a methylating agent to give 
disubstituted piperidine or methyl piperidine 49 can undergo lithiation-trapping with 
DMF, subsequent reduction would give the disubstituted piperidine 54 (Scheme 3.21). 
Each of these methods are presented in turn below. 
 
Scheme 3.21 
To start with, protected N-Boc piperidine 55 was prepared. Boc protection with Boc2O 
gave protected piperidine 17 in 80% yield. This was followed by reaction with 
triisopropylsilyl chloride to give fully protected N-Boc piperidine 55 in 92% yield 
(Scheme 3.22). 
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Scheme 3.22 
An important factor to consider before the lithiation-trapping is the rotamer 
interconversion of the Boc group. The lithiation time can be affected by the orientation 
of the Boc group. In order for lithiation to occur the carbonyl of the Boc group must 
be oriented correctly to direct the organolithium to the site of lithiation (B) in Figure 
3.6.  
 
Figure 3.6 
If there is a slow rate of interconversion of rotamers A and B at the reaction 
temperature, only some of the compound will be in the correct orientation for lithiation 
and therefore the yield of the reaction will be limited. The α-proton of rotamer A is 
too sterically hindered to undergo lithiation, reaction only occurs on rotamer B.83,84 In 
order to calculate the rate of interconversion, VT NMR spectroscopic studies were 
carried out on N-Boc piperidine 55. The rate for the interconversion of the two 
rotamers (A and B), k, can be calculated using the Eyring equation (1). 
𝑘 = (kB ∙ T/h)∙𝑒
(−∆G‡/RT) (1) 
where kB is Boltzmann’s constant, h is Planck’s constant, R is the gas constant and 
ΔG‡ is the Gibbs free energy of activation.  
In the low temperature NMR spectrum, there will be two distinct signals 
corresponding to the two rotamers. As the temperature the spectrum is run at increases, 
the signals move together. When the signals finally merge into one signal, this is the 
coalescence temperature (See Figure 3.7). At the coalescence temperature, Tc, the rate 
constant, k, is given by equation (2). 
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𝑘 = (𝜋 ∙ ∆𝑣0)/√2  (2) 
where Δv0 is the separation in Hertz between the peaks of A and B at the slow rate of 
interconversion. From this, ΔG‡ can be calculated using equation (3). 
∆𝐺‡ =  RT[ln(kB ∙ T/h) − ln𝑘] (3) 
Using this value of ΔG‡, it is possible to calculate the rate constant k at different 
temperatures using the Eyring equation (1). This uses the assumption that the change 
in entropy is zero on changing temperature. Once k is known, it is possible to calculate 
the half-life at a particular temperature using equation (4) 
𝑡1/2 =  ln2/𝑘  (4) 
Using 1H NMR spectroscopy of N-Boc piperidine 55 in toluene-d8 at different 
temperatures, it was possible to calculate the rate constant k at the coalescence 
temperature. The NCH signals at δ 2.68 and δ 2.47 were selected. At –60 °C, Δv0 = 
82.4 Hz (Figure 3.7, a). This gave the rate constant k = 183 s–1 and a half life t1/2 ≈ 
0.003 s at Tc. The two signals coalesced at approximately 10 °C (283 K) (Figure 3.7, 
e). At a temperature of –78 °C (195 K), the half-life can be calculated using equation 
(4). At –78 °C, t1/2 ≈ 5 minutes, whereas at –50 °C, t1/2 ≈ 3 seconds.  
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Figure 3.7: 1H NMR spectra of N-Boc piperidine 55 at different temperatures. 
Using this information, it was possible to identify a suitable temperature for lithiation. 
The results suggest that the rotamer interconversion is rapid enough at both –78 °C 
and –50 °C for lithiation of N-Boc piperidine 55.   
 
The lithiation reaction of N-Boc piperidine 55 was carried out at these two different 
temperatures for different lengths of time using s-BuLi and TMEDA in Et2O. 
Dimethylsulfate was chosen as the electrophile for trapping to give disubstituted 
piperidine trans-56 (Scheme 3.23 and Table 3.2).  
 
Scheme 3.23 
Entry Temperature Time Result 
1 –50 °C 1 h 41% product, 57% starting material 
2 –78 °C 3 h 29% product, 52% starting material 
Table 3.2: The different conditions used for the lithiation-trapping of N-Boc piperidine 55. 
The most promising result was obtained using lithiation at –50 °C for 1 hour, which 
gave disubstituted piperidine trans-56 in 41% yield (Entry 1). The 1H NMR spectrum 
a. –60 °C 
b. –40 °C 
c. –20 °C 
d. 0 °C 
e. 20 °C 
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of the crude product indicated that only one diastereomer was obtained. Literature 
precedent would suggest that the trans diastereomer is obtained preferentially.85 The 
CH2OTIPS group preferentially sits in the axial position to avoid A
1,3 strain between 
the substituent and the Boc group, shown in Figure 3.8. Due to this well-established 
literature precedent it has been assumed that the trans-diastereomer is the major 
product in all the lithiation-trapping reactions in this section.  
 
Figure 3.8 
The carbonyl of the Boc group then directs the deprotonation of the 6-equatorial 
proton, by coordination to the lithium, to give intermediate 57. The electrophile then 
adds with retention of stereochemistry of the lithium to give trans-56 as shown in 
Scheme 3.24. 
 
Scheme 3.24 
It was surprising that such a large amount of starting material was recovered from 
these two reactions, especially in light of the interconversion of rotamers at –50 and –
78 °C. A possible explanation is the incomplete trapping by dimethylsulfate as other 
work in the O’Brien group had shown that this electrophile is one of the slowest to 
trap.86 As the yield of this lithiation-trapping sequence was low and there would also 
be a need for protecting group removal in the synthesis, it was decided to investigate 
the alternative lithiation-trapping sequence.  
 
It was proposed that the lithiation trapping of N-Boc methyl piperidine 49 should be 
investigated.  The lithiation-trapping chemistry of this substrate benefits from the 
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range of different electrophiles that could be used to install the CH2OH group. These 
include DMF, methylchloroformate and CO2 to give the aldehyde, methyl ester and 
carboxylic acid respectively. Although each of these electrophiles would require 
reduction after installation to obtain the desired hydroxymethyl group, this route opens 
up synthetic flexibility. 
 
Although the lithiation-trapping of 2-methyl piperidine 49 is precedented,82,87-89 it was 
desired to optimise the lithiation conditions in our hands. N-Boc 2-methyl piperidine 
49, was synthesised from 2-methyl piperidine 58 and Boc2O in 82% yield (Scheme 
3.25). Trimethylsilyl chloride was chosen as the electrophile for the initial 
optimisation study. The lithiation temperature and time were varied, as shown in Table 
3.3. 
 
Scheme 3.25 
Entry Temperature / °C 
Time / 
h 
Product yield / % 
Recovered starting 
material / % 
1 –78 3  63 15 
2 –78 1 30 26 
3 –50 1 70 2 
4 –40 1 68 17 
5 –40 1.5 85 2 
Table 3.3: Different lithiation conditions used in the lithiation-trapping of 2-methyl 
piperidine 49 and trimethylsilylchloride. 
To start, a lithiation at –78 °C for 3 hours was selected, based on Beak’s literature 
precedent.76,81 This gave a 63% yield of trans-59 (Entry 1). A shorter lithiation time 
(1 h) gave a lower yield (30%, Entry 2). Other reports have suggested that at a higher 
temperature, a shorter lithiation time is possible.82,90,91 Therefore, –40 °C and –50 °C 
were also chosen. The promising result shown at –40 °C for 1 hour (Entry 4) led to 
attempting the lithiation at –40 °C for 1.5 hours which gave the highest yield (85%) 
of disubstituted piperidine trans-59 (Entry 5). Hence, these conditions were used in 
all subsequent lithiation-trapping reactions of 2-methyl piperidine 49.  
121 
 
 
Trapping with DMF as the electrophile allows for installation of an aldehyde ⍺ to the 
nitrogen. Following this transformation with a reduction would then give the desired 
hydroxymethyl substituted piperidine. The optimised lithiation conditions were then 
used for the lithiation-trapping of N-Boc 2-methyl piperidine 49 with DMF and 
subsequent reduction of the aldehyde gave disubstituted piperidine trans-61 (Scheme 
3.26). Electrophile trapping was carried out at –78 °C for 10 minutes before quenching 
with water, which gave an 80:20 mixture of disubstituted aldehydes trans-60 and cis-
60 by 1H NMR spectroscopy of the crude reaction mixture. Reduction of the crude 
aldehyde mixture with sodium borohydride gave an 80:20 mixture of inseparable 
disubstituted alcohols trans-61 and cis-61, isolated in 81% yield over the two steps 
from piperidine 49 (Scheme 3.26). 
 
Scheme 3.26 
The lithiation-trapping of 2-methyl piperidine 49 with DMF was therefore repeated, 
but rather than cooling to –78 °C and adding the electrophile we explored addition the 
electrophile at –40 °C and leaving the mixture to warm to room temperature overnight.  
This gave an 80:20 mixture of disubstituted aldehydes cis-60 and trans-60 by 1H NMR 
spectroscopy of the crude reaction mixture. Assignment was based on comparison to 
literature92, J values for all diagnostic protons could not be obtained due to poor 
resolution. Reduction of the crude aldehyde mixture 60 with sodium borohydride gave 
an 80:20 mixture of inseparable disubstituted alcohols cis-61 and trans-61 in 30% 
yield over two steps (Scheme 3.27). Interestingly, the cis-diastereomer was now the 
major product. 
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Scheme 3.27 
Beak observed a similar in situ epimerisation of an 89:11 mixture of trans-60 and cis-
60 on silica during purification to give an 83:17 mixture of cis-60 and trans-60.81 This 
could be explained by the conformation of the different products. Due to the avoidance 
of A1,3 strain, it is postulated that the lowest energy conformer will put the aldehyde 
group in the axial position to give cis-60 (Scheme 3.28).79,85 These reactions show that 
electrophile trapping at a lower temperature preferentially gives the trans-aldehyde, 
the kinetic product, whereas electrophile trapping at a higher temperature gives the 
cis-aldehyde, the thermodynamic product. 
 
Scheme 3.28 
Although the formation of both of the diastereomers is favourable for synthetic 
versatility and in relation to the desired fragments A16, A19 and A20, the difficulty in 
separation of the different diastereomers meant that an alternative method for the 
synthesis of the fragments was sought. Fortunately, lithiation-trapping of N-Boc 2-
methyl piperidine 49 with CO2 yielded the 2,6-disubstituted piperidine trans-62 as a 
single diastereomer, by 1H NMR spectroscopy, in 82% yield (Scheme 3.29). This 2,6-
disubstituted piperidine trans-62 was then reacted with Me3Si-diazomethane to give 
methyl ester trans-63 in 93% yield (Scheme 3.29). Alternatively, 2,6-disubstituted 
piperidine trans-62 was reacted with potassium carbonate and methyl iodide in DMF 
to give methyl ester 63 in 97% yield. This reaction is more amenable to larger scale 
synthesis (Scheme 3.29). 
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Scheme 3.29 
 
With methyl ester piperidine trans-63 in hand, the final functionalisation was carried 
out to give 2,6-disubstituted piperidine A16. 2,6-Disubstituted ester trans-63 was 
deprotected with HCl, generated in situ from acetyl chloride and ethanol, to give 
deprotected disubstituted piperidine trans-43.HCl (Scheme 3.30).  
 
Scheme 3.30 
Piperidine salt 43.HCl was then converted into the piperidine acetamide trans-64 
through reaction with acetyl chloride in the presence of triethylamine to give the 
acetamide in 96% yield (Scheme 3.31). Subsequent reduction using lithium 
borohydride conditions gave acetamide alcohol fragment A16 in 66% yield (Scheme 
3.31). 
 
Scheme 3.31 
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We have successfully synthesised selected fragment A16 in good yield in five steps 
from N-Boc 2-methylpiperidine. This synthesis is amenable to scale up and provides 
the intermediate piperidine ester trans-63 which could be derivatised further if 
fragment A16 proved interesting. It is envisaged that the intermediate piperidine ester 
trans-63 could be epimerised to give the piperidine ester cis-63, the precursor to 
fragments A19 and A20. Treatment of piperidine ester trans-63 with sodium 
methoxide in methanol could give piperidine ester cis-63 (Scheme 3.32). Deprotection 
with HCl, generated in situ from acetyl chloride and ethanol would give the piperidine 
ester cis-43.HCl (Scheme 3.32).  
 
Scheme 3.32 
Functionalisation with methanesulfonyl chloride or acetyl chloride using our N-
functionalisation conditions and subsequent reduction of the ester would furnish the 
two final fragments A19 and A20 (Scheme 3.33). 
 
Scheme 3.33 
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3.5 Synthesis of 2-hydroxymethyl, 3-methyl disubstituted piperidines 
The synthesis of fragments bearing a 2,3-substitution pattern such as fragments A71 
and A72 (Figure 3.9) has not been reported extensively in the literature. Therefore, the 
synthesis of related disubstituted piperidines bearing ester or carboxylic acid groups 
in the 2-position and alkyl or aryl groups in the 3-position is briefly summarised here.  
 
Figure 3.9: The two selected 2-hydroxymethyl, 3-methyl disubstituted piperidine fragments. 
 
In 2002, Burke and co-workers reported a synthesis of an enantiomerically pure N-
Fmoc protected 3-phenylpipecolic acid for use as a constrained phenylalanine 
analogue.93,94 This synthesis employed commercially available Evans auxiliary 67 to 
install the desired stereochemistry. The diastereoselective 1,4-addition of 
allylmagnesium bromide using a copper bromide dimethyl sulfide complex to 67 gave 
an alkene, which after hydroboration gave alcohol 68 in 65% over two steps (Scheme 
3.34).93 Next, alcohol 68 was protected using tert-butyldimethylsilyl chloride. This 
compound was then subjected to asymmetric azidation to give 69 in 92% yield. In 
order for cyclisation to occur deprotection of the TBS ether was undertaken using 
HF·pyridine to yield alcohol 72 in 95% yield. Synthesis of the piperidine was then 
attempted using imine formation to help cyclisation. Alcohol 72 was subjected to 
Swern oxidation which was then ring closed by reductive amination to give methyl 
ester piperidine 70 in 52% yield. This was then converted into the desired Fmoc 
piperidine 71 in 40% yield (Scheme 3.34) over a total of nine synthetic steps.93 
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Scheme 3.34 
Synthesis of 3-substituted pipecolic methyl esters for use as conformationally 
constrained analogues of peptide-based protease inhibitors was also reported by 
Mallamo and colleagues.95 Here, catalytic hydrogenation proved crucial in obtaining 
cis-disubstituted piperidine 75. Triflate 73 was converted into 3-methyl, 2-ester 
pyridine 74 through a Stille coupling in 50% yield. This pyridine was then converted 
into 3-methyl, 2-ester piperidine 75 by high pressure catalytic hydrogenation in 
quantitative yield (Scheme 3.35). The hydrogenation selectively gave the cis-
diastereomer, which was confirmed by coupling constants observed in the 1H NMR 
spectrum.  
 
Scheme 3.35 
During an investigation into the uses of iridium-catalysed asymmetric allylic 
substitution, Takemoto reported the synthesis of pipecolic acid derivatives and 2,3-
disubstituted piperidine 70.96 Allyl-ester 76 was easily converted into pipecolic acid 
derivative 77 (Scheme 3.36) with a ring closing metathesis reaction as the key step. 
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Conversion of pipecolic acid derivative 77 into trans-disubstituted piperidine 70 was 
achieved by hydrogenation in 52% yield (Scheme 3.36).96   
 
Scheme 3.36 
2-Ester, 3-methyl disubstituted piperidines can also be synthesised using amino zinc 
enolate carbocyclisation reactions. Such reactions were reported by Normant and 
colleagues in the development of methodology for the synthesis of polysubstituted 
piperidines. For example, amino-ester 78 was deprotonated with LDA in Et2O and 
then transmetallated with zinc bromide to obtain the Z-amino zinc enolate. A 6-exo-
trig cyclisation via intramolecular carbo-metallation occurs upon warming to room 
temperature to give piperidine intermediate 79. This intermediate can be treated with 
various electrophiles. In this case, protonation gave disubstituted piperidine cis-80 
(Scheme 3.37).97 
 
Scheme 3.37 
The reaction gives selectively cis-disubstituted piperidines which can be explained by 
the chair-like transition state of the oxygen-centred zinc-enolate-ene-type reactive 
intermediate. The electrophilic double bond occupies a pseudoaxial position and the 
Z-α-amino zinc enolate and the double bond are gauche to each other as shown in 
Figure 3.10.97,98   
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Figure 3.10 
An epimerisation for the conversion of disubstituted piperidine cis-80 into 
disubstituted piperidine trans-80 was also reported by Normant (Scheme 3.38).97 
Deprotonation with LDA at low temperature (–78 °C) and then reprotonation at room 
temperature gave a 35:65 mixture of cis-80 and trans-80. These unusual conditions 
employ a kinetic protonation to give the more stable trans-diastereomer, compared to 
a more typical epimerisation via thermodynamic equilibration. 
 
Scheme 3.38 
Based on this somewhat limited literature precedent, we decided to investigate the use 
of Normant’s amino zinc enolate carbocyclisation methodology in our synthesis 
towards fragments A71 and A72. The lengthy asymmetric synthetic route described 
by Burke and the need for high pressure hydrogenation in Mallamo’s synthesis 
suggested that Normant’s route would be a more favourable way to access 
disubstituted piperidines. In addition, the option to trap with a number of different 
electrophiles after cyclisation opened up the opportunity for further functionalisation 
of the fragments.  
 
The required amino-ester 78 was synthesised in two steps from benzylamine following 
literature procedures.97 Firstly, benzylamine and 5-bromopentene 81 were reacted in 
the presence of sodium iodide to give N-benzyl-N-pentenylamine 82 in 47% yield. 
Subsequent reaction of amine 82 with methyl α-bromoacetate in a nucleophilic 
substitution reaction gave amino ester 78 in 87% yield (Scheme 3.39).  
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Scheme 3.39 
With amino-ester 78 in hand, the amino-zinc enolate carbocyclisation reaction was 
undertaken using similar conditions to those reported by Normant.97 Reaction of 
amino-ester 78 with LHMDS gave the lithium enolate which was subsequently reacted 
with zinc bromide and warmed to room temperature to give cyclised intermediate 79. 
Hydrolysis selectively gave the disubstituted piperidine cis-80 in varying yields (15 to 
40%, Table 3.4).  
 
Entry Description Scale / mmol Yield / % 
1 Standard reaction 0.8 15 
2 
Sonication for 10 minutes after addition to 
reaction mixture 
4.04 40 
3 
Sonication for 10 minutes every 1 h after 
addition of enolate 
2.02 39 
4 
Vigorous stirring of zinc bromide in Et2O 
for 1 h before addition 
40.4 32 
Table 3.4: Different conditions used in the ZnBr2 step. 
These varying yields were thought to be related to the solubility of the zinc bromide 
in Et2O. A standard reaction gave a 15% yield of cis-80 (Entry 1). Zinc bromide has 
poor solubility in Et2O and the reaction mixture was a suspension. Since we believed 
the poor solubility of zinc bromide was hindering the reaction, sonication was used to 
help with solubility. Two different sonication procedures were investigated: the 
reaction mixture was sonicated for 10 minutes after addition of the zinc bromide (Entry 
2) and the reaction mixture was sonicated for 10 minutes every hour during the 5 hours 
stirring at room temperature (Entry 3). The sonication of the reaction mixture in both 
of these cases increased the yield to 40% (Entry 2) and 39% (Entry 3). However, it 
was noticed if the zinc bromide was stirred vigorously in Et2O for one hour before 
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addition to the reaction mixture the zinc bromide was fully solubilised. A similar yield 
(32%, Entry 4) was obtained using this easier procedure.  
 
The fragments selected for the library subset are the trans-diastereomers and therefore 
the reported epimerisation was undertaken next.97 Reaction of disubstituted piperidine 
cis-80 with LDA in Et2O, followed by reprotonation gave a 60:40 mixture of cis-80 
and trans-80 from the 1H NMR spectrum of the crude reaction product. The diagnostic 
signals are the doublet at δ 3.41 with a J value of 5.0 Hz corresponding to cis-80 and 
the doublet at δ 2.64 with a J value of 9.0 Hz corresponding the larger coupling of 
trans-80. They were then separated by column chromatography to give trans-80 in 
57% yield and cis-80 in 40% yield (Scheme 3.40).  
 
Scheme 3.40 
Deprotection of trans-80 using transfer hydrogenation conditions with palladium 
hydroxide and ammonium formate gave free amine trans-75 in quantitative yield 
(Scheme 3.41).99  
 
Scheme 3.41 
With trans-75 in hand, using the conditions described in Section 3.2 for 
functionalisation and reduction would be carried out to give fragments A71 and A72 
(Scheme 3.42). However, due to time constraints, this was not completed. 
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Scheme 3.42 
This amino-zinc cyclisation methodology has furnished the desired precursor 
fragments A71 and A72 in good yield. This methodology is also very versatile. Both 
diastereomers can be obtained and the opportunity to trap the zinc-enolate with 
different electrophiles opens up the possibility of synthetic variation and fragment 
development. The use of the methyl-ester fits well with our N-functionalisation 
strategy and also opens up a route to the synthesis of different fragments.  
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3.6 Synthesis of 3-hydroxymethyl, 4-methyl and 4-hydroxymethyl, 5-methyl 
disubstituted piperidines 
Given the success with the amino zinc enolate carbocyclisation methodology 
described in Section 3.5, we reasoned that the same approach could also be used to 
synthesise fragments A65, A66 and A89, as all of these fragments bear an adjacent 
hydroxymethyl and methyl motif (Figure 3.11).  
 
Figure 3.11 
It was envisaged that with synthesis of suitable amino-esters 85 and 87, 
carbocyclisation reactions would give the desired disubstituted piperidines cis-86 and 
cis-88 respectively (Scheme 3.43). 
  
Scheme 3.43 
Amino esters 85 and 87 were prepared following established routes. Reaction of 
benzylamine with 4-bromobut-1-ene 89 in the presence of sodium iodide and 
potassium carbonate gave N-benzylbut-3-en-1-amine 90 in 38% yield.97 Subsequent 
reaction of this with methyl acrylate in the presence of DBU gave the desired amine-
ester precursor 85 in 74% yield (Scheme 3.44). 
 
133 
 
 
Scheme 3.44 
Synthesis of N-benzylprop-2-en-1-amine 92 was undertaken by nucleophilic 
substitution of benzyl bromide with an excess of allylamine 91 in the presence of 
potassium carbonate to give a yield of 50% of amine 92.100 N-Benzylprop-2-en-1-
amine 92 was then reacted with methyl 4-bromobutyrate and potassium carbonate to 
give the amino-ester 87 in 56% yield (Scheme 3.45). 
 
Scheme 3.45 
With the suitable amino esters in hand, the conditions with pre-stirring of zinc bromide 
in Et2O used in the synthesis of disubstituted piperidine cis-80 (Section 3.5) were 
employed in the attempted synthesis of disubstituted piperidines cis-86 and cis-88. 
Amino-ester 87 was deprotonated with LHMDS and subsequently reacted with zinc 
bromide, warmed to room temperature and then protonated. Unfortunately, no desired 
product 88 was obtained in this case (Scheme 3.46). However, a Claisen condensation 
product 93 was obtained and identified. The Claisen condensation product is formed 
from the initially generated lithium enolate self-condensing with the ester (Scheme 
3.46). The structure of the Claisen condensation by-product was determined using a 
number of analytical techniques. The presence of two carbonyl peaks in both the 13C 
NMR spectrum (δ 205.3 and δ 170.4) and the IR spectrum (1743 cm-1 and 1713 cm-1) 
were indicative of a condensation product. The increased proton count and the dd at δ 
3.59 in the 1H NMR spectrum also suggested the condensation product, which the peak 
at [M + H]+ = 463 in the mass spectrum confirmed.   
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Scheme 3.46 
Reverse addition of the amino-ester 87 to a solution of LHMDS may reduce the 
possibility of Claisen condensation. Addition of LHMDS into the ester solution means 
that the enolate is formed in the presence of a large amount of ester, allowing for 
condensation to occur. However, addition of the ester into a solution of LHMDS 
ensures that the ester concentration remains low compared to the concentration of 
enolate, reducing the chance of condensation. This reaction was attempted, but only 
the condensation product 93 was obtained in 40% yield and none of the desired 
product was observed (Scheme 3.47).  
 
Scheme 3.47 
Despite the unsuccessful results with amino-ester 87, the amino zinc enolate 
carbocyclisation of amino ester 85 was next attempted. The LHMDS conditions as 
above, with vigorous stirring of zinc bromide before addition were used on amino-
ester 85. Unfortunately, no desired or identifiable product was obtained in this case 
(Scheme 3.48).  
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Scheme 3.48 
Although we had no evidence that Claisen condensation is the issue with amino-ester 
85, we decided to explore whether a more sterically hindered ester could supress side 
reactions and therefore tert-butyl ester 95 was investigated. Synthesis of tert-butyl 
amino ester 95 was undertaken. Reaction of amine 89 with tert-butyl acrylate gave 
amino ester 95 in 67% yield (Scheme 3.49). 
 
Scheme 3.49 
This amino ester 95 was then subjected to LHMDS conditions as above and with the 
zinc bromide stirred vigorously before reaction. Deprotonation with LHMDS and 
subsequent reaction with zinc bromide followed by protonation gave no desired 
product 97 or any other identifiable products (Scheme 3.50).  
 
Scheme 3.50 
Despite our efforts neither of the cyclisations gave the desired disubstituted 
piperidines. Amino-ester 87 gave the Claisen self-condensation product which was not 
observed in Section 3.5 for amino-ester 78. This might be explained by the more 
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hindered enolate disfavouring intermolecular reaction. Therefore, the use of a more 
hindered ester may reduce the chance of Claisen condensation. The second amino-
ester (85) produced no identifiable products, which would suggest that Claisen self-
condensation may not be an issue here. However, Normant reported that competitive 
β-elimination was observed in the synthesis of different isomers of disubstituted 
pyrrolidines and led to recovery of amine 92 (Scheme 3.51).98,101 This type of product, 
however, was not observed in our reaction. 
 
Scheme 3.51 
This methodology has not been reported as a synthetic route towards the synthesis of 
disubstituted piperidines and therefore an alternative route is needed for synthesis of 
fragments A65, A66 and A89.  
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3.7 Synthesis of 2-methyl, 3-hydroxymethyl disubstituted piperidines 
Fragments A38, A40, A41 and A42 all bear a 2-methyl, 3-hydroxymethyl substitution 
pattern (Figure 3.12). Synthesis of piperidines with these substituents has not been 
previously reported. However, synthesis of closely related 2-methyl 3-ester 
disubstituted piperidines is known and a number of routes are briefly summarised 
below.  
 
Figure 3.12: The four selected 2-methyl, 3-hydroxymethyl piperidine fragments  
Work by Terashima and co-workers, reported in 1968, focused on the hydrogenation 
of pyridines. It was found that after N-alkylation, 2,3-disubstituted pyridinium salts 
readily underwent hydrogenation to give disubstituted piperidines.102 Terashima 
reported that reaction of ethyl 2-methylnicotinate 99 with methyl p-toluenesulfonate 
gave methylated pyridinium salt 100. This was subsequently hydrogenated at room 
temperature and atmospheric pressure in the presence of a palladium catalyst to give 
the 2,3-disubstituted piperidine 101 in 88% yield (Scheme 3.52). It was expected that 
the cis diastereomer would be formed, although this was not confirmed. 
 
Scheme 3.52 
The synthesis of 2-methyl, 3-ester disubstituted piperidine was described by Albertson 
in 1950. This synthesis relied on the Michael condensation of acrylonitriles and β-
ketoesters with subsequent reduction of the cyano esters in the presence of Raney 
nickel to yield solely disubstituted piperidines.103 In the example most relevant to our 
fragments, the condensation of acrylonitrile with ethyl acetoacetate gave ethyl (2-
cyano-ethyl)-acetoacetate 102 in 63% yield. This nitrile reduction using Raney nickel 
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and cyclisation gave disubstituted piperidine 103 in 86% yield, with no comment on 
the ratio of diastereomers (Scheme 3.53). 103 
 
Scheme 3.53 
In more recent work, Lhommet reported in 2005, the synthesis of disubstituted 
piperidine via β-enamino carbonyl substructures. The key step of this synthesis 
involves the condensation of (S)-phenylglycinol with prepared tricarbonyl compounds 
to give β-enamino carbonyl derivatives. These can then be converted easily into 
disubstituted piperidines 107.104 A range of tricarbonyl compounds can be synthesised 
from activated methylene compounds and α,β-unsaturated carbonyl compounds. 
Tricarbonyl compound 104 was prepared by Michael reaction of a dicarbonyl 
compound with acrolein on solid Al2O3.
104 The tricarbonyl compound 104 can then be 
reacted with (S)-phenylglycinol in CH2Cl2 to give the β-enamino carbonyl derivative 
105 in 96% yield as a 40:60 mixture of diastereomers (Scheme 3.54).104 
 
Scheme 3.54 
In a subsequent paper, Lhommet and co-workers reported a number of methods to 
manipulate the β-enamino carbonyl derivative 105. Treatment of β-enamino carbonyl 
derivative 105 with sodium triacetoxy borohydride gave disubstituted piperidine 106 
in 93% yield (Scheme 3.55). In this reaction, the double bond is diastereoselectively 
reduced and the oxazolidine ring-opened. Subsequent hydrogenolysis and Boc 
protection gave piperidine cis-107 in 96% yield (Scheme 3.55).105 Hydrogenolysis of 
β-enamino carbonyl derivative 105 in the presence of platinum on carbon gave directly 
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the deprotected piperidine cis-108, which was subsequently treated with Boc2O to 
yield protected piperidine cis-107  in 70% overall yield (Scheme 3.55).105 
 
Scheme 3.55 
Finally, hydrogenolysis of β-enamino carbonyl derivative 105 in the presence of PtO2 
gave a mixture of bicycles 109 in 78% yield. Subsequent treatment with sodium 
triacetoxy borohydride cleaved the oxazolidine ring to give piperidine 110 in 93% 
yield. Alternatively, cleavage and deprotection of the bicycles 109 with hydrogen and 
palladium hydroxide and then treatment with Boc2O gave protected piperidine cis-107 
in 89% yield (Scheme 3.56).105 This variety of methods for manipulation of the β-
enamino carbonyl derivative 105 gives a greater opportunity for synthetic 
development. 
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Scheme 3.56 
Hebbe and co-workers have reported a condensation and aza-annulation approach in 
the synthesis of β-enamino derivatives and δ-lactams in a number of 
publications.106,107 Here, Hebbe uses an aza-annulation reaction of β-enaminocarbonyl 
compounds bearing a hydroxyl function which can act as an internal nucleophile. The 
condensation reaction of (S)-phenylglycinol and methyl acetoacetate gave β-
enaminoester 111, which can subsequently undergo aza-anulation.106 Reaction of β-
enaminoester 111 with acryloyl chloride 112 gave bicycle 113 in 85% yield as a 
mixture of diastereomers (ratio not reported). The two diastereomers were separated 
using silica gel chromatography, but individual yields were not reported (Scheme 
3.57).  
 
Scheme 3.57 
Hebbe described the importance of the methyl group in the aza-annulation reaction, 
suggesting that the methyl group enhances the electron density on the α-carbon 
promoting reaction. Following formation of the bicycle 113, Hebbe and colleagues 
investigated the reduction of the lactam and opening of the oxazolidine ring. Treatment 
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of cis-113 with borane dimethylsulfide gave the disubstituted piperidine cis-110 in 
61% yield (Scheme 3.58). The deprotected piperidine cis-108 was obtained after 
hydrogenolysis in 69% yield (Scheme 3.58). The same synthetic route was applied to 
the trans-diastereomer. 
 
Scheme 3.58 
The high yields and the short linear sequence of Hebbe’s route led us to pursue this 
route for the synthesis of the disubstituted piperidines desired for our library sub-set. 
However, racemic phenyl glycinol was used for this synthesis as racemic mixtures of 
the selected fragments were desired. This methodology did, however, give the option 
for asymmetric synthesis should it be required at a later stage.  
 
The β-enaminoester 111 was synthesised following Hebbe’s method with the 
condensation reaction of phenylglycinol 114 and methyl acetoacetate 115 in 
quantitative yield and used without purification (Scheme 3.59).106 
 
Scheme 3.59 
The aza-annulation step to form the bicyclic lactam by reaction of β-enaminoester 111 
and acryloyl chloride 112 proceeded in 57% yield to give an inseparable 75:25 mixture 
of cis-113 and trans-113 (Scheme 3.60). The diastereomers were assigned by analogy 
with Hebbe’s results, with diagnostic signals in the 1H NMR spectrum at δ 4.55 (cis-
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113) and δ 4.39 (trans-113) and δ 3.99 (cis-113) and δ 3.93 (trans-113) for the protons 
adjacent to the oxygen in the oxazolidine ring. Despite a number of different attempts, 
we were unable to separate the two diastereomers. 
 
Scheme 3.60 
The lactam was reduced and the oxazolidine ring was opened after treatment of the 
bicycle 113 with borane dimethylsulfide to give a 70:30 mixture of diastereomers cis-
110 and trans-110 in 42% yield. Unfortunately, again despite our best efforts, we were 
unable to separate the different diastereomers (Scheme 3.61). 
 
Scheme 3.61 
Therefore, hydrogenolysis to remove the nitrogen protecting group and then treatment 
with Boc2O gave the N-Boc disubstituted piperidine cis-107 and trans-107 in 40% and 
30% yield respectively (Scheme 3.62). The diastereomers were assigned using 1H 
NMR spectroscopy in an analogous way to Hebbe.106 The trans-diastereomer was 
assigned based on the 3J coupling between the proton at the 3-position and the proton 
at the 2-position (12.5 Hz). Unfortunately, due to the poor resolution of the 1H NMR 
spectrum of the cis-diastereomer, a small coupling of the 3-position proton signal at δ 
2.42-2.38 could not be determined.  
143 
 
 
Scheme 3.62 
This route has provided us with the precursors for fragments A38, A40, A41 and A42, 
and the procedures described earlier for nitrogen functionalisation and ester reduction 
could be used to obtain the final fragments (Scheme 3.63).  
 
Scheme 3.63 
The route, however, has proved challenging at a number of points. Both diastereomers 
are accessible with this methodology, which is ideal for accessibility to different 
diastereomers, but their separation is very difficult, even after a number of attempts. 
There are a number of steps in the route and yields are generally quite low, but reaction 
optimisation might improve this. This methodology does, however, benefit from an 
asymmetric version that could be useful for fragment optimisation or development if 
required. 
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3.8 Synthetic approach to cis-disubstituted piperidine fragments 
Fragments A25, A26, A65, A66 and A89 are all cis-disubstituted piperidines (Figure 
3.13) and therefore it was thought desirable to try and synthesise these compounds 
with the same methodology. We postulated that hydrogenation of disubstituted 
pyridines may provide a strategy for the synthesis of these types of compounds. 
 
Figure 3.13 
A number of disubstituted pyridine hydrogenations have been reported in the 
literature,108,109 A high pressure hydrogenation reaction was reported in the synthesis 
of 3-methyl, 4-ester disubstituted piperidine cis-117 by Saunders and colleagues. 3,4-
Disubstituted pyridine 116 was treated with H2 in the presence of platinum oxide to 
give cis-disubstituted piperidine 117, although the yield was not reported (Scheme 
3.64).110 A range of different methyl and ester disubstituted pyridines would provide 
access to the fragments shown in Figure 3.13.  
 
Scheme 3.64 
A possible alternative approach to the synthesis of disubstituted piperidines from 
pyridines could be via tetrahydropyridines. Thomas and colleagues reported that 
treatment of 3-ester, 4-phenyl pyridine 118 with ethyl iodide and subsequent reduction 
with sodium borohydride gave the tetrahydropyridine 119 (Scheme 3.65). Simple 
hydrogenation of 119 with a palladium catalyst gave a mixture of cis and trans 
disubstituted piperidines 120 (Scheme 3.65).111 
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Scheme 3.65 
In a similar fashion, Baker and colleagues accessed a 2,5-tetrahydropyridine 123 from 
methyl 6-methylnicotinate 121. The synthesis involves the formation of quaternary 
ammonium salt 122 and subsequent reduction with sodium borohydride to give 
tetrahydropyridine 123 (Scheme 3.66).112 Although not reported, the hydrogenation 
method as reported by Thomas could be used to give a 2,5-disubstituted piperidine.  
 
Scheme 3.66 
With the literature precedence and as pyridine reduction would provide rapid and easy 
access to a range of disubstituted piperidines, this is the route we investigated first.  
 
The availability and ease of preparation of the 3-methyl, 4-ester pyridine meant that 
the hydrogenation reaction was carried out on this system. The desired pyridine was 
prepared from pyridine 124 through hydrolysis of the nitrile to give carboxylic acid 
125 and subsequent methyl ester 126 formation as described by Grygorenko (Scheme 
3.67).113 
 
Scheme 3.67 
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With the suitable disubstituted piperidine 126 in hand the hydrogenation could be 
undertaken. The atmospheric pressure hydrogenation with platinum oxide as the 
catalyst was attempted. However, none of the desired product was obtained and only 
starting material was recovered (Scheme 3.68). The hydrogenation was then repeated 
at a high pressure in the presence of a palladium catalyst at a high temperature. Again 
only starting material was recovered and none of the desired product obtained (Scheme 
3.68). Another attempt with both a palladium and platinum catalyst at high pressure 
also gave no desired product and full recovery of starting material (Scheme 3.68). It 
was decided after this attempt had failed that an alternative route for the synthesis of 
these types of compounds from pyridines would be explored. 
 
Scheme 3.68 
Before synthesis was attempted on the disubstituted pyridines, a model study based on 
the literature routes to find suitable conditions was undertaken.114,115 Benzyl bromide 
was chosen as the nitrogen substituent, due to ease of manipulation later in the 
synthesis. Reaction of 1 equivalent of benzyl bromide with methylnicotinate 128 at 
reflux gave full conversion into pyridinium salt 129. Pyridinium salt 129 was then 
reacted with 9 equivalents of sodium borohydride at low temperature to give 
tetrahydropyridine 130 in 21% yield (Scheme 3.69). 
 
Scheme 3.69 
With suitable conditions in hand, reduction of 3,4-disubstituted pyridine 126 was 
attempted. Treatment with benzyl bromide and subsequent reduction gave the 
disubstituted tetrahydropyridine 132 in 44% yield (Scheme 3.70). 
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Scheme 3.70 
Finally, the reduction of 2,5-disubstituted pyridine 121 was attempted. Treatment, as 
before, with benzyl bromide gave the pyridinium salt 133, and subsequent treatment 
with sodium borohydride gave 2,5-tetrahydropyridine 134 in 29% yield (Scheme 
3.71).  
 
Scheme 3.71 
We have thus been able to successfully synthesise two tetrahydropyridines, which, 
following hydrogentation using the conditions described by Thomas would give 
desirable disubstituted piperidines. Unfortunately, due to time constraints this was not 
completed. The final fragments A25, A26 and A89 could be obtained following ester 
reduction, deprotection and N-functionalisation.  
 
This initial work has shown that reduction of pyridines to piperidines is a viable 
method for fragment synthesis. The synthetic route via tetrahydropyridines has shown 
promise, but further optimisation is required to increase yields and explore substrate 
scope. The availability and accessibility of different pyridines offers increased 
synthetic scope and may offer a route to the more challenging targets. The double bond 
may also offer an additional synthetic handle for fragment generation in the future.  
 
148 
 
3.9 Conclusions and Overview 
We have presented the synthesis towards a number of the selected disubstituted 
piperidine fragments. We were able to group fragments in order to reduce the number 
of different synthetic routes required. This worked well for some fragments. For 
example, we were able to apply enolate alkylation chemistry in the synthesis of five 
geminal disubstituted piperidines. We also made initial progress to investigate 
pyridine reduction as a method to synthesise a number of different piperidines and 
early results look promising. We have tried to keep the number of different synthetic 
steps to a minimum and developed a general route for N-functionalisation starting 
from an N-Boc ester piperidine. Generally, yields have been moderate to good and 
some routes are amenable to larger scale synthesis. It has been important to also use 
routes that allow for different functionalisation and fragment generation. For example, 
in some cases, changing the electrophile would allow installation of different groups. 
This work has shown that although disubstituted piperidine is a simple scaffold, the 
synthesis of this type of compound is not trivial and development of robust 
methodology to access these compounds needs further work. 
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Chapter 4:  Lead-oriented Synthesis, Design and 3-
Dimensional Shape Evaluation of a Virtual Lead-like 
Library  
 
In this part of the project, we aimed to design and enumerate a virtual library of lead-
like compounds, with particular focus on more 3-dimensional compounds to access 
new areas of chemical space. As discussed earlier, the prevalence of saturated 
heterocyclic ring structures in approved drug molecules, their interesting 3-
dimensional structure and the expertise already developed in the O’Brien group 
relating to the synthesis of saturated heterocycles led to the investigation of these types 
of compounds.  It was felt that these type of compounds would also be suitable for use 
as interesting synthetic building blocks. 
 
It was planned that pyrrolidine, piperidine and piperazine-based cores which offer 
points for diversification would be investigated (Figure 4.1). Different functional 
groups in these positions would offer a variety of properties and interactions and 
handles for further development of these compounds during lead optimisation. These 
functional groups are also shown in Figure 4.1.  
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Figure 4.1: The six different lead-like scaffolds, showing points of diversification and the 
chosen groups for functionalisation.  
 
The structures generated from these different combinations would then be analysed 
for shape diversity and 3-dimensionality using PMI plots, in order to analyse the 
spread of these compounds across chemical space. We also planned to evaluate the 
physicochemical properties in relation to the properties that are desirable for lead-like 
compounds.  
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4.1 Overview of lead-oriented synthesis 
The drug discovery process is challenging in many aspects and, as discussed earlier 
(Chapter 1), new approaches are being constantly developed to meet the needs of more 
challenging targets and areas.116 Molecular and physical properties play a very 
significant role in the success of compounds through the drug development process. 
Different parameters and criteria have been developed to summarise the requirements 
of different compounds, such as Lipinski’s “Rule of five” for orally bioavailable drugs. 
These have helped medicinal chemists to focus efforts during lead optimisation. A 
number of groups have highlighted that, although these criteria are highly valuable 
during development, the selection of high quality lead compounds is vital to success.  
 
It has been highlighted in a number of reports that the lead optimisation process often 
causes an increase in molecular weight and lipophilicity, which are thought to be the 
main reason for attrition in later drug development and testing stages.6,7,65 Nadin and 
colleagues from GlaxoSmithKline reported that compounds with cLogP < 3 and a 
polar surface area ˃ 75 Å2 have a better safety profile in pre-clinical studies and 
molecules with a molecular weight < 400 and cLogP < 4 are more successful in drug-
like character assays, such as solubility, bioavailability, plasma-protein binding and in 
vivo clearance assays.65 It is also widely reported that the more lipophilic the 
compound, the more promiscuous a compound is, giving more off-target activity and 
toxicity.65 
 
Therefore, in a similar way to fragment-based drug discovery described in Section 1.1, 
it can be desirable to start with smaller compounds to allow for expansion during lead 
optimisation. This is exemplified in Figure 4.2 as reported by Nadin and colleagues.65 
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Figure 4.2: Diagram showing the “Lead-like” area of chemical space compared to the 
Lipinski’s “Rule of 5” and fragment space.65  
 
As with fragment libraries, there are a number of advantages to screening smaller lead-
like compounds compared to current HTS libraries. These smaller compounds are able 
to sample chemical space more efficiently which results in a higher probability of 
finding hits. There is also more chance of successful binding as smaller compounds 
have less chance of mis-match and clashes with the active site. Along with making 
compounds smaller, Nadin suggested that shape should be a key consideration when 
designing lead-like compounds.65 As discussed, increased lipophilicity is a key cause 
of attrition and therefore reducing or restricting the number of aromatic rings in lead-
like compounds could help to prevent issues further in development. Increased sp3 
character has also been reported as a positive characteristic for screening compounds. 
Work by Lovering showed that compounds that have successfully progressed through 
the different stages of drug development have more sp3 character.40 
 
All of these different physical properties and parameters have been drawn together to 
give a set of criteria specifically for lead-like compounds. These are as follows: 
 14 ≤ Heavy atoms ≤ 26 (giving a molecular weight range of around 200 to 350 
Da). 
 –1 ≤ LogP ≤ 3 
 Aromatic rings ≤ 3 
 Avoid reactive and unfavourable groups 
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A number of groups have analysed different compound collections against these 
criteria to assess the lead-likeness of compound collections.65,117 An analysis of 
commercially available compounds showed that more than 99% of compounds did not 
fit these criteria and in a separate analysis it was found that a large proportion of 
compounds reported in synthetic methodology papers fall outside of these guidelines. 
This and the uneven sampling of chemical space synthetically has led to a call to 
develop synthetic methodologies to prepare more relevant lead-like compounds, ie. 
Lead-oriented synthesis. 
 
Nelson and co-workers noted that the poor availability of diverse lead-like compounds 
comes from an inherent lack of good synthetic methods to synthesise these types of 
compounds.117,118 Therefore both current methodology and new methodology needs 
to be developed and adapted for use in lead-oriented synthesis. Initially, Nadin and 
colleagues highlighted the need for a similar approach to synthesis as that used in 
diversity-oriented synthesis, first reported by Schreiber and colleagues.65,119 Although 
diversity-oriented synthesis produces a large number of diverse compounds using 
elegant routes and cascades, the molecular weight and physical properties are 
generally not suitable for lead-like compounds and do not routinely produce 
compounds in drug-like chemical space. Lead-oriented synthesis is concerned with the 
production of a number of compounds with specific molecular properties with utility 
in the drug discovery and optimisation process, as defined by Nadin and colleagues.65  
 
Nadin and colleagues highlighted a simple set of guidelines that lead-oriented 
synthesis should meet.65 These are:  
 Produce a wide range of lead-like chemical structures, 
 Efficiently produce compounds using cheap reagents and mild conditions 
amenable for use in array formats, 
 Tolerate a wide range of polar functional groups, 
 Produce molecules without multiple residual reactive centres. 
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With this in mind, Nelson and co-workers highlighted that although the synthetic 
methods used in diversity-oriented synthesis may not be practical for lead-like 
compound synthesis, the principles may be applied, such as the combinatorial 
variation of the molecular scaffold. They reported that the “build, couple, pair” process 
used in diversity-oriented synthesis can be readily applied to simpler starting 
materials, giving lead-like compounds after linking and cyclisation.117 In a separate 
report, they applied this methodology to the synthesis of 52 different lead-like 
scaffolds. They employed a simple two- or three-step synthesis (Scheme 4.1). The first 
step involves the reaction of an allylic carbonate 135 with an amine 136 to furnish a 
cyclisation precursor 137. These cyclisation precursors can then be cyclised either 
once or twice depending on functional groups available for reaction. Late-stage 
functionalisation of the cyclisation products then yielded a wide range of compounds 
with lead-like properties. 118 
 
Scheme 4.1 
After preparation of the 52 scaffolds, the late-stage functionalisation was carried out 
virtually, with 59 different medicinally relevant capping groups. This gave a total of 
19 530 compounds in the virtual library. Representative protected scaffolds are shown 
in Figure 4.3. Subsequent analysis of these compounds found that 59% had lead-like 
molecular properties as defined earlier and that after analysis of sp3 centres it was 
found that a high number of compounds had a diverse shape. This method provided 
medicinal chemically relevant compounds, with suitable properties for use in lead-like 
screening libraries. 118 
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Figure 4.3: Example of some of the 52 scaffolds prepared in one or two cyclisation steps. 
Deprotection and functionalisation would give a range of lead-like compounds. 
 
Lead-oriented synthesis has received more attention in recent times and a number of 
groups have adopted a similar approach for the synthesis of lead-like compounds. For 
example, Marsden, Nelson and co-workers reported the aminomethylhydroxylation of 
alkenes as a method to synthesise small molecules120 and Nortcliffe and Moody 
synthesised a number of azepanes and oxepanes for use in drug discovery.121 A report 
by Clausen and co-workers employed a 3-component cascade reaction in the synthesis 
of over 500 compounds based on trisubstituted γ-lactams.122 These recent reports 
highlight the values of this method as a viable approach for the synthesis of lead-like 
compounds for use in drug discovery. 
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4.2 Organometallic routes to lead-like compounds: O’Brien group chemistry 
Lead-oriented synthesis aims to provide a simple and effective method to produce 
diverse lead-like compounds. It was envisaged that organolithium-mediated routes 
would provide good methodology to access the desired library of compounds. This 
synthesis work was undertaken by others in the O’Brien group and is presented in a 
publication from 201599. A summary of the synthetic routes used by others to furnish 
the different scaffolds is presented briefly below. 
 
Scaffolds S1 and S2 were synthesised by α-lithiation of N-Boc piperazine 141, 
originally reported by Beak.76 It was found by earlier workers that the diamine-free 
lithiation reported by O’Brien90 was suitable for this lithiation. The lithiation with 1.3 
equivalents of s-BuLi of N-Boc piperazine in THF, followed by trapping with cyclic 
ketones 142 or 143 and stirring at room temperature for 24 hours gave the carbamates 
144 or 145 in 64% and 42% yields respectively (Scheme 4.2). Warming to room 
temperature and stirring promoted the attack of the alkoxide onto the Boc group to 
give the cyclic carbamate. By using N-Boc protected ketones as the electrophile and 
orthogonally protecting the two nitrogens of the piperazine, differential deprotection 
and further functionalisation of the products was possible.  
 
Scheme 4.2 
In a similar approach to the piperazine above, pyridinyl N-Boc pyrrolidine 146 was 
subjected to a lithiation-trapping process by earlier workers. In this case, however, the 
reaction site is benzylic and therefore different lithiation conditions were employed, 
as developed by a number of groups.123-125 Generally, a higher temperature was 
employed in order to allow for Boc rotamer interconversion and n-BuLi was used in 
order to selectively deprotonate the more acidic benzylic proton. Therefore, lithiation 
was carried out using n-BuLi at –50 °C for 30 minutes in THF. N-Benzyl piperidine-
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4-one or N-Boc azetidine-4-one were used to trap the lithiated intermediate and 
cyclisation onto the Boc group gave the pyrrolidine spirocyclic compounds 147 and 
148 (Scheme 4.3). These scaffolds can then be subjected to deprotection and further 
N-functionalisation.  
 
Scheme 4.3 
The final scaffold was a 2,3-disubstituted piperidine which was synthesised, by earlier 
workers, from N-benzyl amino alcohols syn-152 and anti-152. These N-benzyl amino 
alcohols were prepared in a three-step synthesis from N-Boc pyrrolidine 149 (Scheme 
4.4). Lithiation-trapping using 3-pyridine carboxaldehyde gave a 70:30 mixture of 
diastereomers syn-150 and anti-150, which upon deprotection with TFA gave the free 
amine 151 as a 70:30 mixture. As the later ring expansion required a nucleophilic N-
alkyl substituent reductive amination was carried out to give the N-benzyl protected 
amino alcohols syn-152 and anti-152 both in 30% yield (Scheme 4.4). 
 
Scheme 4.4 
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Next, the aziridinium ion-based ring expansion was carried out, by earlier workers, on 
each of the diastereomers syn-152 and anti-152. Trifluoroacetylation and ring 
expansion over 48 hours with subsequent hydrolysis with NaOH gave the desired 
piperidines syn-153 and anti-153 in 76% and 79% yields respectively (Scheme 4.5).   
 
Scheme 4.5 
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4.3 Computational analysis of 3-dimensional shape 
The scaffolds S1 to S6 and the different functionalisation groups described above can 
be combined and enumerated to generate a virtual lead-like compound library, with 
designed synthesis of such compounds in place. It was envisaged that the compounds 
could then be analysed for shape diversity and coverage of chemical space. The virtual 
library was enumerated as shown in Figure 4.4, by combining the different scaffolds 
with the different substituents.  
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Figure 4.4: The different scaffolds, substituents and how they will be combined to give a 
virtual lead-like compound library. 
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The lowest energy conformation of each of the virtual 190 compounds was then 
generated and subsequent PMI analysis was carried out using a Pipeline Pilot protocol 
(details in Section 6.1.5). Firstly, the unprotected scaffolds were analysed and the PMI 
plot is shown in Figure 4.5, with labels to highlight where each scaffold appears on 
the PMI plot. It was decided that only the lowest energy conformation of these 
compounds would be investigated, this was to make this analysis more distinctive 
from the analysis described in previous chapters. Also, generally, only analysis of the 
lowest energy conformation is presented in the literature.  
 
 
Figure 4.5: PMI plot showing the lowest energy conformation of each of the six scaffolds. 
 
This plot shows that the different scaffolds occupy quite different areas of the plot, 
with L-51 and L-76 providing the most 3-dimensional shape. There also appears to be 
quite a difference in position of the two piperazine fragments L-1 and L-26. This is 
interesting as there is only the side ring that differs between the two structures. These 
also lie quite close to the rod-disc axis, suggesting a flatter, less 3-dimensional 
conformation.  
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Each of the scaffolds was then analysed in turn. Firstly, the spirocyclic fused 
piperazine group of compounds based on S-1 and S-2 (L-1 to L-50). The PMI plots 
are shown in Figure 4.6 (a) and (b).  
     
Figure 4.6: PMI plots showing the lowest energy conformations of the lead-like compounds 
derived from scaffold S-1 (a) and S-2 (b). 
 
This plot clearly shows that both of these sets of compounds lie very close to the rod-
disc axis, and are surprisingly flat and less 3-dimensional. This result is unusual as the 
spirocyclic nature of these compounds was expected to give quite architecturally 
interesting and 3-dimensional shapes.  
 
Figure 4.7 shows the two PMI plots for each of the 25-member compound sets derived 
from S-3 and S-4. The fully unprotected version of these scaffolds (L-51 and L-76) 
gave conformations in the most 3-dimensional areas of the plot. Therefore, it was 
hoped that after functionalisation, a large coverage of chemical space would be 
achieved. These compounds have more of a spread across the plot, with compounds 
from S-4 (L-76 to L-100) having more compounds towards the right side of the plot. 
These compounds generally have a larger spread across the plot compared to the 
piperazine compounds (L-1 to L-50) above, suggesting more diversity in shape. 
(a) (b) 
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Figure 4.7: PMI plots showing the lowest energy conformations of the lead-like compounds 
derived from scaffolds S-3 (a) and S-4 (b). 
 
Finally, the piperidine compounds generated from the ring expansion of N-benzyl 
pyrrolidine, scaffolds S-5 and S-6 (L-101 to L-190), were analysed. The PMI plots in 
Figure 4.8 shows the two PMI plots for each of the 45-member compound sets. 
 
 
 
 
 
 
(a) (b) 
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Figure 4.8: PMI plots showing the lowest energy conformations of the lead-like compounds 
derived from scaffolds S-5 (a) and S-6 (b). 
 
These plots show that these compounds have a much larger spread across the plot and 
access more 3-dimensional areas of space. This is quite different to the unprotected 
compounds shown in Figure 4.5. The compounds produced from the syn-piperidines 
(Figure 4.8 (a)) have a number of compounds in the top right of the plot, whereas the 
anti-piperidine compounds spread more towards the bottom part of the plot, towards 
the disc vertex (Figure 4.8 (b). These results are quite surprising as these scaffolds, on 
paper, appear the most simple.  
 
The PMI plots were then combined to give an overall impression of the full 190-
member virtual lead-like library produced from these scaffolds. The PMI plot is shown 
in Figure 4.9. 
(a) (b) 
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Figure 4.9: PMI plot showing the lowest energy conformations of all the 190 lead-like 
compounds. 
 
Further analysis was carried out to determine the number of compounds that are in the 
more 3-dimensional area of the plot. It was decided that this more 3-dimensional area 
of the plot could be defined as the area where a conformer’s NPR1 value is ≥ 0.35 and 
NPR2 value is ≥ 0.7.  
 
Table 4.1 shows the total number of compounds in the selected area for each of the 
different scaffolds and the full 190-member library.  
 Scaffold 
Number of Compounds with 
NPR1 ≥ 0.35 and NPR2 ≥ 0.7 
Total number of 
compounds 
1 S-1 0 25 
2 S-2 3 25 
3 S-3 7 25 
4 S-4 13 25 
5 S-5 29 45 
6 S-6 25 45 
7 Full 190-member library 77 190 
Table 4.1: The number of compounds from each scaffold in the desirable 3-dimensional area 
of the plot.  
These data highlight the difference between each of the scaffolds, clearly showing how 
the piperidine compounds provide the most 3-dimensional compounds. This also 
highlights how despite the idea to design more 3-dimensional fragments, and although 
they look 3-dimensional on paper, analysis of the conformer shape shows that these 
compounds are generally quite flat and close to the undesirable rod-disc axis of the 
PMI plot. This should not detract, however, from the more 3-dimensional lead-like 
compounds that access new and interesting areas of chemical space.  
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4.4 Analysis of the lead-like nature of compounds in the virtual library 
As discussed above, it is desirable that lead-like compounds fit within certain 
physicochemical parameters in order to offer the best properties for further elaboration 
and development in drug discovery programmes. These criteria are defined as: 
 –1 ≤ AlogP ≤ 3 
 14 ≤ number of heavy atoms ≤ 26  
 Total polar surface area ≥ 50 Å2 
These properties were assessed for the enumerated virtual lead-like library. A Pipeline 
Pilot protocol was used to determine a range of different properties. It is therefore 
important to look at the library as a whole and analyse the spread of values across the 
library. 
 
The full 190-member compound library was analysed and the average, smallest and 
largest values were determined (Table 4.2). 
 Data MW (HAC) ALogP 
Molecular 
PSA / Å2 
H Bond 
Acceptor 
H Bond 
Donor 
1 Average 331.55 (23.5) 0.627 66.6 4.22 0.589 
2 Smallest 179.24 (13) -3.54 43.8 2 0 
3 Largest 467.46 (32) 4.08 121.1 6 2 
Table 4.2: Analysis of the different physicochemical properties of the full 190-member 
library. 
This shows that the average for each of the properties fall within the desirable range 
for lead-like compounds. The smallest and largest values from the whole library, 
however, fall quite far out of these criteria and therefore the spread of the number of 
compounds across the different property ranges was investigated. 
 
Heavy atom count gives a good indication of molecular weight and therefore the 
spread of heavy atom count was analysed as a representation of the spread of 
molecular weight for the whole library (Table 4.3). Table 4.3 shows a spread of 
compounds across the different heavy atom counts, with only a few compounds in the 
extreme groups. It is desirable for lead-like compounds to have between 14 and 26 
heavy atoms and most of the compounds fit within this range. Although there are some 
167 
 
compounds that fall outside this and these may be too heavy to be considered for the 
library. 
Heavy atom 
number range 
10 to 13 14 to 17 18 to 21 22 to 25 26 to 29 30 to 33 
Percentage of 
total library / % 
3 8 23 34 27 6 
Table 4.3: The percentage of compounds in the library in different heavy atom count groups. 
 
Most compounds have an AlogP between 0 and 1, which is ideal for lead-like 
compounds, as shown in Table 4.4.  
ALogP Range -4 -3 -2 -1 0 1 2 3 4 
Percentage of 
total library / % 
1 7 7 15 29 23 12 5 1 
Table 4.4: The percentage of compounds in the library in different AlogP groups. 
 
The polar surface area of the compounds in the virtual library was also assessed and 
the results in Table 4.5 show most compounds have a polar surface area greater than 
the desirable 50 Å2 for lead-like compounds and only a small number below 50 Å2 or 
greater than 100 Å2, which is very promising for our library. 
PSA Range / Å2 
40 to 
49 
50 to 
59 
60 to 
69 
70 to 
79 
80 to 
89 
90 to 
99 
100 
to 
109 
110 
to 
119 
120 
to 
129 
Percentage of 
total library / % 
14 33 22 8 13 8 1 1 1 
Table 4.5: The percentage of compounds in the library in different polar surface area groups. 
 
A number of groups have discussed the importance of monitoring the number of 
aromatic rings in lead-like compounds, some specifically suggesting that there should 
be no more than 3 present. Therefore, our virtual library was assessed for this, with 
results in Table 4.6, shows that all compounds have 3 or fewer aromatic rings. This 
may be as a result of targeting more architecturally interesting compounds. 
Number of 
aromatic rings 
0 1 2 3 
Percentage of total 
library / % 
17 51 28 4 
Table 4.6: The percentage of compounds in the library with 0, 1, 2, or 3 aromatic rings. 
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A summary of the number of compounds that match each of the criteria is shown in 
Table 4.7. This table shows that for individual properties a large proportion of 
compounds fit within the desired criteria. However, when all of the criteria are taken 
into consideration only 34% of the library fits within the defined criteria, which 
increases to 48% when only heavy atom count is used as a weight restrictor. This is 
slightly disappointing as the compounds were designed with lead-criteria in mind. 
However, these criteria could be used to help focus synthesis in the direction of the 
most desirable compounds. 
  MW HAC ALogP 
Molecular 
PSA / Å2 
Aromatic 
Rings 
All 
Criteria 
1 
Number of 
compounds 
108 137 150 160 190 64 
2 
Percentage of 
total library 
57 72 79 84 100 34 
Table 4.7: The number of compounds and percentage of the library that fit with the desirable 
lead-like compound criteria. 
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4.5 Combination of 3-dimensional compounds and suitable physicochemical 
properties 
As discussed above, another main consideration when selecting compounds for a lead-
like library and subsequent screening is not only the physicochemical properties but 
the 3-dimensional shape of the compounds. In Section 4.3, the compounds in our 
virtual lead-like library were assessed for their spread across chemical space and for 
their shape diversity. This analysis can now be combined with the analysis of 
physicochemical properties. In Section 4.3, 77 compounds (41%) were in the most 
spherical area of the plot (NPR1 ≥ 0.35 and NPR2 ≥ 0.7) and in Section 4.4, 64 
compounds (34%) had suitable lead-like properties. However, only 42 compounds 
(22%) fit with all the physicochemical criteria and the 3-dimensional criteria. If 
molecular weight is not used as an additional size criteria there are 46 compounds 
(24%) of compounds that fit. These 42 compounds are shown on the PMI plot in 
Figure 4.10. Figure 4.11 shows the structures of the four most spherical lead-like 
compounds. 
 
Figure 4.10: PMI plot of the lowest energy conformation of the 42 compounds that fit both 
the 3-dimensional criteria and the lead-like physicochemical properties. 
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Figure 4.11: The four most spherical lead-like compounds that satisfy the lead-like 
physicochemical properties too. 
 
The PMI plot in Figure 4.10 clearly shows that our enumerated virtual lead-like library 
contains some relevant lead-like compounds that cover a large area of chemical space. 
It should be highlighted that only 22 compounds with the desirable lead-like physical 
properties are in the most 3-dimensional area of chemical space. This is a promising 
result suggesting that it is possible to design compounds that have desirable physical 
properties and are architecturally interesting and diverse. By narrowing down and 
selecting compounds with desirable shape and physical properties, it also helps to 
focus synthesis in the direction of the most favourable compounds.  
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4.6 Conclusion and future work 
We aimed to develop a small range of synthetic methods for use in lead-oriented 
synthesis to produce a range of lead-like compound scaffolds. We then wanted to 
enumerate a virtual library based on these scaffolds and analyse for lead-like 
properties and for 3-dimensional structure. Specifically, saturated heterocycles were 
investigated and pyrrolidine, piperidine and piperazine scaffolds were developed. 
These scaffolds were then virtually functionalised in a number of ways with a number 
of medicinally chemically relevant groups, which offered key interaction points and 
handles for further functionalisation. The enumerated library was then analysed for 
coverage of chemical space using PMI plots, and was found to cover a large area, with 
41% of compounds in the more desirable 3-dimensional area of chemical space. The 
physicochemical properties of the virtual library were analysed and it was found that 
on average the values for the library fell within the desired criteria. This was further 
investigated and it was found that the 34% of compounds fit within all the criteria. 
Combining these analyses gave 22% of compounds that fit both criteria. This gives a 
good starting point to enumerate synthesis too, focussing on the most desirable 
compounds.  
 
The most notable finding throughout this analysis is the difficulty in designing 3-
dimensional compounds on paper. Some of the spirocyclic scaffolds that we expected 
to be most 3-dimensional actually appeared in the more unfavourable, 2-dimensional 
area of the plot. The piperidine-based scaffolds actually produced the most 3-
dimensional compounds, possibly due to vectors accessed from the chair conformation 
of this scaffold. This may also suggest that the simpler scaffolds provide more 
architecturally interesting compounds and conformations.  
 
We have developed some interesting lead-like compounds that access new areas of 
pharmaceutical space and have applied organolithium chemistry in a lead-oriented 
synthesis setting. This approach to design and analyse compounds could be applied to 
new or different synthetic methodology. The computational methods to generate and 
analyse virtual libraries can be applied to help focus the synthesis of the most desirable 
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lead-like compounds and build up structurally and architecturally diverse lead-like 
compound libraries with suitable physicochemical properties. 
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Chapter 5:  Conclusions and Future Work 
We have presented a new and innovative method to design, computationally assess 
and select 3-dimensional fragments to explore pharmaceutical space and the 
subsequent synthesis of some of these fragments. Our method, to design and assess 
the shape diversity of different fragments before synthesis, is novel compared to 
current literature methods. The investigation of different conformations of a given 
fragment also sets our work apart. We sought to investigate the use of saturated 
heterocycles as a means to introduce structural and shape diversity into fragment 
libraries and access under-represented areas of chemical space. Our approach focussed 
on medicinally relevant, different-sized, saturated nitrogen heterocycles with two 
substituents.  
 
In order to analyse these compound sets, we customised a computational pipeline pilot 
workflow through a series of iterations to analyse the shape diversity. By using a 
computational method, we were able to avoid any bias and create an efficient method 
that works for any size data set. We used principal moments of inertia (PMI) plots to 
analyse the structural diversity of all the isomers of the six different compound sets 
and, from these, developed selection criteria and rules to select the compounds that 
accessed the under-represented, 3-dimensional area of chemical space. We found that 
a suitable number of compounds were selected from very similar cut-offs for all of the 
systems. Using the generated PMI plots and associated data, we have demonstrated 
that shape diversity can be obtained from simple scaffolds and that the selection 
criteria and rules could be employed in the selection of small sub-set libraries. These 
libraries focussed on the more under-represented, 3-dimensional area of the PMI plot 
and new areas of pharmaceutical space and move away from the undesirable rod-disc 
axis. 
 
The different selected substituent and scaffold sub-set libraries were combined and 
compared to both the full library and to a commercially available library, the 
Maybridge “Rule of 3” core 1000 fragment library. This analysis highlighted that our 
fragments access more of the under-represented, 3-dimensional area of chemical space 
than a current commercial library. Although we expected the physicochemical 
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properties to be in-line with the “Rule of 3” guidelines, the physicochemical properties 
were computationally generated and analysed. It was found that in general our 
fragments fit within the “Rule of 3” guidelines. The properties also offered flexibility 
to further develop and grow the fragments while still maintaining good 
physicochemical properties, ideal for further stages of the drug development process. 
 
From our computational analysis, we demonstrated that shape diversity can be 
obtained from simple scaffolds and that using saturated compounds allowed access to 
more 3-dimensional and complex shapes as well as favourable physicochemical 
properties for fragment development. The computational protocol now works well for 
a number of different scaffolds and compound types and could be employed in the 
analysis of different fragments, and it is currently being used in the group to assess 
different fragment structures. The selection criteria focussed on the 3-dimensional area 
of the PMI plot and could be used or further developed to choose fragments in very 
specific areas of the plot, for example disc-shaped fragments. The introduction of 
different energy conformations is a novel approach and could be investigated in other 
shape analyses, such as plane of best fit. The use of different shape analysis techniques 
to carry out a similar analysis and selection method would also be a very interesting 
comparison, especially to see if similar conformations are generated and how the 
definition of 3-dimensionality varies between these different techniques for our 
specific fragments. The selection of smaller sub-sets of compounds has made synthesis 
more amenable. However, the computational protocol could be further developed to 
focus on specifically shaped fragments and then highlight closely related shaped 
neighbours. This approach could be used to focus synthesis on distinct chemical 
shapes, but allows for synthesis of closely related shape analogues if required.  
 
After selection of our sub-set libraries, the synthesis of the hydroxymethyl piperidine 
fragments was attempted and we have presented the synthesis towards a number of 
these disubstituted piperidine fragments. Our focus was to develop routes to access 
the compounds in the minimum number of steps and synthesise a number of different 
compounds using similar methodology. We were initially able to group the geminal 
disubstituted piperidines together and synthesised five final fragments (A1, A2, A5, 
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A6 and A9) using enolate alkylation chemistry (Scheme 5.1). We were able to 
synthesise intermediates to fragments A71, A72 using amino zinc enolate 
carbocyclisation methodology (Scheme 5.2), but this route was not successful for the 
synthesis of fragments A65, A66 and A89. Initial work on the reduction of different 
pyridines looks promising as a method to access a number of different piperidines, 
including fragment A89 (Scheme 5.3). We were able to develop a general route for N-
functionalisation starting from an N-Boc ester piperidine that furnishes the final 
fragment compounds in moderate to good yields in the minimum number of steps.  We 
have been able to employ some routes that are amenable to larger scale synthesis, 
allowing selected intermediates to be prepared in larger quantities. It has also been 
possible to use routes that allow access to different analogues. For example, in the 
amino zinc enolate carbocyclisation methodology the electrophile used can be varied, 
giving access to a number of different disubstituted piperidines. This ability allows for 
fragment development and growth as well as rapid synthesis of close analogues.  
Scheme 5.1 
 
Scheme 5.2 
 
 
Scheme 5.3 
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This synthetic work has highlighted that although disubstituted piperidine is a simple 
scaffold, the synthesis is not trivial. Despite the simplicity of these compounds a 
significant number have not previously been reported in the literature and there is 
limited reports of synthetic methodology to access known compounds. This combined 
with the difficulty of handling low molecular weight, saturated and often polar 
compounds makes the synthesis very challenging. The development of robust 
methodology to access these compounds and similar simple saturated nitrogen 
heterocycles and for their as building blocks needs further work. Development of 
simple methodology, such as reduction of pyridines, to yield saturated heterocycles 
would provide access to a number of fragments from simple, readily available material 
in a few steps and this should be investigated in the future. Epimerisation of different 
stereocentres would also provide easy access to different diastereomers and would 
reduce the need for different synthetic routes to access different diastereomers. It is 
hoped that fragments such as A19 and A20 could be synthesised using this method 
(Scheme 5.4).  
 
Scheme 5.4 
After synthesis, it is important to test the stability of the compounds. Unfortunately, 
due to time restraints, we were unable to do this for the fragments synthesised. This 
stability in different solvents and under different conditions is very important before 
screening is undertaken in order to ensure erroneous results are avoided. Ultimately, 
it is hoped that these fragments would be tested against different targets. Combining 
the fragments into current libraries would give a good comparison of these selected 3-
dimensional fragments to current fragments.  
 
We were able to apply our novel computational workflow to the shape analysis of 
lead-like compounds. Other work in the O’Brien group led to the synthesis of six lead-
like scaffolds using organolithium chemistry, which were virtually enumerated into a 
range of lead-like compounds. Conformations of the enumerated library were 
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generated and the shape diversity and coverage of chemical space was analysed using 
PMI plots. Our analysis found that 41% of the compounds were in the more desirable 
3-dimensional area of the PMI plot. An interesting and somewhat unexpected finding 
was that what were thought to be the most 3-dimensional fragments on paper did not 
always fall in the more 3-dimensional area of the plot. Some of the spirocyclic 
scaffolds, for example, appeared in the more unfavourable, 2-dimensional area of the 
plot. However, the more simple piperidine-based scaffolds were the most 3-
dimensional compounds. This may be due to the different vectors accessed from the 
chair conformation of this scaffold. It was actually the simpler scaffolds that provided 
more architecturally interesting compounds. 
 
The physicochemical properties of the virtual library were also analysed. We found 
that 34% of compounds fit within all the lead-like criteria. Although, further analysis 
showed that 22% of compounds fit both the 3-dimensional criteria and the lead-like 
physical properties. Although this is not a particularly high proportion of the 
compounds, this information could help to focus the synthesis to the most desirable 
lead-like compounds.  
 
We have been able to employ our computational protocol to lead-like compounds, 
making the analysis of the shape diversity of the virtual library quick and easy. This 
approach to design and analyse compounds could be applied to different synthetic 
methodology and different enumerated libraries. The computational analysis of the 
shape diversity and physicochemical properties can be applied to help focus the 
synthesis of the most desirable lead-like compounds. The computational approach can 
be used build up structurally and architecturally diverse lead-like compound libraries 
with suitable physicochemical properties.  
 
Using our customised computational workflow to analyse shape diversity of different 
compounds, both fragments and lead-like compounds, it has been possible to 
demonstrate that simple compounds can give diverse compound shapes, with good 
physical properties. In both stages, we have been able to highlight the most 3-
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dimensional compounds with the most suitable physical properties. This type of 
analysis is highly beneficial if carried out before starting synthesis, as it can help to 
focus the synthesis on the most suitable compounds, negating the unnecessary 
synthesis of compounds with poor properties. This is important for many reasons: it 
helps to reduce cost, makes processes more efficient and decreases the impact on the 
environment. The analysis is rapid and efficient and can be used to direct synthesis of 
similar compounds if hits are found. That said, the synthesis of these simple 
compounds is challenging and there is a need to develop more efficient methods to 
access such simple compounds if this approach is to be successful and taken up by 
others. 
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Chapter 6:  Experimental 
6.1 Computational Methods 
Computational analysis and protocol development was carried out in collaboration 
with Paul Bond and Rod Hubbard at York Structural Biology Laboratory (YSBL).62 
Coding and programming was carried out by Paul Bond. Pipeline pilot protocol 
workflow designed by Mary Wheldon in collaboration with Paul Bond. Data analysis 
carried out by Mary Wheldon.  
6.1.1 General methods  
Shape analysis 
A SMILES file containing the SMILES strings for all fragment compounds was 
generated using ChemDraw 12.0. 
 
3-Dimensional structures were generated Pipeline Pilot 8.5.0.200, 2011, Accelrys 
Software Inc. Generated conformations were used to generate the three Principal 
Moments of Inertia (I1, I2 and I3) which were then normalised by dividing the two 
lower values by the largest (I1/I3 and I2/I3) using Pipeline Pilot built-in components.  
Principal moments of inertia (PMI) about the principal axes of a molecule were 
calculated according to the following rules:126  
1. The moments of inertia are computed for a series of straight lines through the 
centre of mass. 
2. Distances are established along each line proportional to the reciprocal of the 
square root of I on either side of the centre of mass. The locus of these distances 
forms an ellipsoidal surface. The principal moments are associated with the 
principal axes of the ellipsoid. 
The PMI plots were then generated with these data in Excel 2013.  
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Molecular properties  
All physical properties were calculated using Pipeline Pilot built-in components.  
 
ALogP component: calculates ALogP using the Ghose and Crippen octanol-water 
partition coefficient method.127 
 
Number of hydrogen donors component: number of heteroatoms (oxygen, nitrogen, 
sulfur, or phosphorus) with one or more lone pairs, excluding atoms with positive 
formal charges, amide and pyrrole-type nitrogens, and aromatic oxygen and sulfur 
atoms in heterocyclic rings. 
 
Number of hydrogen acceptors component: number of heteroatoms (oxygen, nitrogen, 
sulfur, or phosphorus) with one or more attached Hydrogen atoms. 
 
Molecular polar surface area component: Calculates the polar surface area for each 
molecule using a 2-dimensional approximation using a method based on the published 
method of Selzer and co-workers.128 
 
6.1.2 Initial protocol 
Prior to conformer generation a wash step was performed, which involved ionising the 
molecule at pH 7.4, converting to the canonical tautomer and adding hydrogens. 3-
dimensional coordinates were then generated using the built-in Conformation 
Generator component from the Discovery Studio Component Collection. The 
conformation method was set to BEST with an energy threshold of 20 kcal mol-1, 
maximum of 255 conformers for each compound. Within the same Conformation 
Generator component the conformations were minimised using 1000 steps of Steepest 
Descent with a RMS gradient tolerance of 3 and 200 steps of Conjugate Gradient with 
a RMS gradient tolerance of 0.1. A CHARMm forcefield with Momany-Rone partial 
charges was used for the minimisations. Initial minimisations were performed without 
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an implicit solvent model, but a Generalised Born solvent model was later added. 
Similar conformations were then filtered using a chosen RMSD threshold of 0, 0.5 or 
1. Finally, conformations were filtered based on a chosen maximum relative energy 
threshold of 7 or 20 kcal mol-1. 
 
6.1.3 Analysis of enantiomers 
Prior to conformer generation a wash step was performed, which involved ionising the 
molecule at pH 7.4, converting to the canonical tautomer and adding hydrogens. 3-
dimensional coordinates were then generated using the built-in Conformation 
Generator component from the Discovery Studio Component Collection. Two copies 
of the molecule were generated, the original and mirror image. Conformers were 
generated using the BEST method in Catalyst using the rel option, run directly on the 
server and not through the built-in Conformation Generator component with a chosen 
maximum relative energy threshold of 20 kcal mol-1, maximum of 255 conformers for 
each compound. Conformations were read and mirrored if the wrong enantiomer is 
generated. Duplicates were filtered with a chosen RMSD threshold of 0.1. 
Minimisation was performed using the CHARMm forcefield with Momany-Rone 
partial charge estimation and a Generalised Born implicit solvent model. Duplicates 
are filtered again with a RMSD threshold of 0.1. 
 
6.1.4 New version of protocol 
Prior to conformer generation a wash step was performed, which involved stripping 
salts and ionising the molecule at pH 7.4. Any stereocentre created here was left with 
undefined stereochemistry. SMILES strings were converted to their canonical 
representation. A list of allowed chirality at each centre is generated and a SMILES 
file with all possible stereoisomers was written. Conformers were generated using the 
BEST method in Catalyst using the rel option, run directly on the server and not 
through the built-in Conformation Generator component with a chosen maximum 
relative energy threshold of 20 kcal mol-1, maximum of 255 conformers for each 
compound. Conformations were read, ones that cannot be represented by the canonical 
SMILES are discarded, with the remaining ones standardised to a single enantiomer. 
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Duplicates were filtered with a RMSD threshold of 0.1. Minimisation with 200 steps 
of Conjugate Gradient minimisation with an RMS gradient tolerance of 0.1 was 
performed using the CHARMm forcefield with Momany-Rone partial charge 
estimation and a Generalised Born implicit solvent model. Duplicates were filtered 
again with a RMSD threshold of 0.1. 
 
6.1.5 Analysis of lead-like library 
Prior to conformer generation a wash step was performed, which involved ionising the 
molecule at pH 7.4, adding explicit hydrogens and outputting the canonical tautomer. 
Conformers were generated using the BEST method in Catalyst with a maximum 
relative energy threshold of 20 kcal mol-1. These conformations were then minimised 
using 1000 steps of Steepest Descent with a RMS gradient tolerance of 3 and 200 steps 
of Conjugate Gradient with an RMS gradient tolerance of 0.1. Minimisation was 
performed using the CHARMm forcefield with Momany-Rone partial charge 
estimation and a Generalised Born implicit solvent model. The lowest energy 
conformer was selected. 
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6.2 Synthetic Methods 
6.2.1 General Methods 
All non-aqueous reactions were carried out under oxygen-free Ar using flame-dried 
glassware. Et2O and THF were freshly distilled from sodium and benzophenone 
respectively. Alkyllithiums were titrated against N-benzylbenzamide before use.129 
TMEDA, Me3SiCl and methyl iodide used in lithiations were distilled over CaH2 
before use. Dimethylformamide was obtained from the dry solvent still and CO2 was 
dried over CaCl2 before use in lithiation reactions. Petrol refers to the fraction of 
petroleum ether boiling in the range of 40-60 °C and was purchased in Winchester 
quantities. Brine refers to a saturated solution. Water is distilled water. 
Flash column chromatography was carried out using Fluka Chemie GmbH silica (220-
440 mesh). Thin layer chromatography was carried out using commercially available 
Merk F254 aluminium backed silica plates. Proton (400 MHz) and carbon (100.6 MHz) 
NMR spectra were recorded on a Jeol ECX-400 instrument using an internal 
deuterium lock. For samples recorded in CDCl3, chemical shifts are quoted in parts 
per million relative to CHCl3 (δH 7.26) and CDCl3 (δC 77.0, central line of triplet). For 
samples recorded in DMSO-d6, chemical shifts are quoted on parts per million relative 
to DMSO (δH 2.50, central line of quintet) and DMSO-d6 (δC 39.52, central line of 
septet). Carbon NMR spectra were recorded with broad band decoupling and assigned 
using DEPT experiments. Coupling constants (J) are quoted in Hertz. Melting points 
were carried out on a Gallenkamp melting point apparatus. Infrared spectra were 
recorded on an ATI Mattson Genesis FT-IR spectrometer. Electrospray high and low 
resonance mass spectra were recorded at room temperature on a Bruker Daltronics 
micrOTOF spectrometer. 
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6.2.2 General Procedures 
General Procedure A: Methyl ester formation and Boc protection 
Thionyl chloride (3.09 mL, 42.6 mmol, 1.1 eq.) was added dropwise over 5 min to a 
stirred solution of the carboxylic acid (38.7 mmol, 1.0 eq.) in MeOH (50 mL) at 0 °C 
under Ar. The resulting solution was stirred and heated at reflux for 1 h. The mixture 
was then allowed to cool to rt and the solvent was evaporated under reduced pressure 
to give the crude methyl ester. Triethylamine (5.40 mL, 38.7 mmol, 1.0 eq.) was added 
to a stirred solution of crude methyl ester in CH2Cl2 (25 mL) at rt under Ar. Then, a 
solution of di-tert-butyl dicarbonate (8.45 g, 38.7 mmol, 1.0 eq.) in CH2Cl2 (25 mL) 
was added. The resulting solution was stirred at rt for 18 h. The solids were removed 
by filtration and the filtrate was evaporated under reduced pressure to give a wet solid. 
The wet solid was dissolved in Et2O (50 mL) and washed with 1 M HCl(aq) (2 x 25 
mL) and saturated NaHCO3(aq) (10 mL). The organic layer was dried (MgSO4) and 
evaporated under reduced pressure to give the crude product. 
 
General Procedure B: Reduction of methyl esters 
A solution of the methyl ester (4.11 mmol, 1.0 eq.) in THF (20 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (156 mg, 4.11 mmol, 
1.0 eq.) in THF (30 mL) at 0 °C under Ar. The resulting mixture was stirred at 0 °C 
for 1 h and then H2O (0.7 mL), 20% NaOH(aq) (1.4 mL) and H2O (0.7 mL) were 
carefully added. The mixture was allowed to warm to rt and the solids were removed 
by filtration through Celite. H2O (20 mL) was then added to the filtrate and the mixture 
was extracted with Et2O (3 x 50 mL). The combined organic extracts were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product.  
 
General Procedure C: N-Boc deprotection using HCl in Et2O 
Hydrogen chloride (0.93 mL of a 2.0 M solution in Et2O, 1.86 mmol, 4.0 eq.) was 
added to a stirred solution of the N-Boc amine (0.46 mmol, 1.0 eq.) in Et2O (1 mL) at 
rt under Ar. The resulting solution was stirred at rt for 18 h. The solvent was then 
evaporated under reduced pressure to give the crude product. 
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General Procedure D: N-Boc deprotection using HCl in EtOAc 
Acetyl chloride (0.93 mL, 13.2 mmol, 4.0 eq.) was added dropwise (CARE - 
exothermic, vigorous reaction) to a stirred solution of N-Boc methyl ester 16 (3.29 
mmol, 1.0 eq.) and EtOH (0.77 mL, 13.2 mmol, 4.0 eq.) in EtOAc (20 mL) at rt under 
Ar. The resulting solution was stirred at rt or stirred and heated at reflux for 18 h. The 
solvent was then evaporated under reduced pressure to give the crude product. 
 
General Procedure E: Reduction of N-Boc to N-Me 
A solution of the N-Boc piperidine (0.88 mmol, 1.0 eq.) in THF (20 mL) was added 
dropwise to a stirred suspension of lithium aluminium hydride (165 mg, 4.36 mmol, 
5.0 eq.) in THF (30 mL) at 0 °C under Ar. The resulting mixture was allowed to warm 
to rt for 30 min and then stirred at heated at reflux for 24 h. After being allowed to 
cool to rt, the mixture was cooled to 0 °C then H2O (1.4 mL), 20% NaOH(aq) (2.8 mL) 
and H2O (1.4 mL) were carefully added. The mixture was allowed to warm to rt and 
the solids were removed by filtration through Celite. The filtrate was evaporated under 
reduced pressure to give the crude product. 
 
General Procedure F: N-Acetylation 
Acetyl chloride (0.12 mL, 1.67 mmol, 3.0 eq.) was added to a stirred solution of the 
amine hydrochloride salt (0.557 mmol, 1.0 eq.) and triethylamine (0.23 mL, 1.67 
mmol, 3.0 eq.) in CH2Cl2 (2 mL) at rt under Ar. The resulting solution was stirred at 
rt for 18 h. H2O (2 mL) was added and the reaction mixture was extracted with 
CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product. 
 
General Procedure G: N-Sulfonation 
Methanesulfonyl chloride (0.13 mL, 1.67 mmol, 3.0 eq.) was added to a stirred 
solution of the amine hydrochloride salt (0.56 mmol, 1.0 eq.) and triethylamine (0.23 
mL, 1.67 mmol, 3.0 eq.) in CH2Cl2 (2 mL) at rt under Ar. The resulting solution was 
stirred at rt for 18 h. H2O (2 mL) was added and the reaction mixture was extracted 
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with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (MgSO4) and 
evaporated under reduced pressure to give the crude product.  
 
General Procedure H: Enolate alkylation 
Lithium bis(trimethylsilyl)amide (1.0 M solution in THF, 0.750 mmol, 1.5 eq.) or  
potassium bis(trimethylsilyl)amide (0.5 M solution in toluene, 0.750 mmol, 1.5 eq.) 
was added to a stirred solution of methyl ester (122 mg, 0.50 mmol, 1.0 eq.) (and N,N′-
dimethylpropylene urea (0.75 mL, 1.5 eq.) if used) in THF (0.93 mL or 10 mL) at –78 
°C under Ar. The resulting mixture was stirred at –78 °C for 1 h. Then, methyl iodide 
(0.75 mmol, 1.5 eq.) was added. The resulting solution was allowed to warm to rt over 
4 h and then stirred at rt for 16 h. Saturated NH4Cl(aq) (0.5 mL) was added and the 
mixture was extracted with Et2O (3 x 5 mL). The combined organic extracts were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product. 
 
General procedure I: Methyl ester reduction with LiBH4 
Lithium borohydride (4.0 M solution in THF, 8.00 mmol, 8.0 eq.) was added to a 
stirred solution of methyl ester (1.00 mmol, 1.0 eq.) in THF (10 mL) at rt under Ar. 
The resulting solution was stirred at rt for 3-5 h. H2O (5 mL) was added and the 
mixture was extracted with EtOAc (3 x 10 mL). The combined organic extracts were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product.  
 
General procedure J: Amino zinc enolate carbocyclisation reaction 
Lithium bis(trimethylsilyl)amide (1.0 M solution in THF, 40.4 mmol, 2.0 eq.) was 
added to a stirred solution of ester-alkene 78 (20.2 mmol, 1.0 eq.) in Et2O (300 mL) at 
–20 °C under Ar. The resulting solution was stirred at –20 °C for 10 min and then 
allowed to warm to rt for 20 min. The mixture was then cooled to –40 °C. A solution 
of zinc bromide (9.10 g, 40.4 mmol, 2.0 eq.) in dry Et2O (40.4 mL) (NOTE: zinc 
bromide should be stirred vigorously in Et2O for 1 h before reaction to aid dissolution) 
was added. The resulting mixture was allowed to warm to rt and stirred at rt for 5 h. 
The mixture was then cooled to 0 °C and a 2:1 solution of saturated NH4Cl(aq)-
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NH4OH(aq) (40 mL) was added. The resulting mixture was then allowed to warm to rt 
and stirred at rt for 18 h. The mixture was extracted with Et2O (3 x 50 mL). The 
combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. 
 
General procedure K: Methyl ester formation 
Concentrated H2SO4 (2.54 mL, 46.7 mmol, 3.7 eq.) was added to a stirred solution of 
pyridine carboxylic acid 125 (12.7 mmol, 1.0 eq.) in MeOH (20 mL) at rt under air. 
The resulting solution was stirred and heated at reflux for 20 h. After being allowed to 
cool to rt, the solvent was evaporated under reduced pressure. H2O (20 mL) and cold 
saturated K2CO3(aq) (20 mL) was added until pH ˃ 10 was reached and the mixture 
was extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product.  
 
General procedure L: Benzylation of pyridine ester 
Benzyl bromide (0.86 mL, 7.29 mmol, 1.0 eq.) was added to a stirred solution of 
pyridine ester 128 (7.29 mmol, 1.0 eq.) in MeCN (18 mL) at rt under air. The resulting 
solution was stirred and heated at reflux for 3 h. After being allowed to cool to rt, the 
solvent was evaporated under reduced pressure to give the crude benzyl pyridinium 
bromide.  
 
General procedure M: Pyridine reduction using sodium borohydride 
Sodium borohydride (2.48 g, 65.6 mmol, 9.0 eq.) was added portionwise (CARE - 
vigorous reaction) to a stirred solution of benzyl pyridinium bromide (7.29 mmol, 1.0 
eq.) in MeOH (20 mL) and H2O (10 mL) at 0 °C under air. The resulting yellow 
solution was allowed to warm to rt and stirred at rt for 2 h. The solvent was then 
evaporated under reduced pressure to give a thick yellow oil. H2O (10 mL) was added 
and the mixture was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product.  
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6.2.3 Experimental procedures and characterisation data 
1-tert-Butyl 2-methyl piperidine-1,2-dicarboxylate 16 
 
Using general procedure A, thionyl chloride (3.09 mL, 42.6 mmol, 1.1 eq.), pipecolic 
acid 15 (5.00 g, 38.7 mmol, 1.0 eq.) in MeOH (50 mL) and then triethylamine (5.40 
mL, 38.7 mmol, 1.0 eq.) in CH2Cl2 (25 mL) and di-tert-butyl dicarbonate (8.45 g, 38.7 
mmol, 1.0 eq.) in CH2Cl2 (25 mL) gave the crude product. Purification by flash 
chromatography on silica with 80:20 hexane-Et2O as eluent gave methyl ester 16  
(8.88 g, 94%) as a colourless oil, RF (80:20 hexane-Et2O) 0.2; 
1H NMR (400 MHz, 
CDCl3) (50:50 mixture of rotamers) δ 4.89 (br s, 0.5H, NCHCO), 4.72 (br s, 0.5H, 
NCHCO), 4.05-3.87 (m, 1H, NCH), 3.723 (s, 1.5H, OMe), 3.721 (s, 1.5H, OMe), 2.96 
(br dd, J = 13.0, 13.0 Hz, 0.5H, NCH), 2.86 (br dd, J = 13.0, 13.0 Hz, 0.5H. NCH), 
2.19 (br d, J = 12.0 Hz, 1H, CH), 1.73-1.57 (m, 4H, CH), 1.45 (s, 9H, CMe3), 1.29-
1.15 (m, 1H, CH); 13C NMR (101.6 MHz, CDCl3) (rotamers) δ 172.4 (C=O), 155.5 
(C=O), 79.9 (CMe3), 55.0 (NCH), 53.7 (NCH), 52.0 (OMe), 42.1 (NCH2), 41.0 
(NCH2), 28.3 (CMe3), 26.8 (CH2), 24.8 (CH2), 20.8 (CH2). Spectroscopic data 
consistent with those reported in the literature.68 
Lab book reference: mcw/3/44/1 
 
tert-Butyl 2-(hydroxymethyl)piperidine-1-carboxylate 17 
 
A solution of 2-piperidine methanol 18 (1.00 g, 8.68 mmol, 1.0 eq.) in CH2Cl2 (25 
mL) and triethylamine (4.36 mL, 31.3 mmol, 3.6 eq.) was added dropwise to a stirred 
solution of di-tert-butyl dicarbonate (2.27 g, 10.4 mmol, 1.2 eq.) in CH2Cl2 (25 mL) 
at 0 °C under Ar. The resulting solution was allowed to warm to rt and stirred at rt for 
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16 h. H2O (20 mL) was added and the mixture was extracted with CH2Cl2 (3 x 15 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
90:10 petrol-Et2O as eluent gave N-Boc piperidine 17 (1.49 g, 80%) as a white solid, 
mp 61-64 °C (lit.,21 76-77 °C); RF (9:1 Et2O-petrol) 0.3;  
1H NMR (400 MHz, CDCl3) 
δ 4.31-4.25 (m, 1H, NCH), 3.93 (br d, J = 13.0 Hz, 1H, NCH), 3.81 (dd, J = 11.0, 9.0 
Hz, 1H, CHOH), 3.60 (dd, J = 11.0, 5.5 Hz, 1H, CHOH), 2.94-2.77 (m, 1H, NCH), 
2.08 (br s, 1H, CH), 1.72-1.38 (m, 5H, CH), 1.46 (s, 9H, CMe3); 
13C NMR (101.6 
MHz, CDCl3) δ 156.2 (C=O), 79.8 (CMe3), 61.7 (CH2OH), 52.5 (NCH), 39.8 (NCH2), 
28.4 (CMe3), 25.2 (CH2), 25.1 (CH2), 19.6 (CH2). Spectroscopic data consistent with 
those reported in the literature.68 
Lab Book Reference: mcw/1/82 
Using general procedure B, methyl ester 16 (1.00 g, 4.11. mmol, 1.0 eq.) and lithium 
aluminium hydride (156 mg, 4.11 mmol, 1.0 eq.) in THF (50 mL) gave the crude 
product. Purification by flash chromatography on silica with 60:40 hexane-Et2O and 
then Et2O as eluent gave amino alcohol 17 (781 mg, 88%) as a white solid.  
Lab Book Reference: mcw/3/41/2 
 
2-(Hydroxymethyl)piperidine hydrochloride salt 18.HCl 
 
Using general procedure D, hydrogen chloride (0.93 mL of a 2.0 M solution in Et2O, 
1.86 mmol, 4.0 eq.) and N-Boc amino alcohol 17 (100 mg, 0.46 mmol, 1.0 eq.) in Et2O 
(1 mL) gave amine hydrochloride salt 18 (76 mg, quant) as a yellow oil, IR (ATR) 
3368 (OH or NH), 2949, 2754, 1652, 1402, 1324, 1050, 568 cm–1; 1H NMR (400 MHz, 
DMSO-d6) δ 8.73 (br s, 1H, NH), 8.42 (br s, 1H, NH), 5.37 (dd, J = 4.5, 4.5 Hz, 1H, 
OH), 3.57 (ddd, J = 11.0, 4.0, 4.0 Hz, 1H), 3.49-3.42 (m, 1H), 3.17 (br d, J = 12.0 Hz, 
1H), 3.02 (br s, 1H), 2.82 (br dd, J = 12.0, 12.0 Hz, 1H), 1.77-1.66 (m, 3H, CH), 1.61-
1.33 (m, 3H, CH); 13C NMR (101.6 MHz, DMSO-d6) δ 61.4 (OCH2), 57.3 (NCH), 
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43.7 (NCH2), 24.7 (CH2), 21.9 (CH2), 21.3 (CH2); MS (ESI) m/z 116 [M
+, 100]; 
HMRS (ESI) m/z calcd for C6H14NO M
+ 116.1070, found 116.1067 (+2.5 ppm error). 
Lab Book Reference: mcw/3/58/c 
 
(1-Methylpiperidin-2-yl)methanol 19 
 
Using general procedure E, N-Boc piperidine 16 (243 mg, 1.00 mmol, 1.0 eq.) in THF 
(20 mL) and lithium aluminium hydride (189 mg, 5.00 mmol, 5.0 eq.) in THF (30 mL) 
gave N-methyl piperidine 19 (106 mg, 82%) as a colourless oil; IR (ATR) 3349 (OH), 
2931, 2855, 2791, 1444, 1144, 1025, 749 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.84 
(dd, J = 11.0, 4.0 Hz, 1H, CHOH), 3.39 (dd, J = 11.0, 2.0 Hz, 1H, CHOH), 2.87 (br d, 
J = 11.5 Hz, 1H, NCH), 2.28 (s, 3H, Me), 2.13 (ddd, J = 11.5, 11.5, 3.0 Hz, 1H, NCH), 
1.98-1.92 (m, 1H, NCH), 1.78-1.72 (m, 1H, CH), 1.64-1.56 (m, 3H, CH), 1.55-1.43 
(m, 1H, CH), 1.33-1.20 (m, 1H, CH); 13C NMR (101.6 MHz, CDCl3) δ 64.0 (NCH), 
63.2 (OCH2), 56.6 (NCH2), 42.8 (NMe), 28.4 (CH2), 25.5 (CH2), 24.1 (CH2); MS 
(ESI) m/z 130 [(M + H)+, 100]; HMRS (ESI) m/z calcd for C7H15NO (M + H)
+ 
130.1226, found 130.1232 (–3.9 ppm error). 
Lab Book Reference: mcw/3/79 
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2-(Methoxycarbonyl)piperidine hydrochloride salt 20.HCl 
 
Using general procedure C, acetyl chloride (0.93 mL, 13.2 mmol, 4.0 eq), N-Boc 
methyl ester 16 (800 mg, 3.29 mmol, 1.0 eq.) and EtOH (0.77 mL, 13.2 mmol, 4.0 eq.) 
in EtOAc (20 mL) gave amine hydrochloride salt 20 (485 mg, 82%) as a white solid, 
mp 196-198 °C; IR (ATR) 2906, 2707, 2420, 1745 (C=O), 1430, 1136, 1230, 1017, 
cm–1; 1H NMR (400 MHz, CDCl3) δ 9.90 (br s, 2H, NH2), 3.95 (dd, J = 10.0, 4.0 Hz, 
1H, NCH), 3.84 (s, 3H, OMe), 3.64 (ddd, J = 12.0, 4.0, 4.0, Hz, 1H, NCH), 3.10 (ddd, 
J = 12.0, 10.0, 4.0 Hz, 1H, NCH), 2.33-2.21 (m, 1H, CH), 2.16-1.96 (m, 2H, CH), 
1.94-1.75 (m, 2H, CH), 1.66-1.53 (m, 1H, CH); 13C NMR (101.6 MHz, CDCl3) δ 168.7 
(C=O), 56.7 (NCH), 53.2 (OMe), 43.7 (NCH2), 25.6 (CH2), 21.63 (CH2), 21.59 (CH2); 
MS (ESI) m/z 144 [M+, 100]; HMRS (ESI) m/z calcd for C7H14NO2 M
+ 144.1019, 
found 144.1015 (+2.6 ppm error). 
Lab Book reference: mcw/3/43/c 
 
Methyl 1-acetylpiperidine-2-carboxylate 21 
 
Using general procedure F, acetyl chloride (0.12 mL, 1.67 mmol, 3.0 eq.), methyl 
ester 20 (100 mg, 0.56 mmol, 1.0 eq.) and triethylamine (0.23 mL, 1.67 mmol, 3.0 
eq.) in CH2Cl2 (2 mL) gave the crude product. Purification by flash chromatography 
on silica with 80:20 Et2O-hexane and then Et2O as eluent gave acetamide 21 (102 
mg, 99%) as a colourless oil, RF (80:20 Et2O-hexane) 0.2; IR (ATR) 2944, 2861, 
1736 (C=O, ester), 1639 (C=O, amide), 1419, 1261, 1204, 999 cm–1; 1H NMR (400 
MHz, CDCl3) (80:20 mixture of rotamers) δ 5.38 (d, J = 5.5 Hz, 0.8H, NCHCO), 
4.58-4.49 (m, 0.4H, NCH), 3.76 (s, 0.6H, OMe), 3.72 (s, 2.4H, OMe), 3.72-3.70 (m, 
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0.8H, NCH), 3.27 (ddd, J = 13.0, 13.0, 3.0 Hz, 0.8H, NCH), 2.60 (ddd, J = 13.0, 
13.0, 3.0 Hz, 0.2H, NCH), 2.28-2.21 (m, 1H, CH), 2.13 (s, 2.4H, Me), 2.07 (s, 0.6H, 
Me), 1.77-1.55 (m, 3H, CH), 1.52-1.23 (m, 2H, CH); 1H NMR (400 MHz, DMSO-
d6) (70:30 mixture of rotamers) δ 5.12 (d, J = 5.0 Hz, 0.7H, NCHCO), 4.78 (d, J = 
5.0 Hz, 0.3H, NCHCO), 4.31 (d, J = 12.5 Hz, 0.3H, NCH), 3.74 (br d, J = 12.5 Hz, 
0.7H, NCH), 3.69 (s, 0.9H, OMe), 3.65 (s, 2.1H, OMe), 3.10 (ddd, J = 12.5, 12.5, 
3.0 Hz, 0.7H, NCH), 2.42 (ddd, J = 12.5, 12.5, 3.0 Hz, 0.3H, NCH), 2.18-2.05 (m, 
1H, CH), 2.03 (s, 2.1H, OMe), 1.96 (s, 0.9H, OMe), 1.70-1.13 (m, 5H); 13C NMR 
(101.6 MHz, CDCl3) (rotamers) δ 171.9 (C=O), 171.4 (C=O), 170.6 (C=O), 170.4 
(C=O), 56.8 (OMe), 52.5 (NCH), 52.2 (NCH), 44.2 (NCH2), 39.2 (NCH2), 27.2 
(CH2), 26.6 (CH2), 25.3 (CH2), 24.4 (CH2), 21.6 (Me), 21.5 (Me), 20.9 (CH2), 20.7 
(CH2); MS (ESI) m/z 208 [(M + Na)
+, 100], 186 [(M + H)+, 10]; HMRS (ESI) m/z 
calcd for C9H15NO3 (M + Na)
+ 208.0944, found 208.0953 (–4.2 ppm error). 
Lab Book Reference: mcw/3/50/1 
 
1-(2-(Hydroxymethyl)piperidin-1-yl)ethanone 22 
 
Using general procedure B, acetamide 21 (50 mg, 0.27 mmol, 1.0 eq.) in THF (2 mL) 
and lithium aluminium hydride (10.2 mg, 0.27 mmol, 1.0 eq.) in THF (4 mL) gave the 
crude product. Purification by flash chromatography on silica with 80:20 Et2O-hexane 
and then Et2O as eluent gave amino alcohol 22 (9 mg, 19%) as a colourless oil, RF 
(80:20 Et2O-hexane) 0.2; 
1H NMR (400 MHz, CDCl3) (60:40 mixture of rotamers) δ 
4.81-4.69 (m, 0.6H, NCH), 4.54 (br d, J = 13.5 Hz, 0.4H, NCH), 4.07-3.95 (m, 0.8H), 
3.85-3.72 (m, 0.6H), 3.69-3.59 (m, 1H), 3.56 (dd, J = 10.0, 3.5 Hz, 0.4H), 3.20 (ddd, 
J = 12.5, 12.5, 3.5 Hz, 0.6H), 2.62 (br dd, J = 12.0, 12.0 Hz, 0.6H), 2.15 (s, 1.2H, Me), 
2.12 (s, 1.8H, Me), 1.77-1.21 (m, 6H, CH); 13C NMR (101.6 MHz, CDCl3) (rotamers) 
δ 171.6 (C=O), 170.8 (C=O), 62.2 (OCH2), 60.7 (OCH2), 55.4 (NCH), 51.0 (NCH), 
42.7 (NCH2), 36.6 (NCH2), 26.1 (CH2), 25.5 (CH2), 25.2 (CH2), 25.1 (CH2), 22.0 
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(Me), 21.9 (Me), 19.63 (CH2), 19.57 (CH2); MS (ESI) m/z 180 [(M + Na)
+, 100], 158 
[(M + H)+, 15]; HMRS (ESI) m/z calcd for C8H15NO2 (M + Na)
+ 180.0995, found 
180.0988 (+3.9 ppm error).  
Lab Book Reference: mcw/3/61 
Using general procedure I, lithium borohydride (1.62 mL of a 4.0 M solution in THF, 
6.47 mmol, 8.0 eq.) and methyl ester 21 (150 mg, 0.81 mmol, 1.0 eq.) in THF (10 mL) 
for 5 h gave the crude product. Purification by flash chromatography on silica with 
50:50 EtOAc-hexane and then EtOAc as eluent gave alcohol 22 (36 mg, 29%) as a 
colourless oil. 
Lab book reference: mcw/4/47 
 
Methyl 1-(methylsulfonyl)piperidine-2-carboxylate 23 
 
Using general procedure G, methanesulfonyl chloride (0.13 mL, 1.67 mmol, 3.0 eq.), 
methyl ester 20 (100 mg, 0.56 mmol, 1.0 eq.) and triethylamine (0.23 mL, 1.67 mmol, 
3.0 eq.) in CH2Cl2 (2 mL) gave the crude product. Purification by flash 
chromatography on silica with 80:20, 50:50, 20:80 hexane-Et2O and then Et2O as 
eluent gave sulfonamide 23 (107 mg, 87%) as a white solid, mp 79-81 °C; RF (80:20 
hexane-Et2O) 0.2; IR (ATR) 2954, 2851, 1730 (C=O), 1317 (S=O), 1302, 1148 (S=O), 
966, 769, 519 cm–1; 1H NMR (400 MHz, CDCl3) δ 4.75 (d, J = 5.0 Hz, 1H, NCHCO), 
3.76 (s, 3H, OMe), 3.75-3.69 (m, 1H, NCH), 3.18 (ddd, J = 12.5, 12.5, 3.0 Hz, 1H, 
NCH), 2.94 (s, 3H, Me), 2.29-2.21 (m, 1H, CH), 1.87-1.67 (m, 3H, CH), 1.65-1.52 
(m, 1H, CH), 1.31-1.18 (m, 1H, CH); 13C NMR (101.6 MHz, CDCl3) δ 171.9 (C=O), 
55.7 (OMe), 52.3 (NCH), 42.4 (NCH2), 38.8 (Me), 28.0 (CH2), 24.9 (CH2), 20.5 
(CH2); MS (ESI) m/z 244 [(M + Na)
+, 100], 222 [(M + H)+, 10]; HMRS (ESI) m/z 
calcd for C8H15NO4S (M + Na)
+ 244.0614, found 244.0608 (+2.5 ppm error). 
Lab Book Reference mcw/3/51/2 
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(1-(Methylsulfonyl)piperidin-2-yl)methanol 24 
 
Using general procedure B, sulfonamide 23 (50 mg, 0.23 mmol, 1.0 eq.) in THF (2 
mL) and lithium aluminium hydride (8.6 mg, 0.23 mmol, 1.0 eq.) in THF (4 mL) gave 
the crude product. Purification by flash chromatography on silica with 80:20 hexane-
Et2O as eluent gave amino alcohol 24 (42 mg, 85%) as a colourless oil, RF (80:20 
hexane-Et2O) 0.2; IR (ATR) 3500 (OH), 2932, 2868, 1311 (S=O), 1142 (S=O), 1061, 
963, 769, 586 cm–1; 1H NMR (400 MHz, CDCl3) δ 4.07-3.99 (m, 1H, NCH), 3.91 (dd, 
J = 11.0, 11.0 Hz, 1H, CHOH), 3.73-3.66 (m, 1H, NCH), 3.58 (dd, J = 11.0, 5.0 Hz, 
1H, CHOH), 3.11-3.02 (m, 1H, NCH), 2.95 (s, 3H, Me), 2.31 (br s, 1H, OH), 1.76-
1.61 (m, 4H, CH), 1.58-1.42 (m, 2H, CH); 13C NMR (101.6 MHz, CDCl3) δ 60.7 
(OCH2), 54.9 (NCH), 40.9 (NCH2), 40.0 (Me), 26.0 (CH2), 25.2 (CH2), 19.4 (CH2); 
MS (ESI) m/z 216 [(M + Na)+, 100], 194 [(M + H)+, 15]; HMRS (ESI) m/z calcd for 
C7H15NO3S (M + Na)
+ 216.0665, found 216.0666 (–0.9 ppm error). 
Lab Book Reference: mcw/3/60/1 
 
1-tert-Butyl 2-methyl 2-methylpiperidine-1,2-dicarboxylate 25 
 
(Table 3.1, Entry 1) 
Using general procedure H, lithium bis(trimethylsilyl)amide (0.75 mL of a 1.0 M 
solution in THF, 0.75 mmol, 1.5 eq.), methyl ester 16 (122 mg, 0.50 mmol, 1.0 eq.) in 
THF (0.93 mL) and then methyl iodide (0.05 mL, 0.75 mmol, 1.5 eq.) gave the crude 
product as a 91:9 mixture (by 1H NMR spectroscopy) of methylated methyl ester 25 
and starting methyl ester 16 (95 mg, 68% of methylated ester 25 and 7% of starting 
ester 16) as a colourless oil. 
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Lab Book Reference: mcw/3/34 
(Table 3.1, Entry 2)  
Using general procedure H, potassium bis(trimethylsilyl)amide (1.5 mL of a 0.5 M 
solution in toluene, 0.75 mmol, 1.5 eq.) and methyl ester 16 (122 mg, 0.50 mmol, 1.0 
eq.) in THF (0.93 mL) and then methyl iodide (0.05 mL, 0.75 mmol, 1.5 eq.) gave 
the crude product as a 98:2 mixture (by 1H NMR spectroscopy) of methylated 
methyl ester 25 and starting methyl ester 16 (126 mg, 96% of methylated ester 25 
and 2% of starting ester 16) as a colourless oil. 
Lab Book Reference: mcw/3/35 
(Table 3.1, Entry 3) 
Using general procedure H, lithium bis(trimethylsilyl)amide (0.75 mL of a 1.0 M 
solution in THF, 0.75 mmol, 1.5 eq.), methyl ester 16 (122 mg, 0.50 mmol, 1.0 eq.) 
and N,N′-dimethylpropylene urea (0.09 mL, 0.75 mL, 1.5 eq.) in THF (0.93 mL) and 
then methyl iodide (0.05 mL, 0.75 mmol, 1.5 eq.) gave the crude product as a 42:58 
mixture (by 1H NMR spectroscopy) of methylated methyl ester 25 and starting methyl 
ester 16 (141 mg, 72% of methylated ester 25 and 40% of starting ester 16) as a 
colourless oil. 
Lab Book Reference: mcw/3/36 
Using general procedure H, potassium bis(trimethylsilyl)amide (15 mL of a 0.5 M 
solution in toluene, 7.50 mmol, 1.5 eq.) and methyl ester 16 (1.22 mg, 5.00 mmol, 1.0 
eq.) in THF (10 mL) and then methyl iodide (0.47 mL, 7.50 mmol, 1.5 eq.) gave the 
crude product as a 95:5 mixture (by 1H NMR spectroscopy) of methylated methyl ester 
25 and starting methyl ester 16 (1.26 g, 94% of methylated ester 25 and 5% of starting 
ester 16) as a colourless oil, RF (80:20 hexane-Et2O) 0.2; 
1H NMR (400 MHz, CDCl3) 
for 25: δ 3.84 (ddd, J = 13.5, 4.0, 4.0 Hz, 1H, NCH),  3.70 (s, 3H, OMe), 2.95 (br dd, 
J = 13.5, 13.5 Hz, 1H, NCH), 1.92-1.77 (m, 1H, CH), 1.75-1.53 (m, 5H, CH), 1.40 (s, 
9H, CMe3).
13C NMR (101.6 MHz, CDCl3) for 16: δ 175.6 (C=O, CO2Me), 155.5 
(C=O, Boc), 79.9 (CMe3), 60.3 (NCH2), 52.0 (OMe), 41.0 (CH2), 34.8 (CH2), 28.2 
(CMe3), 23.7 (Me), 18.4 (CH2). Spectroscopic data for 25 consistent with those 
reported in the literature.68 
196 
 
Lab Book Reference: mcw/3/49/1 
 
tert-Butyl 2-(hydroxymethyl)-2-methylpiperidine-1-carboxylate 34 
 
Using general procedure B, a 95:5 mixture of methyl esters 25 and 16 (200 mg, 190 
mg of 25 (0.74 mmol) and 10 mg of 16 (0.041 mmol)) in THF (5 mL) and lithium 
aluminium hydride (30 mg, 0.78 mmol, 1.0 eq.) in THF (30 mL) gave the crude 
product. Purification by flash chromatography on silica with 70:30 and then 50:50 
hexane-Et2O as eluent gave methylated amino alcohol 34 (111 mg, 65% from 25) as 
a colourless oil, RF (50:50 hexane-Et2O) 0.4; 
1H NMR (400 MHz, CDCl3) δ 4.70 (br 
s, 1H, OH), 3.85 (br ddd, J = 12.0, 4.0, 4.0 Hz, 1H, NCH), 3.67-3.59 (m, 2H, CHOH), 
2.96 (ddd, J = 13.5, 12.0, 3.0 Hz, 1H, NCH), 1.68-1.56 (m, 5H, CH), 1.44 (s, 9H. 
CMe3), 1.36-1.31 (m, 1H, CH), 1.23 (s, 3H, Me); 
13C NMR (101.6 MHz, CDCl3) δ 
156.4 (C=O), 80.0 (CMe3), 71.4 (OCH2), 59.5 (CMe), 42.5 (NCH2), 35.4 (CH2), 28.4 
(CMe3), 24.9 (CH2), 19.6 (CH2), 18.2 (Me) and amino alcohol 17 (8 mg, 100% from 
16). Spectroscopic data for 34 consistent with those reported in the literature.68 
Lab Book Reference: mcw/3/56/1 
 
2-(Hydroxymethyl)-2-methylpiperidine hydrochloride salt A1.HCl 
 
Using general procedure D, hydrogen chloride (3.49 mL of a 1.0 M solution in Et2O, 
3.49 mmol, 8.0 eq.) and N-Boc amino alcohol 34 (100 mg, 0.44 mmol, 1.0 eq.) in Et2O 
(1.75 mL) gave amine hydrochloride salt A1.HCl (68 mg, 94%) as a white solid, mp 
120-122 °C; IR (ATR) 3345 (OH or NH), 2943, 2870, 2747, 1671, 1394, 1274, 1253, 
1156, 1049 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 8.95 (s, 1H, NH), 8.46 (s, 1H, 
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NH), 3.96 (br s, 1H, OH), 3.55 (d, J = 11.5 Hz, 1H, CHOH), 3.39 (d, J = 11.5 Hz, 1H, 
CHOH), 2.97-2.89 (m, 2H, NCH), 1.65-1.54 (m, 5H, CH), 1.46-1.42 (m, 1H, CH), 
1.22 (s, 3H, Me); 13C NMR (101 MHz, DMSO-d6) δ 65.0 (OCH2), 57.3 (CMe), 39.0 
(NCH2), 29.45 (CH2), 21.5 (CH2), 18.1 (Me), 17.6 (CH2); MS (ESI) m/z 130 [M 
+, 
100]; HMRS (ESI) m/z calcd for C7H16NO M
+ 130.1226, found 130.1231 (–3.9 ppm 
error). 
Lab Book Reference: mcw/5/15/c 
 
(1,2-Dimethylpiperidin-2-yl)methanol A2 
 
Using general procedure E, N-Boc piperidine 34 (200 mg, 0.88 mmol, 1.0 eq.) in THF 
(20 mL) and lithium aluminium hydride (165 mg, 4.36 mmol, 5.0 eq.) in THF (30 mL) 
gave N-methyl piperidine A2 (96 mg, 76%) as a colourless oil, IR (ATR) 3350 (OH), 
2930, 2862, 1450, 1371, 1106, 1051, 669 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.55 
(d, J = 10.5 Hz, 1H, CHOH), 3.08 (d, J = 10.5 Hz, 1H, CHOH), 2.65 (br d, J = 12.0, 
1H, NCH), 2.44 (ddd, J = 12.0, 12.0, 3.0 Hz, 1H, NCH), 2.17 (s, 3H, NMe), 1.88-1.78 
(m, 1H, CH), 1.62-1.57 (m, 2H, CH), 1.49-1.40 (m, 2H), 1.32-1.24 (m, 1H, CH), 0.86 
(s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) (CMe not resolved) δ 62.8 (OCH2), 50.8 
(NCH2), 37.3 (NMe), 34.1 (CH2), 29.8 (CH2), 20.5 (CH2), 11.7 (Me); MS (ESI) m/z 
144 [(M + H)+, 100]; HMRS (ESI) m/z calcd for C8H17NO (M + H)
+ 144.1383, found 
144.1384 (–0.6 ppm error). 
Lab book reference: mcw/3/98 
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1-tert-Butyl 3-methyl piperidine-1,3-dicarboxylate 36 
 
Using general procedure A, thionyl chloride (1.85 mL, 25.5 mmol, 1.1 eq.), carboxylic 
acid 35 (3.00 g, 23.2 mmol, 1.0 eq.) in MeOH (40 mL) and then triethylamine (3.24 
mL, 23.2 mmol, 1.0 eq.) in CH2Cl2 (20 mL) and di-tert-butyl dicarbonate (5.07 g, 23.2 
mmol, 1.0 eq.) in CH2Cl2 (20 mL) gave the crude product. Purification by flash 
chromatography on silica with 80:20 hexane-Et2O as eluent gave methyl ester 36 (4.56 
g, 81%) as a yellow solid, mp 43-45 °C; RF (80:20 hexaneEt2O) 0.2; 
1H NMR (400 
MHz, CDCl3) δ 4.07 (br s, 1H, NCH), 3.89 (br d, J = 13.0 Hz, 1H, NCH), 3.66 (s, 3H, 
OMe), 2.96 (br s, 1H, NCH), 2.79 (ddd, J = 13.0, 11.0, 3.0 Hz, 1H, NCH), 2.43 (dddd, 
J = 10.5, 10.5, 3.5, 3.5 Hz, 1H, CHCO2Me), 2.06-1.98 (m, 1H, CH), 1.72-1.62 (m, 1H, 
CH), 1.61-1.51 (m, 1H, CH), 1.49-1.35 (m, 10H, CH and CMe3); 
13C NMR (101.6 
MHz, CDCl3) δ 173.8 (C=O, CO2Me), 154.6 (C=O, Boc), 79.6 (CMe3), 51.7 (OMe), 
45.4 (NCH2), 43.6 (NCH2), 41.3 (CH), 28.4 (CMe3), 27.3 (CH2), 24.2 (CH2). 
Spectroscopic data consistent with those reported in the literature.130 
Lab Book reference: mcw/3/15/2 
 
1-tert-Butyl 3-methyl 3-methylpiperidine-1,3-dicarboxylate 37 
 
Using general procedure H, potassium bis(trimethylsilyl)amide (15 mL of a 0.5 M 
solution in toluene, 7.50 mmol, 1.5 eq.) and methyl ester 36 (1.22 mg, 5.00 mmol, 1.0 
eq.) in THF (10 mL) and then methyl iodide (0.47 mL, 7.50 mmol, 1.5 eq.) gave the 
crude product. Purification by flash chromatography on silica with 80:20 hexane-Et2O 
as eluent gave methylated piperidine 37 (1.25 g, 97%) as a colourless oil, IR (ATR) 
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2974, 2863, 1731 (C=O, CO2Me), 1689 (C=O, Boc), 1422, 1364, 1277, 1152, 1001, 
866 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.84 (d, J = 13.0 Hz, 1H, NCH), 3.67 (s, 3H, 
OMe), 3.49-3.38 (m, 1H, NCH), 3.28-3.18 (m, 1H, NCH), 3.11 (d, J = 13.0 Hz, 1H, 
NCH), 2.06-1.97 (m, 1H, CH), 1.62-1.52 (m, 2H, CH), 1.46-1.40 (m, 1H, CH), 1.44 
(s, 9H, CMe3), 1.15 (s, 3H, Me); 
13C NMR (101.6 MHz, CDCl3) (NCH2 signal not 
resolved) δ 176.3 (C=O, CO2Me), 154.7 (C=O, Boc), 79.3 (CMe3), 51.8 (OMe), 42.6 
(NCH2), 33.6 (CH2), 28.4 (CMe3), 22.1 (Me), 21.8 (CH2); MS (ESI) m/z 280 [(M + 
Na)+, 100], 258 [(M + H)+, 15]; HMRS (ESI) m/z calcd for C13H23NO4 (M + Na)
+ 
280.1519, found 280.1512 (+2.7 ppm error). 
Lab Book Reference: mcw/3/72/1 
 
tert-Butyl 3-(hydroxymethyl)-3-methylpiperidine-1-carboxylate 38 
 
Using general procedure B, methyl ester 37 (400 mg, 1.55 mmol, 1.0 eq.) in THF (5 
mL) and lithium aluminium hydride (59 mg, 1.55 mmol, 1.0 eq.) in THF (25 mL) gave 
the crude product. Purification by flash chromatography on silica with 50:50 hexane-
Et2O as eluent gave amino alcohol 38 (323 mg, 91%) as a colourless oil, RF (50:50 
Et2O-hexane) 0.3; IR (ATR) 3446 (OH), 2933, 2862, 1663 (C=O), 1426, 1364, 1245, 
1156, 766 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.83 (d, J = 11.5 Hz, 1H, CH), 3.53 
(dd, J = 11.5, 3.0 Hz, 1H, CH), 3.46-2.80 (m, 3H, CH), 2.51 (d, J = 12.5 Hz, 1H, CH), 
1.69 ( br s, 1H, CH), 1.57-1.39 (m, 2H, CH), 1.46 (s, 9H, CMe3), 1.38-1.28 (m, 1H, 
CH), 0.91 (s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 156.2 (C=O), 79.8 (CMe3), 
66.0 (OCH2), 50.2 (NCH2), 45.4 (NCH2), 35.9 (CMe(CH2OH)), 33.5 (CH2), 28.4 
(CMe3), 23.2 (Me), 21.6 (CH2); MS (ESI) m/z 252 [(M + Na)
+, 100]; HMRS (ESI) m/z 
calcd for C12H23NO3 (M + Na)
+ 252.1570, found 252.1561 (+3.8 ppm error). 
Lab Book Reference: mcw/4/35 
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3-(Hydroxymethyl)-3-methylpiperidine hydrochloride salt A5.HCl 
 
Using general procedure D, hydrogen chloride (1.74 mL of a 2.0 M solution in Et2O, 
3.49 mmol, 8.0 eq.) and N-Boc amino alcohol 38 (100 mg, 0.44 mmol, 1.0 eq.) in Et2O 
(1 mL) gave amine hydrochloride salt A5.HCl (72 mg, 100%) as a thick colourless 
oil, IR (ATR) 3362 (OH or NH), 2943, 2805, 2729, 1595, 1451, 1027, 519 cm–1; 1H 
NMR (400 MHz, DMSO-d6) δ 8.51 (br s, 2H, NH2), 4.86 (br s, 1H, OH), 3.25 (d, J = 
10.5 Hz, 1H, CHOH), 3.20 (d, J = 10.5 Hz, 1H, CHOH), 2.98 (ddd, J = 12.5, 5.0, 5.0 
Hz, 1H, NCH), 2.88-2.80 (m, 2H, CH), 2.75 (d, J = 12.5 Hz, 1H, NCH), 1.69-1.62 (m, 
2H, CH), 1.55-1.47 (m, 1H, CH), 1.51 (ddd, J = 12.5, 5.0, 5.0, 1H, CH), 0.92 (s, 3H, 
Me); 13C NMR (101.6 MHz, DMSO-d6) δ 67.2 (OCH2), 49.2 (NCH2), 43.3 (NCH2), 
33.9 (CMe), 29.8 (CH2), 20.8 (Me), 18.2 (CH2); MS (ESI) m/z 130 [M
+, 100]; HMRS 
(ESI) m/z calcd for C7H16NO M
+ 130.1226, found 130.1231 (–3.5 ppm error). 
Lab Book Reference: mcw/5/11 
 
(1,3-Dimethylpiperidin-3-yl)methanol A6 
 
Using general procedure E, N-Boc piperidine 37 (257 mg, 1.00 mmol, 1.0 eq.) in THF 
(20 mL) and lithium aluminium hydride (190 mg, 5.00 mmol, 5.0 eq.) in THF (30 mL) 
gave N-methyl piperidine A6 (138 mg, 96%) as a colourless oil, IR (ATR) 3337 (OH), 
2934, 2777, 1447, 1211, 1054, 811 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.62 (dd, J = 
10.5, 1.5 Hz, 1H, CHOH), 3.56 (dd, J = 10.5, 1.5 Hz, 1H, CHOH), 2.67 (br s, 2H, 
NCH), 2.20 (s, 3H, NMe), 2.11-2.01 (m, 1H, CH), 1.96 (br d, J = 10.5 Hz, 2H, NCH), 
1.65-1.54 (m, 2H, CH), 1.26-1.14 (m, 1H, CH), 0.77 (s, 3H, Me); 13C NMR (101.6 
MHz, CDCl3) δ 74.3 (OCH2), 62.8 (NCH2), 55.9 (NCH2), 46.4 (Me), 34.9 (CH2), 34.4 
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(CMe), 29.9 (CH2), 23.1 (Me); MS (ESI) m/z 144 [(M + H)
+, 100]; HMRS (ESI) m/z 
calcd for C8H17NO (M + H)
+ 144.1383, found 144.1379 (+2.7 ppm error). 
Lab Book Reference: mcw/3/80 
 
1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 31 
 
Using general procedure A, thionyl chloride (3.09 mL, 42.6 mmol, 1.1 eq.), carboxylic 
acid 38 (5.00 g, 38.7 mmol, 1.0 eq.) in MeOH (50 mL) and then triethylamine (5.40 
mL, 38.7 mmol, 1.0 eq.) in CH2Cl2 (25 mL) and di-tert-butyl dicarbonate (8.45g, 38.7 
mmol, 1.0 eq.) in CH2Cl2 (25 mL) gave the crude product. Purification by flash 
chromatography on silica with 80:20 hexane-Et2O as eluent gave methyl ester 31 (7.98 
g, 85%) as a colourless oil, RF (80:20 hexaneEt2O) 0.1; IR (ATR) 2953, 2860, 1734 
(C=O, CO2Me), 1689 (C=O, Boc), 1448, 1419, 1365, 1158, 1038, 768 cm
–1; 1H NMR 
(400 MHz, CDCl3) δ 4.01 (br d, J = 13.5 Hz, 2H, NCH), 3.68 (s, 3H, OMe), 2.81 (ddd, 
J = 13.5, 11.5, 3.0 Hz, 2H, NCH), 2.44 (tt, J = 11.0, 4.0 Hz, 1H, CHCO2Me), 1.91-
1.81 (m, 2H, CH), 1.67-1.55 (m, 2H, CH), 1.45 (s, 9H, CMe3); 
13C NMR (101.6 MHz, 
CDCl3) δ 175.0 (C=O, CO2Me), 154.7 (C=O, Boc), 79.6 (CMe3), 51.8 (OMe), 43.1 
(NCH2), 41.0 (CH), 28.4 (CMe3), 27.9 (CH2); MS (ESI) m/z 266 [(M + Na)
+, 100]; 
HMRS (ESI) m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, found 266.1355 (+2.6 
ppm error). 
Lab Book Reference: mcw/3/3/2 
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1-tert-Butyl 4-methyl 4-methylpiperidine-1,4-dicarboxylate 33 
 
Using general procedure H, potassium bis(trimethylsilyl)amide (15 mL of a 0.5 M 
solution in toluene, 7.50 mmol, 1.5 eq.) and methyl ester 31 (1.22 mg, 5.00 mmol, 1.0 
eq.) in THF (10 mL) and then methyl iodide (0.47 mL, 7.50 mmol, 1.5 eq.) gave the 
crude product. Purification by flash chromatography on silica with 80:20 hexane-Et2O 
as eluent gave methylated piperidine ester 33 (1.29 g, 100%) as a colourless oil, RF 
(80:20 hexane-Et2O) 0.3; IR (ATR) 2971, 2872, 1729 (C=O, CO2Me), 1691 (C=O, 
Boc), 1459, 1419, 1169, 1147, 1110, 872 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.79-
3.71 (m, 2H, NCH), 3.70 (s, 3H, OMe), 2.98 (br dd, J = 11.0, 11.0 Hz, 2H, NCH), 
2.09-2.02 (m, 2H, CH), 1.45 (s, 9H, CMe3), 1.35 (ddd, J = 14.5, 11.0, 4.5 Hz, 2H, 
CH), 1.20 (s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 177.0 (C=O, CO2Me), 154.9 
(C=O, Boc), 79.4 (CMe3), 51.9 (OMe), 41.7 (CMe), 41.2 (NCH2), 34.6 (CH2), 28.4 
(CMe3), 25.8 (Me); MS (ESI) m/z 280 [(M + Na)
+, 100]; HMRS (ESI) m/z calcd for 
C13H23NO4 (M + Na)
+ 280.1519, found 280.1510 (+3.1 ppm error). 
Lab Book Reference: mcw/3/5/1 
 
tert-Butyl 4-(hydroxymethyl)-4-methylpiperidine-1-carboxylate  39 
 
Using general procedure B, methyl ester 33 (200 mg, 0.78 mmol, 1.0 eq.) in THF (5 
mL) and lithium aluminium hydride (29.5 mg, 0.78 mmol, 1.0 eq.) in THF (30 mL) 
gave the crude product. Purification by flash chromatography on silica with 50:50 
hexane-Et2O as eluent gave amino alcohol 39 (268 mg, 100%) as a colourless oil, RF 
203 
 
(50:50 Et2O-hexane) 0.3; IR (ATR) 3435 (OH), 2972, 2817, 1666 (C=O), 1423, 1247, 
1158, 1047, 860, 735 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.67 (br d, J = 10.5 Hz, 2H, 
NCH), 3.37 (s, 2H, CH2OH), 3.12 (ddd, J = 13.5, 10.5, 3.0 Hz, 2H, NCH), 1.53-1.40 
(m, 11H, CH and CMe3), 1.32-1.23 (m, 2H, CH), 0.98 (s, 3H, Me); 
13C NMR (101.6 
MHz, CDCl3) δ 154.9 (C=O), 79.3 (CMe3), 71.7 (OCH2), 39.9 (NCH2), 33.8 (CMe), 
33.1 (CH2), 28.4 (CMe3), 20.5 (Me); MS (ESI) m/z 252 [(M + Na)
+, 100], 230 [(M + 
H)+, 10]; HMRS (ESI) m/z calcd for C12H23NO3 (M + Na)
+ 252.1570, found 252.1567 
(+1.1 ppm error). 
Lab Book Reference: mcw/3/73/1 
 
4-(Hydroxymethyl)-4-methylpiperidine hydrochloride salt A9.HCl 
 
Using general procedure D, hydrogen chloride (1.74 mL of a 2.0 M solution in Et2O, 
3.49 mmol, 8.0 eq.) and N-Boc amino alcohol 39 (100 mg, 0.44 mmol, 1.0 eq.) in Et2O 
(1 mL) gave amine hydrochloride salt A9·HCl (72 mg, 100%) as a white solid, mp 
120-122 °C; IR (ATR) 3193 (OH or NH), 2984, 2744, 2665, 1610, 1468, 1027, 701, 
611 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 8.50 (s, 2H, NH2), 3.17 (d, J = 5.0 Hz, 
2H, CH2OH), 3.06 (ddd, J = 12.5, 4.0, 4.0 Hz, 2H, NCH), 2.96 (ddd, J = 12.5, 10.0, 
4.0 Hz, 2H, NCH), 1.62 (ddd, J = 14.5, 10.0, 4.0 Hz, 2H, CH), 1.38 (br s, 1H, OH), 
1.34 (ddd, J = 14.5, 4.0, 4.0 Hz, 2H, CH); 13C NMR (101.6 MHz, DMSO-d6) δ 68.9 
(OCH2), 32.6 (NCH2), 29.8 (CH2), 28.1 (CMe), 21.2 (Me); MS (ESI) m/z 130 [M
+, 
100]; HMRS (ESI) m/z calcd for C7H16NO M
+ 130.1226, found 130.1228 (–1.5 ppm 
error). 
Lab Book Reference: mcw/5/12 
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tert-Butyl 2-((triisopropylsilyloxy)methyl)piperidine-1-carboxylate 55 
 
Triisopropylsilyl chloride (0.60 mL, 2.79 mmol, 1.2 eq.) was added dropwise to a 
stirred solution of N-Boc piperidine 17 (500 mg, 2.32 mmol, 1.0 eq.) and imidazole 
(395 mg, 5.81 mmol, 2.5 eq.) in DMF (6 mL) at rt under Ar. The resulting mixture 
was stirred at rt for 16 h. Saturated NH4Cl(aq) (10 mL) was added and the mixture was 
extracted with Et2O (3 x 5 mL). The combined organic extracts were dried (MgSO4) 
and evaporated under reduced pressure to give the crude product. Purification by flash 
chromatography on silica with 95:5 petrol-EtOAc as the eluent gave protected N-Boc 
piperidine 55 (794 mg, 92%) as a colourless oil, RF (9:1 petrol-EtOAc) 0.4; IR (ATR) 
2940, 2865, 1693 (C=O), 1407, 1364, 1170, 1138, 1112, 882, 680, 658 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 4.18 (br s, 1H, NCH), 3.99 (d, J = 12.5 Hz, 1H, NCH), 3.78 (dd, 
J = 9.5, 9.5 Hz, 1H, OCH), 3.65 (dd, J = 9.5, 5.5 Hz, 1H, OCH), 2.74 (dd, J = 12.5, 
12.5 Hz, 1H, NCH), 1.95-1.90 (m, 1H, CH), 1.68-1.35 (m, 5H, CH), 1.43 (s, 9H, 
CMe3) 1.11-1.01 (m, 21H, Si(CHMe2)3); 
13C NMR (101.6 MHz, CDCl3) δ 155.2 
(C=O), 79.2 (CMe3), 61.0 (OCH2), 51.7 (NCH), 40.0 (NCH2), 28.5 (CMe3), 25.3 
(CH2), 24.4 (CH2), 19.1 (CH2), 18.0 (SiCHMe2), 11.9 (SiCH); MS (ESI) m/z 394 [(M 
+ Na)+, 100], 372 [(M + H)+, 10]; HMRS (ESI) m/z calcd for C20H41NO3Si (M + Na)
+ 
394.2748, found 394.2748 (+0.3 ppm error). 
Lab Book Reference: mcw/2/8 
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tert-Butyl 2-methyl-6-((triisopropylsilyloxy)methyl)piperidine-1-carboxylate 
trans-56 
 
s-BuLi (0.72 mL of a 1.3 M solution in hexane, 0.94 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of N-Boc piperidine 55 (268 mg, 0.72 mmol, 1.0 eq.) 
and TMEDA (0.14 mL, 0.94 mmol, 1.3 eq.) in Et2O (8 mL) at ‒50 °C under Ar. The 
resulting yellow solution was stirred at ‒50 °C for 1 h. Then, Me2SO4 (0.14 mL, 1.44 
mmol, 2.0 eq.) was added. The resulting solution was stirred at ‒50 °C for 10 min 
before being allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated 
NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
98:2, 97:3 and 95:5 petrol-EtOAc as eluent gave disubstituted piperidine trans-56 (115 
mg, 41%) as a colourless oil, RF (97:3 petrol-EtOAc) 0.2; IR (ATR) 2942, 2866, 1691 
(C=O), 1386, 1363, 1177, 1161, 1087, 881, 680 cm–1; 1H NMR (400 MHz, CDCl3) δ 
4.03-3.93 (m, 1H, NCH), 3.86-3.79 (m, 1H, NCH), 3.74 (dd, J = 9.5, 4.0 Hz, 1H, 
OCH), 3.56  (dd, J = 9.5, 9.5 Hz, 1H, OCH), 2.05-1.96 (m, 1H, CH), 1.88-1.73 (m, 
2H, CH), 1.70-1.49 (m, 4H, CH), 1.44 (s, 9H, CMe3), 1.22 (d, J = 6.5 Hz, 3H, CHMe), 
1.09-1.01 (m, 20H, Si(CHMe2)3); 
13C NMR (101.6 MHz, CDCl3) δ 155.1 (C=O), 79.0 
(CMe3), 64.2 (OCH2), 52.8 (NCH), 46.7 (NCH), 28.5 (CMe3), 27.0 (CH2), 20.6 (CH2), 
20.5 (Me), 18.0 (SiCHMe2), 13.3 (CH2), 12.3 (SiCH); MS (ESI) m/z 408 [(M + Na)
+, 
100], 386 [(M + H)+, 5]; HMRS (ESI) m/z calcd for C21H43NO3Si (M + H)
+ 386.3085, 
found 386.3088 (–0.7 ppm error) and recovered starting material 55 (152 mg, 57%) as 
a colourless oil. 
Lab Book Reference: mcw/1/96 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 55 (372 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.195 mL, 1.3 mmol, 1.3 eq.) in Et2O (10 mL) at ‒78 °C under Ar. The resulting 
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yellow solution was stirred at ‒78 °C for 3 h. Then, Me2SO4 (0.19 mL, 2.0 mmol, 2.0 
eq.) was added. The resulting solution was stirred at ‒78 °C for 10 min before being 
allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated NH4Cl(aq) (10 mL) 
was added and the mixture was extracted with Et2O (3 x 10 mL). The combined 
organic extracts were dried (MgSO4) and evaporated under reduced pressure to give 
the crude product. Purification by flash chromatography on silica with 98:2, 97:3 and 
95:5 petrol-EtOAc as eluent gave disubstituted piperidine 56 (101 mg, 29%) as a 
colourless oil and recovered starting material 55 (191 mg, 52%) as a colourless oil. 
Lab Book Reference: mcw/1/95 
 
tert-Butyl 2-methylpiperidine-1-carboxylate 49 
 
2-Methyl piperidine 58 (5.0 mL, 42.5 mmol, 1.0 eq.) was added dropwise to a stirred 
solution of di-tert-butyl dicarbonate (10.2 g, 46.8 mmol, 1.1 eq.) in CH2Cl2 (200 mL) 
at 0 °C under Ar. The resulting solution was allowed to warm to rt and stirred at rt for 
16 h. H2O (20 mL) was added and the mixture was extracted with CH2Cl2 (3 x 15 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
90:10 petrol-Et2O as eluent gave N-Boc methyl piperidine 49 (7.6 g, 82%) as a 
colourless oil, RF (90:10 petrol-Et2O) 0.3;  
1H NMR (400 MHz, CDCl3) δ 4.41-4.30 
(m, 1H, NCH), 3.90 (dd, J = 13.5, 3.0 Hz, 1H, NCH), 2.79 (ddd, J = 13.5, 13.5, 2.5 
Hz, 1H, NCH), 1.68-1.45 (m, 5H CH), 1.44 (s, 9H, CMe3), 1.40-1.32 (m, 1H, CH), 
1.10 (d, J = 7.0 Hz, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 155.0 (C=O), 79.0 
(CMe3), 46.0 (NCH), 38.6 (NCH2), 30.1 (CH2), 28.5 (CMe3), 25.7 (CH2), 18.7 (CH2), 
15.7 (Me). Spectroscopic data consistent with those reported in the literature.131 
Lab Book Reference: mcw/2/2 
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(2S*,6R*)-tert-Butyl 2-methyl-6-(trimethylsilyl)piperidine-1-carboxylate trans-
59 
 
(Table 3.3, Entry 5) 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 49 (199 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.19 mL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) at ‒40 °C under Ar. The resulting yellow 
solution was stirred at ‒40 °C for 1.5 h. Then, trimethylsilyl chloride (0.16 mL, 1.3 
mmol, 1.3 eq.) was added. The resulting solution was stirred at ‒40 °C for 10 min 
before being allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated 
NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
95:5 and then 50:50 hexane-Et2O as eluent gave disubstituted piperidine trans-59 (230 
mg, 85%) as a colourless oil, RF (95:5 hexane-Et2O) 0.6; IR (ATR) 2974, 2929, 2861, 
1685 (C=O), 1418, 1296, 1244, 1170, 1107, 835, 636 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 4.33-4.20 (m, 1H, NCH), 2.45 (br d, J = 10.5 Hz, 1H, NCH), 1.70-1.51 (m, 
4H, CH), 1.43 (s, 9H, CMe3), 1.40-1.35 (m, 2H), 1.17 (d, J = 7.0 Hz, 3H, Me), 0.04 
(s, 9H, SiMe3); 
13C NMR (101.6 MHz, CDCl3) δ 155.3 (C=O), 78.6 (CMe3), 48.2 
(NCH), 42.2 (NCH), 30.0 (CH2), 28.5 (CMe3), 26.4 (CH2), 20.5 (CH2), 17.0 (Me), –
0.3 (SiMe3); MS (ESI) m/z 294 [(M + Na)
+, 100], 272 [(M + H)+, 5]; HMRS (ESI) m/z 
calcd for C14H29NO2Si (M + H)
+ 294.1860, found 294.1857 (+7.1 ppm error).  
Lab Book Reference: mcw/2/92/1 
(Table 3.3, entry 1) 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 49 (199 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.19 mL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) at ‒78 °C under Ar. The resulting yellow 
solution was stirred at ‒78 °C for 3 h. Then, trimethylsilyl chloride (0.16 mL, 1.3 
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mmol, 1.3 eq.) was added. The resulting solution was stirred at ‒78 °C for 10 min 
before being allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated 
NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
95:5 and 50:50 hexane-Et2O as eluent gave disubstituted piperidine trans-59 (171 mg, 
63%) as a colourless oil. 
(Table 3.3, Entry 2) 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 49 (199 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.19 mL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) at ‒78 °C under Ar. The resulting yellow 
solution was stirred at ‒78 °C for 1 h. Then, trimethylsilyl chloride (0.16 mL, 1.3 
mmol, 1.3 eq.) was added. The resulting solution was stirred at ‒78 °C for 10 min 
before being allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated 
NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
95:5 and 50:50 hexane-Et2O as eluent gave disubstituted piperidine trans-59 (78.6 mg, 
30%) as a colourless oil. 
(Table 3.3, Entry 3) 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 49 (199 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.19 mL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) at ‒50 °C under Ar. The resulting yellow 
solution was stirred at ‒40 °C for 1 h. Then, trimethylsilyl chloride (0.16 mL, 1.3 
mmol, 1.3 eq.) was added. The resulting solution was stirred at ‒50 °C for 10 min 
before being allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated 
NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
95:5 and 50:50 hexane-Et2O as eluent gave disubstituted piperidine trans-59 (190 mg, 
70%) as a colourless oil. 
(Table 3.3, Entry 4) 
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s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 49 (199 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.19 mL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) at ‒40 °C under Ar. The resulting yellow 
solution was stirred at ‒40 °C for 1 h. Then, trimethylsilyl chloride (0.16 mL, 1.3 
mmol, 1.3 eq.) was added. The resulting solution was stirred at ‒40 °C for 10 min 
before being allowed to warm to rt over 4 h and stirred at rt for 14 h. Saturated 
NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
95:5 and 50:50 hexane-Et2O as eluent gave disubstituted piperidine trans-59 (185 mg, 
68%) as a colourless oil. 
 
tert-Butyl 2-formyl-6-methylpiperidine-1-carboxylate 60 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.30 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc methyl piperidine 49 (199 mg, 1.00 mmol, 1.0 eq.) and 
TMEDA (0.19 mL, 1.30 mmol, 1.3 eq.) in Et2O (7 mL) at ‒40 °C under Ar. The 
resulting yellow solution was stirred at ‒40 °C for 2 h. The solution was then cooled 
to ‒78 °C before addition of dimethylformamide (0.16 mL, 2.00 mmol, 2.0 eq.). The 
resulting solution was stirred at ‒78 °C for 10 min before addition of H2O (10 mL). 
The resulting mixture was then allowed to warm to rt over 1 h. The mixture was 
extracted with Et2O (3 x 10 mL). The combined organic extracts were dried (MgSO4) 
and evaporated under reduced pressure to give the crude product which contained an 
80:20 mixture (by 1H NMR spectroscopy) of aldehydes trans-60 and cis-60 (214 mg) 
as a colourless oil, 1H NMR (400 MHz, CDCl3) δ 9.61 (d, J = 1.0 Hz, 0.2H, CHO), 
9.29 (d, J = 4.5 Hz, 0.8H, CHO), 4.56 (br d, J = 4.5 Hz, 0.2H, NCH), 4.27 (br s, 0.8H, 
NCH), 3.63 (ddd, J = 11.5, 11.5, 4.5 Hz, 0.8H, NCH), 3.54 (ddd, J = 12.0, 2.5, 2.5, 
0.2H, NCH), 1.76-1.52 (m, 6H, CH), 1.46 (s, 9H, CMe3), 1.12 (d, J = 7.0 Hz, 2.4H, 
Me), 1.07 (d, J = 7.0 Hz, 0.6H, Me). 
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Lab Book Reference: mcw/2/97 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.30 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc methyl piperidine 49 (199 mg, 1.00 mmol, 1.0 eq.) and 
TMEDA (0.19 mL, 1.30 mmol, 1.3 eq.) in Et2O (7 mL) at ‒40 °C under Ar. The 
resulting yellow solution was stirred at ‒40 °C for 2 h. Then, dimethylformamide (0.16 
mL, 2.00 mmol, 2.0 eq.) was added. The resulting solution was stirred at ‒40 °C for 
30 min before allowing to warm to rt for 2 h and stirred at rt for 16 h. H2O (10 mL) 
was added and the mixture extracted with Et2O (3 x 10 mL). The combined organic 
extracts were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product which contained a 80:20 mixture (by 1H NMR spectroscopy) of aldehydes cis-
60 and trans-60 (143 mg) as a colourless oil,1H NMR (400 MHz, CDCl3) δ 9.61 (d, J 
= 1.0 Hz, 0.8H, CHO), 9.29 (d, J = 4.0 Hz, 0.2H, CHO), 4.56 (d, J = 5.0 Hz, 0.8H, 
NCH), 4.41-4.32 (m, 0.8H, NCH), 4.27 (br s, 0.2H, NCH), 3.63 (ddd, J = 12.0, 4.0, 
4.0, 0.2H, NCH), 1.75-1.55 (m, 6H, CH), 1.48 (s, 9H, CMe3), 1.12 (d, J = 7.0 Hz, 
0.6H, Me), 1.07 (d, J = 7.0 Hz, 2.4H, Me). 
Lab Book Reference: mcw/2/98 
 
tert-Butyl 2-(hydroxymethyl)-6-methylpiperidine-1-carboxylate 61 
 
Sodium borohydride (107 mg, 2.84 mmol, 3.0 eq.) was added to a stirred solution of 
an 80:20 mixture of aldehydes trans-60 and cis-60 (214 mg, 0.95 mmol, 1.0 eq.) in 
MeOH (3 mL) at 0 °C under Ar. The resulting mixture was allowed to warm to rt and 
stirred at rt for 18 h. The reaction mixture was poured carefully into H2O (10 mL). The 
mixture was extracted with EtOAc (3 x 10 mL). The combined organic extracts were 
washed with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure to 
give the crude product. Purification by flash chromatography on silica with 80:20 and 
then 50:50 hexane-Et2O as eluent gave an 80:20 mixture (by 
1H NMR spectroscopy) 
of diastereomeric disubstituted piperidines trans-61 and cis-61 (186 mg, 81%) as a 
colourless oil, RF (50:50 hexane-Et2O) 0.1; IR (ATR) 3460 (OH), 3412 (OH), 2969, 
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2943, 2872, 1657 (C=O), 1397, 1365, 1167, 1056, 876 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 4.31-4.24 (m, 0.8H, NCH), 4.24-4.17 (m, 0.2H, NCH), 3.80-3.73 (m, 0.8H, 
CHOH), 3.72-3.69 (m, 0.8H, CHOH), 3.68-3.61 (m, 1.4H, CHOH and NCH), 2.95 (br 
s, 1H, OH), 1.80-1.48 (m, 6H, CH), 1.47-1.44 (m, 9H, CMe3), 1.19 (d, J = 7.0 Hz, 
2.4H, Me), 1.15 (d, J = 7.0 Hz, 0.6H, Me); 13C NMR (101.6 MHz, CDCl3) δ 156.6 and 
154.3 (C=O), 80.1 and 79.8 (CMe3), 66.5 (OCH2), 54.3 and 51.6 (NCH), 48.5 and 45.9 
(NCH), 30.1 (CH2), 28.6 and, 28.1 (CMe3), 25.6 and 25.1 (CH2), 22.6 and 20.6 (Me), 
18.5 and 16.1 (CH2), 14.4 (CH2); MS (ESI) m/z 252 [(M + Na)
+, 100]. 230 [(M + H)+, 
5]; HMRS (ESI) m/z calcd for C12H23NO3 (M + Na)
+ 252.1570 found 252.1559 (+4.1 
ppm error). 
Lab Book Reference: mcw/2/99/3 
 
(2S,6S)-1-(tert-Butoxycarbonyl)-6-methylpiperidine-2-carboxylic acid trans-62 
 
s-BuLi (1.0 mL of a 1.3 M solution in hexane, 1.3 mmol, 1.3 eq.) was added dropwise 
to a stirred solution of N-Boc piperidine 49 (199 mg, 1.0 mmol, 1.0 eq.) and TMEDA 
(0.19 mL, 1.3 mmol, 1.3 eq.) in Et2O (7 mL) at ‒40 °C under Ar. The resulting yellow 
solution was stirred at ‒40 °C for 1.5 h. Then, CO2 (excess) was bubbled through the 
reaction mixture at ‒40 °C for 10 min. H2O (10 mL) was added. 1 M HCl(aq) (15 mL) 
was added and the mixture extracted with Et2O (3 x 10 mL). The combined organic 
extracts were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash chromatography on silica with 90:10 CH2Cl2-Et2O and 
0.5% acetic acid and then 70:30 CH2Cl2-Et2O and 0.5% acetic acid as eluent gave 
piperidine carboxylic acid trans-62 (199 mg, 82%) as a white solid, mp 82-84 °C; RF 
(90:10 CH2Cl2-Et2O) 0.2; IR (ATR) 2977, 2944, 1698 (C=O), 1445, 1380, 1365, 1227, 
868, 779, 512 cm–1; 1H NMR (400 MHz, CDCl3) δ 4.24-4.18 (m, 1H, NCH), 4.18 (dd, 
J = 7.0, 5.0 Hz, 1H, NCH), 2.09-1.80 (m, 3H, CH), 1.69-1.49 (m, 3H, CH), 1.45 (s, 
9H, CMe3), 1.18 (d, J = 7.0 Hz, 3H, Me); 
13C NMR (101.6 MHz, CDCl3) δ 178.3 
(C=O, CO2Me), 156.4 (C=O, Boc), 80.9 (CMe3), 53.8 (NCH), 47.6 (NCH), 28.3 
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(CMe3), 27.7 (CH2), 25.6 (CH2), 18.8 (Me), 15.0 (CH2); MS (ESI) m/z 266 [(M + Na)
+, 
100], 244 [(M + H)+, 5]; HMRS (ESI) m/z calcd for C12H21NO4 (M + Na)
+ 266.1363, 
found 266.1355 (+2.9 ppm error). 
Lab Book Reference: mcw/2/95/2 and mcw/3/57/2 
 
 
 (2R*,6S*)-1-tert-Butyl 2-methyl 6-methylpiperidine-1,2-dicarboxylate trans-63 
 
Potassium carbonate (2.56 g, 18.5 mmol, 3.0 eq) was added to a stirred solution of 
piperidine carboxylic acid 62 (1.50 g, 61.7 mmol, 1.0 eq.) in dimethylformamide (20 
mL) at rt under Ar. The resulting suspension was stirred at rt for 30 min before the 
addition of methyl iodide (1.15 mL, 18.5 mmol, 3.0 eq.). The mixture was then stirred 
at rt for 18 h. The solvent was evaporated under reduced pressure and H2O (10 mL) 
and EtOAc (10 mL) were added. The mixture was extracted with EtOAc (3 x 20 mL). 
The combined organic extracts were washed with 10% Na2S2O3(aq) (15 mL) and the 
mixture extracted with EtOAc (20 mL). The combined organic extracts were dried 
(MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash chromatography on silica with 80:20 hexane-Et2O as eluent gave 
piperidine methyl ester trans-63 (1.55 g, 97%) as a yellow oil, RF (80:20 hexane-Et2O) 
0.2; IR (ATR) 2972, 2950, 1746 (C=O, CO2Me), 1692 (C=O, Boc), 1390, 1364, 1163, 
1112, 735 cm–1; 1H NMR (400 MHz, CDCl3) δ 4.26-4.17 (m, 1H, NCH), 4.12 (dd, J 
= 7.0, 5.0 Hz, 1H, NCH), 3.72 (s, 3H, OMe), 2.04-1.92 (m, 1H, CH), 1.91-1.78 (m, 
2H, CH), 1.67-1.48 (m, 3H, CH), 1.43 (s, 9H, CMe3), 1.16 (d, J = 7.0 Hz, 3H, Me); 
13C NMR (101.6 MHz, CDCl3) δ 173.8 (C=O, CO2Me), 156.0 (C=O, Boc), 80.1 
(CMe3), 54.1 (NCH), 52.0 (OMe), 47.5 (NCH), 28.3 (CMe3), 28.0 (CH2), 26.2 (CH2), 
18.8 (Me), 15.5 (CH2); MS (ESI) m/z 280 [(M + Na)
+, 100], 258 [(M + H)+, 15]; 
HMRS (ESI) m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 280.1507 (+4.2 
ppm error). 
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Lab Book Reference: mcw/3/59/1 
(Trimethylsilyl)diazomethane (0.31 mL of a 2.0 M solution in hexane, 0.62 mmol, 3.0 
mmol) was added to a stirred solution of piperidine carboxylic acid 62 (50 mg, 0.21 
mmol, 1.0 eq.) in MeOH (1 mL) and toluene (2.5 mL) at 0 °C, under Ar. The resulting 
solution was stirred at 0 °C for 20 min. Then, acetic acid (0.02 mL, 0.412 mmol, 2.0 
eq.) was added. The solvent was evaporated under reduced pressure to give the crude 
product. Purification by flash chromatography on silica with 90:10 hexane-Et2O as 
eluent gave piperidine methyl ester trans-63 (49 mg, 93%) as a colourless oil. 
Lab Book Reference: mcw/2/77/2 
 
2- trans-(Methoxycarbonyl)-6-methylpiperidine hydrochloride salt 43.HCl 
 
Using general procedure C, acetyl chloride (0.66 mL, 9.32 mmol, 4.0 eq), N-Boc 
methyl ester 63 (600 mg, 2.33 mmol, 1.0 eq.) and EtOH (0.54 mL, 9.32 mmol, 4.0 eq.) 
in EtOAc (15 mL), heated at reflux, gave amine hydrochloride salt 43.HCl (451 mg, 
100%) as a white solid, mp 132-133 °C; IR (ATR) 3336 (NH), 3038, 1680 (C=O), 
1604, 1287, 1173, 1003, 848 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 2H, 
NH2), 4.38 (dd, J = 5.0, 5.0 Hz, 1H, NCHCO2Me), 3.77 (s, 3H, OMe), 3.48-3.40 (m, 
1H, NCHMe), 2.02-1.87 (m, 2H, CH), 1.80-1.64 (m, 2H, CH), 1.51-1.33 (m, 2H, CH), 
1.27 (d, J = 6.5 Hz, 3H, Me); 13C NMR (101.6 MHz, DMSO-d6) δ 169.1 (C=O), 53.0 
(NCH), 52.7 (NCH), 48.9 (OMe), 28.5 (CH2), 24.4 (CH2), 18.2 (CH2), 17.2 (Me); MS 
(ESI) m/z 158 [M+, 100]; HMRS (ESI) m/z calcd for C8H16NO2 M
+ 158.1176, found 
158.1181 (–3.4 ppm error). 
Lab book reference: mcw/4/64 
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Methyl trans-1-acetyl-6-methylpiperidine-2-carboxylate 64 
 
Using general procedure F, acetyl chloride (0.33 mL, 4.65 mmol, 3.0 eq.), amine 
hydrochloride salt 43 (300 mg, 1.54 mmol, 1.0 eq.) and triethylamine (0.64 mL, 4.65 
mmol, 3.0 eq.) in CH2Cl2 (5 mL) gave the crude product. Purification by flash 
chromatography on silica with 70:30 EtOAc-hexane and then EtOAc as eluent gave 
acetamide 64 (307 mg, 96%) as a colourless oil, RF (EtOAc) 0.3; IR (ATR) 2954, 
2872, 1737 (C=O, CO2Me), 1642 (C=O, amide), 1404, 1199, 1172, 1010 cm
–1; 1H 
NMR (400 MHz, CDCl3) (85:15 mixture of rotamers) δ 4.40 (br s, 0.15H, NCH), 4.33 
(br s, 0.15H, NCH), 4.21 (dd, J = 7.5, 5.0 Hz, 0.85H, NCH) 4.17-4.08 (m, 0.85H, 
NCH), 3.72 (s, 3H, OMe), 2.17 (s, 0.45H, COMe), 2.15 (s, 2.55, COMe), 2.06-1.82 
(m, 3H, CH), 1.76-1.53 (m, 3H, CH), 1.25 (d, J = 6.5 Hz, 3H, Me); 13C NMR (101.6 
MHz, CDCl3) (rotamers) δ 173.0 (C=O), 171.8 (C=O), 52.9 (NCH), 52.14 (NCH), 
52.08 (NCH), 49.0 (NCH), 30.3 (OMe), 27.7 (CH2), 25.6 (CH2), 21.3 (COMe), 19.6 
(Me), 15.1 (CH2); MS (ESI) m/z 222 [(M + Na)
+, 100], 200 [(M + H)+, 5]; HMRS 
(ESI) m/z calcd for C10H17NO3 (M + Na)
+ 222.1101, found 222.1103 (–0.8 ppm error). 
Lab book reference: mcw/4/52 
 
1-(trans-2-(Hydroxymethyl)-6-methylpiperidin-1-yl)ethanone A16 
 
Using general procedure I, lithium borohydride (2.0 mL of a 4.0 M solution in THF, 
8.0 mmol, 8.0 eq.) and methyl ester 64 (200 mg, 1.00 mmol, 1.0 eq.) in THF (10 mL) 
for 3 h gave the crude product. Purification by flash chromatography on silica with 
50:50 EtOAc-hexane and then EtOAc as eluent gave recovered methyl ester 64 (130 
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mg, 65%) as a colourless oil and alcohol A16 (37 mg, 22%, 66%, based on recovery 
of piperidine ester 64) as a colourless oil, RF (EtOAc) 0.2; IR (ATR) 3285 (OH), 2932, 
2871, 1614 (C=O), 1419, 1052, 697, 600 cm–1;  1H NMR (400 MHz, CDCl3) (90:10 
mixture of rotamers) δ 4.77 (br s, 0.1H, NCH), 4.62 (br s, 0.9H, NCH), 4.04 (br s, 
0.9H, NCH), 3.77 (br s, 2H, CH2OH), 3.68 (br d, J = 7.5 Hz, 0.1H, NCH), 2.17 (s, 
0.3H, COMe), 2.15 (s, 2.7H, COMe), 1.84-1.57 (m, 6H, CH), 1.30 (d, J = 7.0 Hz, 3H, 
Me); 13C NMR (101.6 MHz, CDCl3) δ 171.6 (C=O), 65.8 (CH2OH), 55.1 (NCH), 50.9 
(NCH), 28.6 (CH2), 25.6 (CH2), 23.1 (COMe), 18.6 (Me), 16.4 (CH2); MS (ESI) m/z 
194 [(M + Na)+, 100], 172 [(M + H)+, 25]; HMRS (ESI) m/z calcd for C9H17NO2 (M 
+ Na)+ 194.1151, found 194.1147 (+2.4 ppm error). 
Lab book reference: mcw/5/9 
 
N-Benzylpent-4-en-1-amine 82 
 
Sodium iodide (158 mg, 1.05 mmol, 0.05 eq.) was added to a stirred solution of 
benzylamine (11.5 mL, 106 mmol, 5.0 eq.) and 5-bromopent-1-ene 81 (2.5 mL, 21.1 
mmol, 1.0 eq.) in EtOH (50 mL) at rt, under Ar. The resulting suspension was then 
stirred and heated at 75 °C for 16 h. After being allowed to cool to rt, the solvent was 
evaporated under reduced pressure. Then, 1 M KOH(aq) (50 mL) was added and the 
mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash chromatography on silica with 80:20 EtOAc-hexane and then 
EtOAc as eluent gave amine 82 (3.58 g, 97%) as a yellow oil, RF (EtOAc) 0.2; 
1H 
NMR (400 MHz, CDCl3) δ 7.37-7.19 (m, 5H, Ph), 5.81 (ddt, J = 17.0, 10.0, 6.5 Hz, 
1H, =CH), 5.00 (ddt, J = 17.0, 2.0, 2.0 Hz, 1H, =CH), 4.95 (ddt, J = 10.0, 2.0, 1.0 Hz, 
1H, =CH), 3.79 (s, 2H, NCH2Ph), 2.65 (t, J = 7.0 Hz, 2H, NCH2CH2), 2.17-2.04 (m, 
2H, CH2), 1.62 (tt, J = 7.0, 7.0 Hz, 2H, CH2); 
13C NMR (101.6 MHz, CDCl3) δ, 140.5 
(ipso-Ph), 138.5 (=CH), 128.4 (Ph), 128.1 (Ph), 126.9 (Ph), 114.6 (=CH2), 54.0 
(NCH2), 48.9 (NCH2), 31.5 (CH2), 29.2 (CH2). Spectroscopic data consistent with 
those reported in the literature.97 
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Lab Book Reference: mcw/4/62  
 
Methyl 2-(benzyl(pent-4-en-1-yl)amino)acetate 78 
 
Methyl α-bromo acetate (1.94 mL, 20.5 mmol, 1.2 eq.), was added to a stirred solution 
of amine 82 (3.00 g, 17.1 mmol, 1.0 eq.) and triethylamine (2.86 mL, 20.5 mmol, 1.2 
eq.) in DMSO (420 mL) at rt under Ar. The resulting solution was stirred at rt for 5 h. 
A solution of 2:1 saturated NH4Cl(aq)-NH4OH(aq) (100 mL) was added and the mixture 
was extracted with Et2O (3 x 100 mL). The combined organic extracts were washed 
with brine (25 mL), dried (MgSO4) and evaporated under reduced pressure to give the 
crude product. Purification by flash chromatography on silica with 70:30 hexane-Et2O 
as eluent gave ester-alkene amine 78 (3.70 g, 87%) as a colourless oil, RF (70:30 
hexane-Et2O) 0.3; 
1H NMR (400 MHz, CDCl3) δ 7.37-7.20 (m, 5H, Ph), 5.80 (ddt, J 
= 16.5, 10.0, 7.0 Hz, 1H, =CH), 4.99 (ddt, J = 16.0, 1.5, 1.5 Hz, 1H, =CH), 4.96-4.90 
(m, 1H, =CH), 3.77 (s, 2H, CH2CO2Me), 3.68 (s, 3H, OMe), 3.31 (s, 2H, NCH2Ph), 
2.64 (t, J = 7.0 Hz, 2H, NCH2), 2.07 (br dt, J = 7.0, 7.0 Hz, 2H, CH2), 1.59 (tt, J = 7.0, 
7.0 Hz, 2H, CH2); 
13C NMR (101.6 MHz, CDCl3) δ 172.0 (C=O), 139.0 (ipso-Ph), 
138.5 (=CH), 128.9 (Ph), 128.2 (Ph), 127.0 (Ph), 114.5 (=CH2), 58.2 (NCH2), 54.0 
(NCH2), 53.3 (NCH2), 51.2 (OMe), 31.3 (CH2), 26.8 (CH2). Spectroscopic data 
consistent with those reported in the literature.97 
Lab book reference: mcw/4/15/2 
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Methyl cis-1-benzyl-3-methylpiperidine-2-carboxylate 80 
 
(Table 3.4, Entry 1) 
Lithium bis(trimethylsilyl)amide (1.62 mL of a 1.0 M solution in THF, 1.62 mmol, 
2.0 eq.) was added to a stirred solution of ester-alkene 78 (200 mg, 0.80 mmol, 1.0 
eq.) in Et2O (13 mL) at –20 °C under Ar. The resulting solution was stirred at –20 °C 
for 10 min and then allowed to warm to rt for 20 min. The mixture was then cooled to 
–40 °C. The lithium enolate solution was added dropwise via cannula transfer to a 
stirred solution of zinc bromide (365 mg, 1.62 mmol, 2.0 eq.) in dry Et2O (1.62 mL) 
at –40 °C under Ar. The resulting mixture was allowed to warm to rt and stirred at rt 
for 5 h. The mixture was then cooled to 0 °C and a 2:1 solution of saturated NH4Cl(aq)-
NH4OH(aq) (5 mL) was added. The resulting mixture was then allowed to warm to rt 
and stirred at rt for 18 h. The mixture was extracted with Et2O (3 x 10 mL). The 
combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
90:10 hexane-Et2O as eluent gave piperidine cis-80 (53.4 mg, 15%) as a colourless 
oil.  
Lab book reference: mcw/3/90 
(Table 3.4, Entry 2) 
Lithium bis(trimethylsilyl)amide (8.08 mL of a 1.0 M solution in THF, 8.08 mmol, 
2.0 eq.) was added to a stirred solution of ester-alkene 78 (1.00 g, 4.04 mmol, 1.0 eq.) 
in Et2O (20 mL) at –20 °C under Ar. The resulting solution was stirred at –20 °C for 
10 min and then allowed to warm to rt for 20 min. The mixture was then cooled to –
40 °C. The lithium enolate solution was added dropwise to a stirred solution of zinc 
bromide (1.82 g, 8.08 mmol, 2.0 eq.) in dry Et2O (40 mL) at –40 °C under Ar. The 
resulting mixture was then sonicated for 5 minutes to encourage dissolution of zinc 
bromide and then was allowed to warm to rt and stirred at rt for 5 h. The mixture was 
then cooled to 0 °C and a 2:1 solution of saturated NH4Cl(aq)-NH4OH(aq) (5 mL) was 
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added. The resulting mixture was then allowed to warm to rt and stirred at rt for 18 h. 
The mixture was extracted with Et2O (3 x 10 mL). The combined organic extracts 
were dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash chromatography on silica with 90:10 hexane-Et2O as eluent gave 
piperidine cis-80 (394 mg, 40%) as a colourless oil. 
Lab book reference: mcw/4/8 
(Table 3.4, Entry 3) 
Lithium bis(trimethylsilyl)amide (4.04 mL of a 1.0 M solution in THF, 4.04 mmol, 
2.0 eq.) was added to a stirred solution of ester-alkene 78 (500 mg, 2.02 mmol, 1.0 
eq.) in Et2O (10 mL) at –20 °C under Ar. The resulting solution was stirred at –20 °C 
for 10 min and then allowed to warm to rt for 20 min. The mixture was then cooled to 
–40 °C. The lithium enolate solution was added dropwise to a stirred solution of zinc 
bromide (910 mg, 4.04 mmol, 2.0 eq.) in dry Et2O (20 mL) at –40 °C under Ar. The 
resulting mixture was then was allowed to warm to rt. The mixture was sonicated for 
10 minutes every hour to aid dissolution of zinc bromide for 5 h,. The mixture was 
then cooled to 0 °C and a 2:1 solution of saturated NH4Cl(aq)-NH4OH(aq) (5 mL) was 
added. The resulting mixture was then allowed to warm to rt and stirred at rt for 18 h. 
The mixture was extracted with Et2O (3 x 10 mL). The combined organic extracts 
were dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash chromatography on silica with 90:10 hexane-Et2O as eluent gave 
piperidine cis-80 (194 mg, 39%) as a colourless oil. 
Lab book reference: mcw/4/11 
(Table 3.4, Entry 4) 
Using general procedure J, lithium bis(trimethylsilyl)amide (1.0 M solution in THF, 
40.4 mmol, 2.0 eq.), ester-alkene 78 (5.00 g, 20.2 mmol, 1.0 eq.) in Et2O (300 mL), 
zinc bromide (9.10 g, 40.4 mmol, 2.0 eq.) in Et2O (40 mL) and a 2:1 solution of 
saturated NH4Cl(aq)-NH4OH(aq) (40 mL) gave the crude product. Purification by flash 
chromatography on silica with 90:10 hexane-Et2O as eluent gave piperidine cis-80 
(1.62 g, 32%) as a colourless oil, RF (90:10 hexane-Et2O) 0.2; 
1H NMR (400 MHz, 
CDCl3) δ 7.28-7.17 (m, 5H, Ph), 3.65 (s, 3H, OMe), 3.57 (d, J = 13.5 Hz, 1H, NCHPh), 
3.52 (d, J = 13.5 Hz, 1H, NCHPh), 3.41 (d, J = 5.0 Hz, 1H, NCH), 2.95-2.88 (m, 1H, 
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NCH), 2.46 (ddd, J = 11.5, 4.0, 4.0 Hz, 1H, NCH), 1.99-1.89 (m, 1H, CH), 1.66-1.60 
(m, 1H, CH), 1.55-1.41 (m, 3H, CH), 0.86 (d, J = 7.0 Hz, 3H, Me); 13C NMR (101.6 
MHz, CDCl3) δ 172.9 (C=O), 139.0 (ipso-Ph), 128.7 (Ph), 128.1 (Ph), 126.9 (Ph), 66.1 
(NCH), 60.1 (NCH2), 50.4 (OMe), 46.8 (CH2), 33.0 (CHMe), 27.7 (CH2), 25.0 (CH2), 
18.1 (Me). Spectroscopic data consistent with those reported in the literature.97 
Lab book reference: mcw/4/80 
 
Methyl 1-benzyl-3-methylpiperidine-2-carboxylate, trans-80 and cis-80 
 
n-BuLi (0.736 mL of a 2.2 M solution in hexane, 1.62 mmol, 4.0 eq.) was added 
dropwise to a stirred solution of diisopropylamine (0.36 mL, 1.62 mmol, 4.0 eq.) in 
THF (0.97 mL) at 0 °C under Ar. The resulting solution was stirred at 0 °C for 30 min. 
The LDA solution was added dropwise to a stirred solution of cis-piperidine cis-80 
(100 mg, 0.40 mmol, 1.0 eq.) in Et2O (20 mL) at –20 °C under Ar. The resulting 
solution was allowed to warm to rt over 20 min and then stirred at rt for 20 min. The 
mixture was cooled to 0 °C and a 2:1 solution of saturated NH4Cl(aq)-NH4OH(aq) (10 
mL) was added. The resulting mixture was then allowed to warm to rt over 30 min and 
stirred at rt for 18 h. The mixture was extracted with Et2O (3 x 20 mL). The combined 
organic extracts were washed with brine (10 mL), dried (MgSO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash 
chromatography on silica with 90:10 and then 50:50 hexane-Et2O as eluent gave 
recovered piperidine cis-80 (39 mg, 40%) and trans-piperidine trans-80 (57 mg, 57%) 
as a colourless oil, RF (90:10 hexane-Et2O) 0.1; 
1H NMR (400 MHz, CDCl3) δ 7.35-
7.21 (m, 5H, Ph), 3.76 (s, 3H, OMe), 3.71 (d, J = 13.0 Hz, 1H, NCHPh), 3.25 (d, J = 
13.0 Hz, 1H, NCHPh), 2.87 (ddd, J = 11.5, 4.0, 4.0 Hz, 1H, NCH), 2.64 (d, J = 9.0 
Hz, 1H, NCHCO2Me), 1.95-1.86 (m, 2H, CH), 1.78-1.68 (m, 1H, CH), 1.62-1.53 (m, 
2H, CH), 1.06-0.93 (m, 1H, CH), 0.90 (d, J = 6.5 Hz, 3H, Me); 13C NMR (101.6 MHz, 
CDCl3) δ 174.2 (C=O), 137.5 (ipso-Ph), 129.4 (Ph), 128.1 (Ph), 127.1 (Ph), 73.6 
(NCH), 61.0 (NCH2), 51.7 (OMe), 51.2 (NCH2), 34.2 (CHMe), 31.9 (CH2), 24.4 
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(CH2), 18.7 (Me). Spectroscopic data of trans-80 consistent with those reported in the 
literature.97 
Lab book reference: mcw/4/17/2 
 
Methyl trans-3-methylpiperidine-2-carboxylate trans-75 
 
10% Pd(OH)2/C (23 mg, 0.032 mmol, 0.1 eq.) was added to a stirred solution of 
piperidine trans-80 (80 mg, 0.32 mmol, 1.0 eq.) and ammonium formate (408 mg, 
6.47 mmol, 20 eq.) in MeOH (30 mL) at rt, under Ar. The resulting suspension was 
stirred and heated at reflux for 18 h. After being allowed to cool to rt, the solids were 
removed by filtration through Celite and washed with MeOH (50 mL). The filtrate 
was evaporated under reduced pressure to give amine trans-75 (51 mg, 100%) as a 
pale yellow oil, IR (ATR) 2956, 2697, 1741 (C=O) 1578, 1436, 1273, 1210, 765 cm–
1; 1H NMR (400 MHz, CDCl3) δ 3.77 (s, 3H, OMe), 3.42 (br d, J = 12.5 Hz, 1H, NCH), 
3.30 (d, J = 10.5 Hz, 1H, NCHCO2Me), 2.81 (ddd, J = 12.5, 12.5, 5.0 Hz, 1H, NCH), 
1.98-1.77 (m, 4H, CH), 1.35-1.20 (m, 1H, CH), 1.00 (d, J = 6.5 Hz, 3H, Me); 13C 
NMR (101.6 MHz, CDCl3) δ 170.4 (C=O), 63.5 (NCH), 52.5 (OMe), 43.8 (NCH2), 
32.9 (CHMe), 31.8 (CH2), 22.9 (CH2), 18.4 (Me); MS (ESI) m/z 158 [(M + H)
+, 100]; 
HMRS (ESI) m/z calcd for C8H15NO2 (M + H)
+ 158.1176, found 158.1173 (+1.7 ppm 
error). 
Lab book reference: mcw/5/10/c 
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N-Benzylbut-3-en-1-amine 90 
 
Sodium iodide (13.5 g, 90.0 mmol, 1.5 eq.) was added to a stirred suspension of 
benzylamine (6.55 mL, 60.0 mmol, 1.0 eq.), potassium carbonate (12.4 g, 90.0 mmol, 
1.5 eq.) and 4-bromobut-1-ene 89 (7.31 mL, 72.0 mmol, 1.2 eq.) in 
dimethylformamide (190 mL) at rt under Ar. The resulting suspension was stirred and 
heated at reflux for 20 h. After being allowed to cool to rt, H2O (50 mL) was added 
and the mixture was extracted with Et2O (3 x 50 mL). The combined organic extracts 
were washed with brine (50 mL), dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash chromatography on silica with 
80:20 EtOAc-hexane as eluent gave amine 90 (3.70 g, 38%) as a yellow oil, RF (80:20 
EtOAc-hexane) 0.2; 1H NMR (400 MHz, CDCl3) δ 7.31-7.15 (m, 5H, Ph), 5.73 (ddt, 
J = 17.0, 10.0, 7.0 Hz, 1H, =CH), 5.03 (ddt, J = 17.0, 1.5, 1.5, 1H, =CH), 4.98 (br d, 
J = 10.0 Hz, 1H, =CH), 3.74 (s, 2H, NCH2Ph), 2.65 (t, J = 7.0 Hz, 2H, NCH2), 2.23 
(br dt, J = 7.0, 7.0 Hz, 2H, CH2); 
13C NMR (101.6 MHz, CDCl3) δ 140.3 (ipso-Ph), 
136.4 (=CH), 128.4 (Ph), 128.1 (Ph), 126.9 (Ph), 116.4 (=CH2), 53.8 (NCH2), 48.2 
(NCH2), 34.2 (CH2). Spectroscopic data consistent with those reported in the 
literature.132 
Lab book reference: mcw/4/23 
 
Methyl 3-(benzyl(but-3-en-1-yl)amino)propanoate 85 
 
1,8-Diazabicyclo[5.4.0]undec-7-ene (1.85 mL, 12.4 mmol, 0.5 eq.) was added to a 
stirred solution of methylacrylate (3.35 mL, 37.2 mmol, 1.5 eq.) and amine 90 (4.00 
g, 24.8 mmol, 1.0 eq.) in MeCN (15 mL) at rt under Ar. The resulting mixture was 
stirred at rt for 6 h. The solvent was then evaporated under reduced pressure to give 
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the crude product. Purification by flash chromatography on silica with 50:50 EtOAc-
hexane as eluent gave ester-alkene 85 (4.55 g, 74%) as a colourless oil, RF (50:50 
EtOAc-hexane) 0.5; IR (ATR) 3064, 2949, 2805, 1736 (C=O), 1435, 1193, 1174, 910, 
734 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.30-7.16 (m, 5H, Ph), 5.73 (ddt, J = 17.0, 
10.5, 7.0 Hz, 1H, =CH), 4.98 (ddt, J = 17.0, 1.5, 1.5, 1H, =CH), 4.93 (br dd, J = 10.5, 
1.5 Hz, 1H, =CH), 3.61 (s, 3H, OMe), 3.56 (s, 2H, NCH2), 2.78 (t, J = 7.0 Hz, 2H, 
NCH2), 2.48 (t, J = 7.0 Hz, 2H, NCH2), 2.44 (t, J = 7.0 Hz, 2H, CH2CO2Me), 2.20 (br 
dt, J = 7.0, 7.0 Hz, 2H, CH2); 
13C NMR (101.6 MHz, CDCl3) δ 173.1 (C=O), 139.4 
(ipso-Ph), 136.8 (=CH), 128.7 (Ph), 128.1 (Ph), 126.9 (Ph), 115.5 (=CH2), 58.3 
(NCH2), 53.1 (NCH2), 51.5 (OMe), 49.2 (NCH2), 32.5 (CH2), 31.5 (CH2); MS (ESI) 
m/z 248 [(M + H)+, 100]; HMRS (ESI) m/z calcd for C15H21NO2 (M + H)
+ 248.1645, 
found 248.1624 (+1.4 ppm error). 
Lab book reference: mcw/4/5 
 
N-Benzylprop-2-en-1-amine 92 
 
Benzyl bromide (6.0 mL, 50.5 mmol, 1.0 eq.) was added dropwise over 30 min to a 
stirred suspension of potassium (8.37 g, 60.5 mmol, 1.2 eq.) in allylamine 91 (30.2 
mL, 404 mmol, 8.0 eq.) at rt under Ar. The resulting mixture was stirred at rt for 3 h. 
The solids were removed by filtration through Celite and the filtrate was evaporated 
under reduced pressure to give the crude product. Purification by Kügelrohr short path 
distillation gave 92 (3.66 g, 50%) as a colourless oil, bp 69-71 °C / 991 mbar; 1H NMR 
(400 MHz, CDCl3) δ 7.36-7.22 (m, 5H, Ph), 5.94 (ddt, J = 16.5, 10.0, 6.0 Hz, 1H, 
=CH), 5.21 (ddt, J = 16.5, 1.5, 1.5 Hz, 1H, =CH), 5.12 (br dd, J = 10.0, 1.5 Hz, 1H, 
=CH), 3.80 (s, 2H, NCH2Ph), 3.29 (ddd, J = 6.0, 1.5, 1.5 Hz, 2H, NCH2), 1.50 (br s, 
1H, NH); 13C NMR (101.6 MHz, CDCl3) δ 140.2 (ispo-Ph), 136.7 (=CH), 128.4 (Ph), 
128.2 (Ph), 126.9 (Ph), 116.0 (=CH2), 53.2 (NCH2), 51.7 (NCH2). Spectroscopic data 
consistent with those reported in the literature.133 
Lab book reference: mcw/4/6/1 
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Methyl 4-(allyl(benzyl)amino)butanoate 87 
 
Methyl 4-bromobutyrate (2.57 mL, 20.4 mmol, 1.0 eq.) was added to a stirred 
suspension of potassium carbonate (5.63 g, 40.8 mmol, 2.0 eq.) and amine 92 (3.00 g, 
20.4 mmol, 1.0 eq.) in DMF (40 mL) at rt under Ar. The resulting mixture was stirred 
and heated at 100 °C for 18 h. After being allowed to cool to rt, H2O (20 mL) was 
added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic 
extracts were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash chromatography on silica with 70:30 hexane-Et2O as 
eluent gave ester-alkene amine 87 (2.86 g, 56%) as a colourless oil, RF (70:30 hexane-
Et2O) 0.3; IR (ATR)  2949, 2799, 1736 (C=O), 1435, 1251, 1170, 736, 698 cm
–1; 1H 
NMR (400 MHz, CDCl3) δ 7.37-7.17 (m, 5H, Ph), 5.85 (ddt, J = 17.0, 10.0, 6.5 Hz, 
1H, =CH), 5.17 (ddt, J = 17.0, 1.5, 1.5, 1H, =CH), 5.12, (ddt, J = 10.0, 1.5, 1.5, 1H, 
=CH), 3.64 (s, 2H, OMe), 3.55 (s, 2H, NCH2Ph), 3.05 (ddd, J = 6.5, 1.5, 1.5, 1H, 
NCH2), 2.44 (t, J = 7.0 Hz, 2H, NCH2), 2.33 (t, J = 7.0 Hz, 2H, CH2CO2Me), 1.80 (tt, 
J = 7.0, 7.0, 2H, CH2); 
13C NMR (101.6 MHz, CDCl3) δ 174.2 (C=O), 139.6 (ipso-
Ph), 135.9 (=CH), 128.8 (Ph), 128.1 (Ph), 126.8 (Ph), 117.2 (=CH2), 58.1 (NCH2), 
56.6 (NCH2), 52.3 (NCH2), 51.4 (OMe), 31.7 (CH2), 22.4 (CH2);  MS (ESI) m/z 248 
[(M + H)+, 100]; HMRS (ESI) m/z calcd for C15H21NO2 (M + H)
+ 248.1645, found 
248.1646 (–0.5 ppm error). 
Lab book reference: mcw/4/7 
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Methyl 6-(allyl(benzyl)amino)-2-(2-(allyl(benzyl)amino)ethyl)-3-oxohexanoate 
93 
 
Using general procedure J, lithium bis(trimethylsilyl)amide (8.08 mL of a 1.0 M 
solution in THF, 8.08 mmol, 2.0 eq.), ester-alkene 87 (1.00 g, 4.04 mmol, 1.0 eq.) in 
Et2O (52 mL), zinc bromide (1.82 g, 8.08 mmol, 2.0 eq.) in Et2O (8 mL) and a 2:1 
solution of saturated NH4Cl(aq)-NH4OH(aq) (20 mL) gave the crude product. 
Purification by flash chromatography on silica with 50:50 and then 80:20 Et2O-hexane 
as eluent gave Claisen product 93 (232 mg, 25%) as a colourless oil, RF (50:50 hexane-
Et2O) 0.1; IR (ATR) 3063, 2949, 2800, 1743 (C=O, CO2Me), 1713 (C=O, ketone), 
1452, 1251, 1073, 917 cm–1;  1H NMR (400 MHz, CDCl3) δ 7.34-7.17 (m, 10H, Ph), 
5.87-5.76 (m, 2H, =CH), 5.22-5.07 (m, 4H, =CH2), 3.64 (s, 3H, OMe), 3.59 (dd, J = 
7.0, 7.0 Hz, 1H, (C=O)CH(CO2Me)), 3.53 (s, 2H, NCH2Ph), 3.51 (s, 2H, NCH2Ph), 
3.06-3.01 (m, 4H, NCH2), 2.53 (ddd, J = 18.0, 7.0, 7.0 Hz, 1H, NCH), 2.45-2.34 (m, 
5H, CH), 1.99 (dt, J = 7.0, 7.0 Hz, 2H, CH), 1.72 (tt, J = 7.0, 7.0 Hz, 2H, CH2); 
13C 
NMR (101.6 MHz, CDC3) δ 205.3 (C=O, ketone), 170.4 (C=O, CO2Me), 139.6 (ipso-
Ph), 139.2 (ipso-Ph), 135.8 (=CH), 135.6 (=CH), 129.0 (Ph), 128.8 (Ph), 128.18 (Ph), 
128.15 (Ph), 127.0 (Ph), 126.8 (Ph), 117.6 (=CH2), 117.3 (=CH2), 66.7 (CH), 58.1 
(NCH2), 57.9 (NCH2), 56.6 (NCH2), 56.4 (OMe), 52.23 (NCH2), 52.20 (NCH2), 50.7 
(NCH2), 39.9 (CH2), 25.7 (CH2), 20.8 (CH2); MS (ESI) m/z 463 [(M + H)
+, 100]; 
HMRS (ESI) m/z calcd for C29H38N2O3 (M + H)
+ 463.2955, found 463.2941 (+3.2 
ppm error). 
Lab book reference: mcw/4/9 
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Attempted synthesis of methyl 1-benzyl-4-methylpiperidine-3-carboxylate 97 
 
Using general procedure J, lithium bis(trimethylsilyl)amide (1.0 M solution in THF, 
4.04 mmol, 2.0 eq.), ester-alkene 85 (500 mg, 2.02 mmol, 1.0 eq.) in Et2O (30 mL), 
zinc bromide (910 mg, 4.04 mmol, 2.0 eq.) in Et2O (4.04 mL) and a 2:1 solution of  
saturated NH4Cl(aq)-NH4OH(aq) (10 mL) gave no identifiable product.  
Lab book reference: mcw/4/14 
 
tert-Butyl 3-(benzyl(but-3-en-1-yl)amino)propanoate 95 
 
1,8-Diazabicyclo[5.4.0]undec-7-ene (1.39 mL, 9.30 mmol, 0.5 eq.) was added to a 
stirred solution of tert-butyl acrylate (4.09 mL, 27.9 mmol, 1.5 eq.) and amine 89 (3.00 
g, 18.6 mmol, 1.0 eq.) in MeCN (9 mL) at rt under Ar. The resulting mixture was 
stirred at rt for 6 h. The solvent was then evaporated under reduced pressure to give 
the crude product. Purification by flash chromatography on silica with 50:50 EtOAc-
hexane as eluent gave ester-alkene 95 (3.61 g, 67%) as a colourless oil, RF (50:50 
hexane-Et2O) 0.2; IR (ATR) 2977, 2931, 1726 (C=O), 1453, 1366, 1252, 1151, 734, 
697 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.29-7.15 (m, 5H, Ph), 5.71 (ddt, J = 17.0, 
10.5, 7.0 Hz, 1H, =CH), 4.95 (ddt, J = 17.0, 1.5, 1.5, 1H, =CH2), 4.93-4.88 (m, 1H, 
=CH2), 3.53 (s, 2H, CH2Ph), 2.74 (t, J = 7.0 Hz, 2H, NCH2), 2.45 (t, J = 7.0 Hz, 2H, 
NCH2), 2.33 (t, J = 7.0 Hz, 2H, CH2), 2.21-2.14 (m, 2H, CH2), 1.39 (s, 9H, O
tBu); 13C 
NMR (101 MHz, CDCl3) δ 172.1 (C=O), 139.6 (ipso-Ph), 136.9 (=CH), 128.7 (Ph), 
128.1 (Ph), 126.8 (Ph), 115.4 (=CH2), 80.2 (CMe3), 58.3 (CH2), 53.0 (CH2), 49.5 
(CH2), 33.8 (CH2), 31.5 (CH2), 28.1 (CMe3); MS (ESI) m/z 290 [(M + H)
+, 100]; 
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HMRS (ESI) m/z calcd for C18H27NO2 (M + H)
+ 290.2115, found 290.2110 (+1.7 ppm 
error). 
Lab book reference: mcw/4/25 
 
Attempted synthesis of tert-butyl 1-benzyl-4-methylpiperidine-3-carboxylate 97 
 
Using general procedure J, lithium bis(trimethylsilyl)amide (1.0 M solution in THF, 
6.91 mmol, 2.0 eq.), ester-alkene 95 (1.00 g, 3.45 mmol, 1.0 eq.) in Et2O (20 mL), 
zinc bromide (1.55 g, 6.91 mmol, 2.0 eq.) in Et2O (30 mL) and a 2:1 solution of  
saturated NH4Cl(aq)-NH4OH(aq) (15 mL) gave no identifiable product.  
Lab book reference: mcw/4/30 
 
(E)-Methyl 3-((2-hydroxy-1-phenylethyl)amino)but-2-enoate 111 
 
Methyl acetoacetate 115 (2.16 mL, 20.0 mmol, 1.1 eq.) was added to a stirred solution 
of phenylglycinol 114 (2.50 g, 18.2 mmol, 1.0 eq.) in MeOH (90 mL) at rt under Ar. 
The resulting solution was stirred and heated at reflux for 24 h. After being allowed to 
cool to rt, the solvent was evaporated under reduced pressure to give crude 
enaminoester 111 (4.28 g, 100%) as a pale yellow solid, mp 92-93 °C (lit.106 61 °C), 
1H NMR (400 MHz, CDCl3) δ 9.22 (d, J = 8.0 Hz, 1H, NH), 7.40-7.24 (m, 5H, Ph), 
4.67 (ddd, J = 8.0, 7.0, 4.0, 1H, NCH), 4.56 (s, 1H, =CH), 3.87 (dd, J = 11.0, 4.0 Hz, 
1H, CH), 3.79 (dd, J = 11.0, 7.0 Hz, 1H, CH), 3.67 (s, 3H, OMe), 1.93 (br s, 1H, OH), 
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1.82 (s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 171.1 (C=O), 161.9 (=C), 139.7 
(ipso-Ph), 128.9 (Ph), 127.8 (Ph), 126.4 (Ph), 84.1 (=CH), 67.3 (CH2OH), 59.1 (NCH), 
50.2 (OMe), 19.8 (Me). Spectroscopic data consistent with those reported in the 
literature.106 
Lab book reference: mcw/4/3 
 
Methyl 8a-methyl-5-oxo-3-phenylhexahydro-2H-oxazolo[3,2-a]pyridine-8-
carboxylate cis-113 and trans-113 
 
Acryloyl chloride 112 (1.38 mL, 17.0 mmol, 1.0 eq.) was added to a stirred solution 
of enamino ester 111 (4.00 g, 17.0 mmol 1.0 eq.) in THF (180 mL) at 0 °C under Ar. 
The resulting solution was stirred at 0 °C for 3 h. Saturated NaHCO3(aq) (30 mL) was 
added and the mixture was extracted with Et2O (3 x 25 mL). The combined organic 
extracts were dried (MgSO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash chromatography on silica with 60:40, 30:70 hexane-
EtOAc as eluent gave a 75:25 mixture (by 1H NMR spectroscopy) of oxazololactams 
cis-113 and trans-113 (1.61 g, 57%) as a yellow oil, RF (60:40 hexane-EtOAc) 0.1; 
1H 
NMR (400 MHz, CDCl3) δ 7.37-7.19 (m, 5H, Ph), 5.34 (dd, J = 8.0, 8.0 Hz, 0.75H, 
CHPh), 5.31-5.27 (m, 0.25H, CHPh), 4.55 (dd, J = 8.0, 8.0, 0.75H, CHO), 4.39 (dd, J 
= 8.0, 8.0 Hz, 0.25H, CHO), 3.99 (dd, J = 9.0, 8.0 Hz, 0.75H, CHO), 3.93 (dd, J = 9.0, 
8.0 Hz, 0.25H, CHO), 3.78 (s, 2.25H, OMe), 3.71 (s, 0.75H, OMe), 3.16 (dd, J = 4.0, 
4.0 Hz, 0.25H, CHCO2Me), 2.79-2.74 (m, 0.75H, CH), 2.73-2.71 (m, 0.25H, CH),  
2.70-2.65 (m, 0.75H, CH), 2.56-2.43 (m, 1H, CH), 2.22-2.11 (m, 2H, CH2), 1.55 (s, 
0.75H, Me), 1.48 (s, 2.25H, Me); 13C NMR (101.6 MHz, CDCl3) δ 171.5 (C=O, trans), 
171.4 (C=O, cis), 169.2 (C=O, trans), 168.4 (C=O, cis), 139.6 (ipso-Ph, trans), 139.2 
(ipso-Ph, cis), 128.7 (Ph, cis), 128.6 (Ph, trans), 127.4 (Ph, cis), 127.3 (Ph, trans), 
125.7 (Ph, trans), 125.5 (Ph, cis), 93.9 (CMe, cis), 93.8 (CMe, trans), 70.1 (OCH2, 
cis), 70.1 (OCH2, trans), 59.4 (NCH, trans), 58.6 (NCH, cis), 52.4 (OMe, cis), 51.9 
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(OMe, trans), 50.1 (CH, cis), 47.0 (CH, trans), 29.7 (CH2, cis), 27.5 (CH2, trans), 25.9 
(Me, trans), 20.5 (Me, cis), 20.2 (CH2, cis), 19.9 (CH2, trans).  Spectroscopic data 
consistent with those reported in the literature.106 
Lab book reference: mcw/4/54 
 
Methyl 1-(2-hydroxy-1-phenylethyl)-2-methylpiperidine-3-carboxylate cis-110 
and trans-110 
 
BH3·Me2S (6.91 mL of a 2 M solution in THF, 13.8 mmol, 4.0 eq.) was added to a 
stirred solution of a 75:25 mixture of oxazololactams cis-113 and trans-113 (1.00 g, 
3.45 mmol, 1.0 eq.) in THF (40 mL) at rt under Ar. The resulting solution was stirred 
at rt for 24 h. H2O (20 mL) was added carefully (CARE - vigorous reaction) and the 
mixture was extracted with Et2O (3 x 25 mL). The combined organic extracts were 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash chromatography on silica with 60:40 hexane-EtOAc and then 
EtOAc as eluent gave a 70:30 mixture (by 1H NMR spectroscopy) of piperidines cis-
110 and trans-110 (402 g, 42%) as a yellow oil, RF (60:40 hexane-EtOAc) 0.1; 
1H 
NMR (400 MHz, CDCl3) δ 7.38-7.13 (m, 5H, Ph), 4.29 (dd, J = 10.5, 5.0 Hz, 0.3H, 
CHO), 3.98 (dd, J = 10.5, 10.5 Hz, 0.3H, CHO), 3.92 (dd, J = 6.5, 6.5 Hz, 0.7H, 
CHPh), 3.87-3.74 (m, 1.4H, CHO), 3.67 (s, 0.9H, OMe),  3.62 (s, 2.1H, OMe), 3.58 
(dd, J = 10.5, 5.0 Hz, 0.3H, CHPh), 3.20-3.12 (m, 0.7H, NCH), 2.90 (ddd, J = 12.0, 
4.0, 4.0 Hz, 0.3H, NCH), 2.82-2.64 (m, 2H, NCH), 2.39-2.28 (m, 1H, CH), 1.90-1.62 
(m, 3H, CH), 1.55-1.36 (m, 1H, CH), 1.25 (d, J = 6.5 Hz, 0.9H, Me), 1.03 (d, J = 6.5 
Hz, 2.1H, Me); 13C NMR (101.6 MHz, CDCl3) δ 175.3 (C=O, trans), 174.1 (C=O, 
cis), 138.8 (ipso-Ph, trans),  135.6 (ipso-Ph, cis), 128.7 (Ph, trans), 128.5 (Ph, cis), 
128.3 (Ph, trans), 128.2 (Ph, cis), 127.8 (Ph, trans), 127.6 (Ph, cis), 64.0 (NCH, cis), 
61.8 (OCH2, cis), 60.9 (NCH, trans), 59.4 (OCH2, trans), 54.5 (OMe, trans), 52.7 
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(OMe, cis), 51.6 (NCH, trans), 51.4 (NCH, cis), 51.0 (CH, trans), 46.4 (CH, cis), 45.0 
(NCH2, trans), 43.7 (NCH2, cis), 27.8 (CH2, trans), 25.0 (CH2, trans), 23.8 (CH2, cis), 
23.6 (CH2, cis), 12.0 (Me, cis), 18.4 (Me, trans). Spectroscopic data consistent with 
those reported in the literature.106 
 
Methyl 2-methylpiperidine-3-carboxylate trans-107 and cis-107 
 
10% Pd/C (192 mg, 0.18 mmol, 0.5 eq.) was added to a stirred solution of a 70:30 
mixture of piperidines cis-110 and trans-110 (100 mg, 0.36 mmol, 1.0 eq.) in MeOH 
(9 mL) at rt under Ar. The reaction flask was evacuated under reduced pressure and 
back-filled with Ar three times. After the final evacuation, H2 was charged and the 
reaction mixture stirred at rt under a H2 atmosphere for 24 h. The solids were removed 
by filtration through Celite and washed with MeOH (15 mL). The filtrate was 
evaporated under reduced pressure to give deprotected piperidine 108 as shown by 1H 
NMR spectroscopy. Di-tert-butyl dicarbonate (218 mg, 0.10 mmol, 1.45 eq.) was 
added to a stirred solution of the crude deprotected piperidine 108 in CH2Cl2 (5 mL) 
at 0 °C under Ar. The solution was then allowed to warm to rt over 3 h and stirred at 
rt for 30 h. H2O (2 mL) was added and the mixture was extracted with CH2Cl2 (3 x 5 
mL). The combined organic extracts were dried (MgSO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash chromatography on 
silica with 80:20 and then 50:50 hexane-Et2O as eluent gave N-boc-piperidine cis-107 
(51 mg, 40%) as a clear oil, RF (50:50 hexane-Et2O) 0.3; IR (ATR) 2972, 1735 (C=O, 
CO2Me), 1687 (C=O, Boc), 1413, 1363, 1174, 1147, 1130 cm
–1; 1H NMR (400 MHz, 
CDCl3) δ 4.87 (br q, J = 7.0 Hz, 1H, NCH), 3.94 (br dd, J = 13.5, 4.0 Hz, 1H, NCH2), 
3.69 (s, 3H, OMe), 2.81 (ddd, J = 13.5, 13.5, 3.5 Hz, 1H, NCH), 2.42-2.38 (m, 1H, 
CH), 2.04 (br dd, J = 13.5, 3.5 Hz, 1H, CH), 1.82-1.58 (m, 3H, CH), 1.45 (s, 9H, 
CMe3), 1.21 (d, J = 7.0 Hz, 3H, Me); 
13C NMR (101.6 MHz, CDCl3) δ 173.9 (C=O, 
CO2Me), 154.8 (C=O, Boc), 79.2 (CMe3), 51.8 (OMe), 47.2 (NCH), 43.8 
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(CHCO2Me), 37.7 (NCH2), 28.4 (CMe3), 21.8 (CH2), 20.5 (CH2), 16.5 (Me); MS (ESI) 
m/z 280 [(M + Na)+, 100]; HMRS (ESI) m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, 
found 280.1525 (–2.3 ppm error) and N-boc-piperidine trans-107 (38 mg, 30%) as a 
clear oil, RF (50:50 hexane-Et2O) 0.2; IR (ATR) 2950, 1736 (C=O, CO2Me), 1687 
(C=O, Boc), 1407, 1364, 1240, 1146, 1000, 832 cm–1; 1H NMR (400 MHz, CDCl3) 
(50:50 mixture of rotamers) δ 4.83 (br s, 0.5H, NCH), 4.63 (br s, 0.5H, NCH), 3.99 
(br d, J = 11.5 Hz, 0.5H, NCH), 3.85 (br d, J = 11.5 Hz, 0.5H, NCH), 3.70 (s, 1.5H, 
OMe), 3.67 (s, 1.5H, OMe), 2.87-2.68 (m, 1H, NCH), 2.62 (ddd, J = 12.5, 4.5, 4.5 Hz, 
1H, CHCO2Me), 1.91-1.61 (m, 4H, CH), 1.46 (s, 9H, CMe3), 1.02 (d, J = 7.0 Hz, 3H, 
Me); 13C NMR (101.6 MHz, CDCl3) (rotamers) δ 173.4 (C=O, CO2Me), 154.6 (C=O, 
Boc), 79.6 (CMe3), 53.4 (NCH2), 51.7 (NCH), 51.6 (NCH), 47.9 (OMe), 46.7 (OMe), 
45.2 (CH), 44.8 (CH), 38.5 (CH2), 37.4 (CH2), 30.3 (CMe3), 28.4 (CMe3), 24.8 (CH2), 
24.5 (CH2), 20.5 (CH2), 12.2 (Me), 12.0 (Me); MS (ESI) m/z 280 [(M + Na)
+, 100]; 
HMRS (ESI) m/z calcd for C13H23NO4 (M + Na)
+ 280.1519, found 280.1516 (+1.1 
ppm error). 
Lab book reference: mcw/4/75 
 
3-Carboxy-4-methylpyridin-1-ium chloride 125.HCl 
 
Sodium hydroxide (3.00 g, 74.5 mmol, 4.4 eq.) was added to a stirred solution of 
cyano-4-methylpyridine 124 (2.00 g, 16.9 mmol, 1.0 eq.) in EtOH (140 mL) and H2O 
(60 mL) at rt under air. The solution was stirred and heated at reflux for 3 h. After 
being allowed to cool to rt, the solvent was evaporated under reduced pressure. H2O 
(20 mL) was added to the residue and then 1 M HCl(aq) (75 mL) was added. The water 
was evaporated under reduced pressure. Hot EtOH (40 mL) was added and the solids 
were removed by filtration. The filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash chromatography on silica with 90:10 EtOAc-
MeOH as eluent gave pyridine carboxylic acid 125.HCl (1.74 g, 59%) as a white solid, 
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mp 150-151 °C, RF (90:10 EtOAc-MeOH) 0.2; IR (ATR) 3044, 1665 (C=O), 1597, 
1427, 1382, 1059, 839, 669 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H, Ar), 
8.45 (d, J = 5.0 Hz, 1H, Ar), 7.93 (br s, 1H, OH), 7.57 (br s, 1 H, NH), 7.28 (d, J = 5.0 
Hz, 1H, Ar), 2.38 (s, 3H, Me); 13C NMR (101.6 MHz, DMSO-d6) δ 168.8 (C=O), 
150.0 (Ar), 147.6 (Ar), 144.9 (ipso-Ar), 132.7 (ipso-Ar), 125.6 (Ar), 19.0 (Me). 
Lab book reference: mcw/4/40 
 
Methyl 4-methylnicotinate 126 
 
Using general procedure K, concentrates H2SO4 (2.54 mL, 46.7 mmol, 3.7 eq.) and 
pyridine carboxylic acid 125.HCl (1.74 g, 10.0 mmol, 1.0 eq.) in MeOH (20 mL) gave 
the crude product. Purification by flash chromatography on silica with EtOAc as eluent 
gave methyl 4-methylnicotinate 126 (1.51 g, 100%) as a clear oil, RF (EtOAc) 0.5; 
1H 
NMR (400 MHz, CDCl3) δ 9.05 (s, 1H, Ar), 8.54 (d, J = 5.0 Hz, 1H, Ar), 7.16 (d, J = 
5.0 Hz, 1H, Ar), 3.91 (s, 3H, OMe), 2.60 (s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) 
δ 166.5 (C=O), 152.1 (Ar), 151.6 (Ar), 149.4 (ipso-Ar), 126.4 (Ar), 125.7 (ipso-Ar), 
52.1 (OMe), 21.2 (Me). Spectroscopic data consistent with those reported in the 
literature.134 
Lab book referemce: mcw/4/44 
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Attempted synthesis of methyl 4-methylpiperidine-3-carboxylate 127 
 
Platinum oxide (4.5 mg, 0.02 mmol, 0.006 eq.) was added to a stirred solution of 
methyl 4-methylnicotinate 126 (500 mg, 3.31 mmol, 1.0 eq.) in EtOH (5.48 mL) and 
6 M HCl(aq) (1 mL) at rt under Ar. The reaction flask was evacuated under reduced 
pressure and back-filled with Ar three times. After the final evacuation, H2 was 
charged and the reaction mixture was stirred vigorously at rt under a H2 atmosphere 
for 24 h. The solids were removed by filtration through Celite and washed with the 
MeOH (20 mL). The filtrate was evaporated under reduced pressure. Then, the residue 
was dissolved in 2 M NH4OH(aq) (10 mL) and the aqueous layer was extracted with 
CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (MgSO4) and 
evaporated under reduced pressure to give recovered methyl 4-methylnicotinate 126 
(490 mg, 98%) as a yellow oil.  
 
10% Pd/C (105 mg, 0.10 mmol, 0.03 eq.) was added to a stirred solution of methyl 4-
methylnicotinate 126 (500 mg, 3.31 mmol, 1.0 eq.) in concentrated HCl(aq) (0.31 mL) 
and MeOH (20 mL) under air in a high pressure pot reactor. After evacuation, H2 was 
charged at 5 bar and the reaction mixture was stirred and heated at 80 °C for 18 h. 
After being allowed to cool to rt, the solids were removed by filtration through Celite 
and washed with MeOH (20 mL). The filtrate was evaporated under reduced pressure. 
1H NMR spectroscopy of the crude product showed that none of the desired product 
had been formed.  
 
Platinum oxide (59.2 mg, 2.61 mmol, 0.09 eq.) and 10% Pd/C (41.3 mg, 0.04 mmol, 
0.013 eq.) was added to a stirred solution of methyl 4-methylnicotinate 126 (438 mg, 
2.89 mmol, 1.0 eq.) in glacial acetic acid(aq) (13 mL) under air in a high pressure pot 
reactor. After evacuation, H2 was charged at 5 bar and the reaction mixture stirred at 
rt for 72 h. The solids were removed by filtration through Celite and washed with 
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MeOH (20 mL). The filtrate was then evaporated under reduced pressure. 1H NMR 
spectrospcopy of the crude product showed that none of the desired product had been 
formed.   
 
1-Benzyl-3-(methoxycarbonyl)pyridin-1-ium bromide 129 
 
Using general procedure L, benzyl bromide (0.86 mL, 7.29 mmol, 1.0 eq.) and methyl 
nicotinate 128 (1.00 g, 7.29 mmol, 1.0 eq.) in MeCN (18 mL) gave benzyl pyridinium 
bromide 129 (2.24 g, 100%) as a yellow oil, 1H NMR (400 MHz, CDCl3) δ 10.09 (br 
d, J = 6.0 Hz, 1H, Ar), 9.68 (s, 1H, Ar), 8.85 (br d, J = 8.0 Hz, 1H, Ar), 8.26 (dd, J = 
8.0, 6.0 Hz, 1H, Ar), 7.71-7.67 (m, 2H, Ph), 7.40-7.34 (m, 3H, Ph), 6.47 (s, 2H, 
NCH2Ph), 3.97 (s, 3H, OMe); 
13C NMR (101.6 MHz, CDCl3) δ 161.4 (C=O), 148.8 
(Ar), 145.3 (Ar), 145.1 (Ar), 132.4 (ipso-Ar), 130.3 (ipso-Ar), 130.1 (Ar), 129.8 (Ar), 
129.7 (Ar), 128.6 (Ar), 64.7 (NCH2), 53.8 (OMe). Spectroscopic data consistent with 
those reported in the literature.135 
Lab book reference: mcw/4/76 
 
Methyl 1-benzyl-1,2,5,6-tetrahydropyridine-3-carboxylate 130 
 
Using general procedure M, sodium borohydride (2.48 g, 65.6 mmol, 9.0 eq.) and 
benzyl pyridinium bromide 129 (2.24 g, 7.29 mmol, 1.0 eq.) in MeOH (20 mL) and 
H2O (10 mL) gave the crude product. Purification by flash chromatography on silica 
with 70:30 and then 50:50 hexane-EtOAc as eluent gave tetrahydropyridine 130 (355 
234 
 
mg, 21%) as a pale yellow oil, RF (50:50 hexane-EtOAc) 0.2; 
1H NMR (400 MHz, 
CDCl3) δ 7.37-7.23 (m, 5H, Ph), 7.03-6.99 (m, 1H, =CH), 3.71 (s, 3H, OMe), 3.65 (s, 
2H, NCH2Ph), 3.24-3.20 (m, 2H, NCH2), 2.53 (t, J = 6.0 Hz, 2H, NCH2), 2.36-2.29 
(m, 2H, CH2); 
13C NMR (101.6 MHz, CDCl3) δ 166.3 (C=O), 138.0 (ipso-Ph), 137.9 
(=CH), 129.1 (=C), 129.0 (Ph), 128.3 (Ph), 127.1 (Ph), 62.4 (NCH2), 51.6 (NCH2), 
51.5 (OMe), 48.3 (CH2), 26.5 (CH2). Spectroscopic data consistent with those reported 
in the literature.136 
Lab book reference: mcw/4/77 
 
1-Benzyl-3-(methoxycarbonyl)-4-methylpyridin-1-ium bromide 131 
 
Using general procedure L, benzyl bromide (0.4 mL, 3.30 mmol, 1.0 eq.) and methyl 
4-methylnicotinate 126 (500 mg, 3.30 mmol, 1.0 eq.) in MeCN (8 mL) gave benzyl 
pyridinium bromide 131 (1.06 g, 100%) as an orange oil, 1H NMR (400 MHz, CDCl3) 
δ 9.85 (dd, J = 6.0, 1.0 Hz, 1H, Ar), 9.48 (d, J = 1.0 Hz, 1H, Ar), 7.93 (d, J = 6.0 Hz, 
1H, Ar), 7.67-7.63 (m, 2H, Ph), 7.44-7.38 (m, 3H, Ph), 6.36 (s, 2H, NCH2Ph), 4.00 (s, 
3H, OMe), 2.85 (s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 162.1 (C=O), 161.0 
(ipso-Ar), 146.5 (Ar), 145.5 (Ar), 132.4 (ipso-Ar), 131.1 (Ar), 130.2 (Ar), 129.74 (Ar), 
129.67 (Ar), 129.2 (ipso-Ar), 64.2 (NCH2), 53.6 (OMe), 22.5 (Me); MS (ESI) m/z 242 
[M+, 100]; HMRS (ESI) m/z calcd for C15H25NO2 M
+ 242.1176, found 242.1177 (–0.4 
ppm error). 
Lab book reference: mcw/4/98 
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Methyl 1-benzyl-4-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate 132 
 
Using general procedure M, sodium borohydride (1.12 g, 29.7 mmol, 9.0 eq.) and 
benzyl pyridinium bromide 131 (1.06 g, 3.30 mmol, 1.0 eq.) in MeOH (6 mL) and 
H2O (3 mL) gave the crude product. Purification by flash chromatography on silica 
with 80:20 and then 50:50 hexane-EtOAc as eluent gave 4-methyl tetrahydropyridine 
132 (436 mg, 44%) as a pale yellow oil, RF (50:50 hexane-EtOAc) 0.2; IR (ATR) 
2948, 2764, 1714 (C=O), 1433, 1243, 1216, 1061, 737, 697 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.38-7.20 (m, 5H, Ph), 3.69 (s, 3H, OMe), 3.61 (br s, 2H, NCH2Ph), 3.25-
3.18 (m, 2H, NCH2), 2.50 (br t, J = 6.0 Hz, 2H, NCH2), 2.29-2.25 (m, 2H, CH2), 2.09 
(s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 167.2 (C=O), 147.4 (=C), 138.1 (ipso-
Ph), 129.1 (Ph), 128.3 (Ph), 127.1 (Ph), 122.3 (=C), 62.4 (NCH2Ph), 53.3 (NCH2), 
51.1 (OMe), 48.9 (NCH2), 34.4 (CH2), 21.4 (Me); MS (ESI) m/z 246 [(M + H)
+, 100]; 
HMRS (ESI) m/z calcd for C15H19NO2 (M + H)
+ 246.1489, found 246.1481 (+1.7 ppm 
error). 
Lab book reference: mcw/5/2 
 
1-Benzyl-5-(methoxycarbonyl)-2-methylpyridin-1-ium bromide 133 
 
Using general procedure L, benzyl bromide (0.4 mL, 3.30 mmol, 1.0 eq.) and methyl 
6-methylnicotinate 121 (500 mg, 3.30 mmol, 1.0 eq.) in MeCN (8 mL) gave benzyl 
pyridinium bromide 133 (1.06 g, 100%) as a yellow oil, 1H NMR (400 MHz, CDCl3) 
δ 9.47 (d, J = 1.0 Hz, 1H, Ar), 8.80 (dd, J = 8.0, 1.0 Hz, 1H, Ar), 8.15 (d, J = 8.0 Hz, 
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1H, Ar), 7.44-7.40 (m, 3H, Ph), 7.38-7.33 (m, 2H, Ph), 6.31 (s, 2H, NCH2Ph), 3.99 (s, 
3H, OMe), 3.15 (s, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 161.6 (C=O), 160.5 
(ipso-Ar), 146.6 (Ar), 144.8 (Ar), 130.9 (Ar), 130.8 (ipso-Ar), 129.9 (Ar), 129.8 (Ar), 
128.6 (Ar), 128.4 (ipso-Ar), 63.0 (NCH2), 53.7 (OMe), 22.5 (Me). Spectroscopic data 
consistent with those reported in the literature.135 
Lab book reference: mcw/4/78 
 
Methyl 1-benzyl-6-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate 134 
 
Using general procedure M, sodium borohydride (1.12 g, 29.7 mmol, 9.0 eq.) and 
benzyl pyridinium bromide 133 (1.06 g, 3.30 mmol, 1.0 eq.) in MeOH (6 mL) and 
H2O (3 mL) gave the crude product. Purification by flash chromatography on silica 
with 80:20 and then 50:50 hexane-EtOAc as eluent gave 2-methyl tetrahydropyridine 
134 (234 mg, 29%) as a pale yellow oil, RF (50:50 hexane-EtOAc) 0.4; IR (ATR) 
2950, 2803, 1711 (C=O), 1435, 1255, 1116, 722, 697 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.39-7.21 (m, 5H, Ph), 7.03-6.94 (m, 1H, =CH), 3.77 (d, J = 13.5 Hz, 1H, 
CHPh), 3.70 (s, 3H, OMe), 3.55 (d, J = 13.5 Hz, 1H, CHPh), 3.27-3.23 (m, 2H, NCH), 
2.94 (m, 1H, NCHMe), 2.54-2.45 (m, 1H, CH), 2.08-1.99 (m, 1H, CH), 1.05 (d, J = 
6.5 Hz, 3H, Me); 13C NMR (101.6 MHz, CDCl3) δ 166.3 (C=O), 138.9 (ipso-Ph), 
137.2 (=CH), 128.8 (Ph), 128.3 (Ph), 128.2 (=C), 127.0 (Ph), 57.6 (NCH2Ph), 51.5 
(OMe), 49.8 (NCH), 47.1 (NCH2), 32.7 (CH2), 14.0 (Me); MS (ESI) m/z 246 [(M + 
H)+, 100]; HMRS (ESI) m/z calcd for C15H19NO2 (M + H)
+ 246.1489, found 246.1486 
(–0.8 ppm error). 
Lab book reference: mcw/4/79 
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Abbreviations 
∆ Heat 
A1,3 Allylic 1,3-Strain 
aq Aqueous 
Bn Benzyl 
Boc t-Butoxycarbonyl 
br Broad 
cbz Carboxybenzyl 
CHARMm Chemistry at HARvard Macromolecular Mechanics 
cm-1 Wavenumber 
d Doublet 
Da Dalton(s) 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DMF Dimethylformamide 
DMPU N,N′-Dimethylpropylene urea 
DMSO Dimethylsulfoxide 
E+ Electrophile 
Eq. Equivalents 
ESI Electrospray ionisation 
Et2O Diethyl ether 
EtOAc Ethyl acetate 
FBDD Fragment based drug discovery 
FDA Food and drug administration 
Fmoc Fluorenylmethyloxycarbonyl 
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H bond Hydrogen bond 
HAC Heavy atom count 
Het Ar Heteroaryl 
HRMS High resolution mass spectrometry 
HTS High throughput screening 
IR Infra-red 
J Coupling constant in Hz 
KHMDS Potassium bis(trimethylsilyl)amide 
LDA Lithium diisopropylamide 
LHMDS Lithium bis(trimethylsilyl)amide 
m Multiplet 
M Molar 
m/z Mass to charge ratio 
M+ Molecular ion 
Me Methyl 
MS Mass spectrometry 
Ms Mesyl 
MW Molecular weight 
NMR Nuclear Magnetic Resonance 
npr Normalised PMI ratio 
O-Su N-Hydroxysuccinimide 
PAINS Pan-assay interference compounds 
PBF Plane of Best Fit 
Petrol Petroleum Ether (fraction which boils at 40-60 °C) 
PhF 9-Phenyl-9-fluorenyl 
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PMI Principal moment of inertia 
ppm Parts per million 
PrATs Promiscuous 2-AminoThiazoles 
PSA Polar surface area 
q Quartet 
RF Retention Factor 
RMS Root Mean Square 
RMSD Root Mean Square Deviation 
ROCS Rapid Overlay of Chemical Structures 
rt Room Temperature 
s Singlet 
SMILES Simplified molecular-input line-entry system 
SPR Surface plasmon resonance 
t Triplet 
TBS tert-Butyldimethylsilyl 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIPS triisopropylsilyl 
TMEDA N,N,N’,N’-Tetramethylethylenediamine 
Trisyl 2,4,6-Triisopropylbenzenesulfonyl 
VT NMR Variable Temperature Nuclear Magnetic Resonance 
δ Chemical Shift 
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